Collected Works of Michael J. Keating

Introduction

Dr. Michael J. Keating’s development of fludarabine continues to play a major role in clinical research as this drug is now established as the most important single agent in CLL and a major component of treatment for patients with low-grade lymphoma, acute myelogenous leukemia, myelodysplastic syndrome and those undergoing marrow stem-cell transplantation. At present, he is working on developing new potentially curative therapies for CLL and rational combinations of new agents for the treatment of leukemias and other hematologic malignancies.

Dr. Keating is a Professor of Medicine and Internist in Hematology at the University of Texas MD Anderson Cancer Center. He has been a member of the faculty of the MD Anderson Cancer Center (MDA) since 1977 and works as a physician in the Department of Leukemia.

Collected Works

1973

• Keating MJ, Penington DG. Prophylaxis against septicaemia in acute leukaemia: the use of oral framycetin. Med J Aust. 1973 Aug 4;2(5):213-7.

1974

• Penington DG, Keating MJ. Prognosis of acute leukaemia in adults. Med J Aust. 1974 Jun 29;1(26):1031-5.

1977

• Keating MJ, Freireich EJ, McCredie KB, Bodey GP, Hersh E, Hester JP, Rodriguez V, Hart J. Acute leukemia in adults, 1977. CA Cancer J Clin. 1977 Jan-Feb;27(1):2-25.
• Keating MJ, Sethi MR, Bodey GP, Samaan NA.Hypocalcemia with hypoparathyroidism and renal tubular dysfunction associated with aminoglycoside therapyCancer. 1977 Apr;39(4):1410-4.
• Keating MJ, Rodriguez V, Bodey GP. Protected environments and microbial suppression in cancer therapy. Am J Clin Nutr. 1977 Nov;30(11):1904-10.
• Benjamin RS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ.A phase 1 and 2 trial of rubidazone in patients with acute leukemia. Cancer Res. 1977 Dec;37(12):4623-8.
• Bodey GP, Rodriguez V, Valdivieso M, Keating M. Gram-negative bacillary infections in cancer patients. S Afr Med J. 1977 Dec 17;52(26):1049-55.

1978

• Ezaki K, Hersh EM, Keating M, Dyre S, Hollinshead A, McCredie KB, Mavlight GM, Gutterman JU.Active specific immunization with allogeneic leukemia associated antigens or irradiated allogeneic leukemia cells in acute leukemia.Cancer. 1978 Jan;41(1):70-83.
• Rodriguez V, McCredie KB, Keating MJ, Valdivieso M, Bodey GP, Freireich EJ. Isophosphamide therapy for hematologic malignancies in patients refractory to prior treatment. Cancer Treat Rep. 1978 Apr;62(4):493-7.
• Rodriguez V, Bodey GP, Freireich EJ, McCredie KB, Gutterman JU, Keating MJ, Smith TL, Gehan EA.Randomized trial of protected environment–prophylactic antibiotics in 145 adults with acute leukemia. Medicine (Baltimore). 1978 May;57(3):253-66.
• Freireich EJ, Keating MJ, Gehan EA, McCredie KB, Bodey GP, Smith T. Therapy of acute myelogeneous leukemiaCancer. 1978 Aug;42(2 Suppl):874-82.
• Dicke KA, McCredie KB, Spitzer G, Zander A, Peters L, Verma DS, Stewart D, Keating M, Stevens EE. Autologous bone marrow transplantation in patients with adult acute leukemia in relapse. Transplantation. 1978 Sep;26(3):169-73.

1979

• McCredie KB, Keating MJ, Dicke KA, Bodey GP, Smith T, Freireich EJ.Treatment of adult acute myeloblastic leukemia. Haematol Blood Transfus. 1979;23:89-92.
• Keating MJ, Bodey GP, Valdivieso M, Rodriguez V.A randomized comparative trial of three aminoglycosides–comparison of continuous infusions of gentamicin, amikacin and sisomicin combined with carbenicillin in the treatment of infections in neutropenic patients with malignanciesMedicine (Baltimore). 1979 Mar;58(2):159-70.
• Benjamin RS, Keating MJ, Swenerton KD, Legha S, McCredie KB. Clinical studies with rubidazone. Cancer Treat Rep. 1979 May;63(5):925-9.
• Issell BF, Keating MJ, Valdivieso M, Bodey GP.Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients. Am J Med Sci.
• Benjamin RS, Keating MJ, Valdivieso M, McCredie KB, Livingston RA, Burgess MA, Rodriguez V, Bodey GP, Gottlieb JA. Phase I-II study of piperazinedione in adults with solid tumors and acute leukemia. Cancer Treat Rep. 1979 Jun;63(6):939-43.
• Bodey GP, McCredie KB, Keating MJ, Freireich EJ. Treatment of acute leukemia in protected environment unitsCancer. 1979 Aug;44(2):431-6.
• Stewart DJ, Benjamin RS, McCredie KB, Murphy S, Keating M.The effectiveness of rubidazone in hairy cell leukemia (leukemic reticuloendotheliosis). Blood. 1979 Aug;54(2):298-304.

1980

• Gehan EA, Smith TL, Buzdar AU, Keating MJ, Freireich EJ. Knowledge acquisition from historical data: application to breast cancer patients. Bull Cancer. 1980;67(4):437-45.
• Yap HY, Blumenschein GR, Keating MJ, Hortobagyi GN, Tashima CK, Loo TL. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep. 1980 Feb-Mar;64(2-3):279-83.
• Dosik GM, Barlogie B, Smith TL, Gehan EA, Keating MJ, McCredie KB, Freireich EJ. Pretreatment flow cytometry of DNA content in adult acute leukemia. Blood. 1980 Mar;55(3):474-82.
• Plunkett W, Hug V, Keating MJ, Chubb S.Quantitation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapyCancer Res. 1980 Mar;40(3):588-91.
• Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Spitzer G, Hersh E, Gutterman J, Freireich EJ. Factors related to length of complete remission in adult acute leukemia. Cancer. 1980 Apr 15;45(8):2017-29.
• Dreizen S, McCredie KB, Bodey GP, Keating MJ, Patt YZ.Superficial head and neck metastases in adults with widespread cancer. Postgrad Med. 1980 May;67(5):171-6, 179-80, 183-4 passim.
• Legha SS, Keating MJ, Zander AR, McCredie KB, Bodey GP, Freireich EJ. 4′-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemiaAnn Intern Med. 1980 Jul;93(1):17-21.
• Mavlight GM, Stuckey SE, Cabanillas FF, Keating MJ, Tourtellotte WW, Schold SC, Freireich EJ.Diagnosis of leukemia or lymphoma in the central nervous system by beta 2-microglobulin determination. N Engl J Med. 1980 Sep 25;303(13):718-22.
• Stewart DJ, Keating MJ.Radiation exposure as a possible etiologic factor in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer. 1980 Oct 1;46(7):1577-80.

1981

• Quesada JR, Hersh EM, Keating M, Zander A, Hester J.Hairy cell leukemia: clinical effects of the methanol extraction residue (MER) of BCG, lithium carbonate and mononuclear cell-enriched leukocyte transfusionsLeuk Res. 1981;5(6):463-76.
• Yap BS, McCredie KB, Keating MJ, Bodey GP, Freireich EJ. Asparaginase and methotrexate combination chemotherapy in relapsed acute lymphoblastic leukemia in adults. Cancer Treat Rep. 1981;65(Suppl 1):83-7.
• McCredie KB, Keating MJ, Bodey GP, Gehan EA, Smith T, Freireich EJ. Prognostic factors in response to anthracyclines. Cancer Treat Rep. 1981;65(Suppl 4):83-6.
• Stewart DJ, Keating MJ, McCredie KB, Smith TL, Youness E, Murphy SG, Bodey GP, Freireich EJ. Natural history of central nervous system acute leukemia in adults. Cancer. 1981 Jan 1;47(1):184-96.
• Granatek CH, Ezaki K, Hersh EM, Keating MJ, Rasmussen S.Antibody responses of remission leukemia patients receiving active specific and nonspecific immunotherapyCancer. 1981 Jan 15;47(2):272-9.
• Dreizen S, McCredie KB, Keating MJ. Chemotherapy-induced oral mucositis in adult leukemia. Postgrad Med. 1981 Feb;69(2):103-8, 111-2. 
• Barlogie B, Plunkett W, Raber M, Latreille J, Keating M, McCredie K.In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia. Cancer Res. 1981 Mar;41(3):1227-35.
• McCredie KB, Bodey GP, Freireich EJ, Hester JP, Rodriguez V, Keating MJ. Chemoimmunotherapy of adult acute leukemia. Cancer. 1981 Mar 15;47(6):1256-61.
• Stewart DJ, Keating MJ, Youness E, Burgess MA. Long-term chemotherapy-induced remission in a probable case of hairy cell leukemia. Cancer Treat Rep. 1981 Mar-Apr;65(3-4):313-5.
• Rosenblum MG, Keating MJ, Yap BS, Loo TL.Pharmacokinetics of [14C]methylglyoxal-bis-guanylhydrazone) in patients with leukemia. Cancer Res. 1981 May;41(5):1748-50.
• Zander AR, Vellekoop L, Spitzer G, Verma DS, Litam J, McCredie KB, Keating M, Hester JP, Dicke KA. Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia. Cancer Treat Rep. 1981 May-Jun;65(5-6):377-81.
• Yap BS, McCredie KB, Keating MJ, Bodey GP, Freireich EJ. Phase I–II study of 3-deazauridine in adults with acute leukemia. Cancer Treat Rep. 1981 May-Jun;65(5-6):521-4.
• Keating MJ, Lawson R, Grose W, Bodey GP.Combination therapy with ticarcillin and sulfamethoxazole-trimethoprim for infections in patients with cancerArch Intern Med. 1981 Jun;141(7):926-30.
• Keating MJ, Smith TL, McCredie KB, Bodey GP, Hersh EM, Gutterman JU, Gehan E, Freireich EJ. A four-year experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemiaCancer. 1981 Jun 15;47(12):2779-88.
• Keating MJ, McCredie KB, Benjamin RS, Bodey GP, Zander A, Smith TL, Freireich EJ.Treatment of patients over 50 years of age with acute myelogenous leukemia with a combination of rubidazone and cytosine arabinoside, vincristine, and prednisone (ROAP)Blood. 1981 Sep;58(3):584-91.

1982

• Hersh EM, Quesada J, Keating MJ, Rasmussen S, Murphy SG, Gschwind C, Morgan J.Host defence factors and prognosis in hairy cell leukemia. Leuk Res. 1982;6(5):625-37.
• Bodey GP, Grose WE, Keating MJ.Use of trimethoprim-sulfamethoxazole for treatment of infections in patients with cancer. Rev Infect Dis. 1982 Mar-Apr;4(2):579-85.
• Plunkett W, Benjamin RS, Keating MJ, Freireich EJ. Modulation of 9-beta-D-arabinofuranosyladenine 5′-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2′-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenineCancer Res. 1982 May;42(5):2092-6.
• Dreizen S, McCredie KB, Keating MJ, Bodey GP.Oral infections associated with chemotherapy in adults with acute leukemia. Postgrad Med. 1982 Jun;71(6):133-8, 143-6.
• Januszewicz E, Firkin FC, Chesterman CN, Garson OM, Beswick W, Keating MJ, Penington DG.Retrospective analysis of 158 cases of adult acute leukaemia: factors influencing prognosis and treatment responseAust N Z J Med. 1982 Jun;12(3):238-45.
• Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ.Causes of initial remission induction failure in acute myelogenous leukemia. Blood. 1982 Aug;60(2):309-15.
• Legha SS, Keating MJ, McCredie KB, Bodey GP, Freireich EJ.Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults. Blood. 1982 Aug;60(2):484-90. 
• Keating MJ, Smith TL, Gehan EA, McCredie KB, Bodey GP, Freireich EJ.A prognostic factor analysis for use in development of predictive models for response in adult acute leukemiaCancer. 1982 Aug 1;50(3):457-65. https://doi.org/10.1002/1097-0142(19820801)50:3%3C457::aid-cncr2820500313%3E3.0.co;2-k
• Smith TL, Gehan EA, Keating MJ, Freireich EJ.Prediction of remission in adult acute leukemia: development and testing of predictive models. Cancer. 1982 Aug 1;50(3):466-72.
• Stewart DJ, Keating MJ. Second malignancies in hairy cell leukemia (leukemic reticuloendotheliosis). Am J Hematol. 1982 Sep;13(2):167-9.
• Zander AR, Vellekoop L, Dicke KA, Keating MJ, McCredie KB, Legha SS, Spitzer G, Verma D, Bodey GP. High-dose AMSA and autologous bone marrow transplantation in relapsed acute leukemia. Cancer Treat Rep. 1982 Nov;66(11):1991-2.
• Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E, Freireich EJ.Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA. 1982 Nov 19;248(19):2481-6.

1983

• Barlogie B, Maddox AM, Johnston DA, Raber MN, Drewinko B, Keating MJ, Freireich EJ. Quantitative cytology in leukemia research. Blood Cells. 1983;9(1):35-55.
• Maddox AM, Keating MJ, Trujillo J, Cork A, Youness E, Ahearn MJ, McCredie KB, Freireich EJ. Philadelphia chromosome-positive adult acute leukemia with monosomy of chromosome number seven: a subgroup with poor response to therapyLeuk Res. 1983;7(4):509-22.
• Quesada JR, Keating MJ, Libshitz HI, Llamas L. Bone involvement in hairy cell leukemia. Am J Med. 1983 Feb;74(2):228-31.
• Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ. Phase II trial of mitoxantrone in refractory acute leukemia. Cancer Treat Rep. 1983 Apr;67(4):389-90.
• Dreizen S, McCredie KB, Keating MJ, Luna MA. Malignant gingival and skin “infiltrates” in adult leukemia. Oral Surg Oral Med Oral Pathol. 1983 Jun;55(6):572-9.
• Fainstein V, Bodey GP, Elting L, Bolivar R, Keating MJ, McCredie KB, Valdivieso M. A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patientsJ Antimicrob Chemother. 1983 Jul;12(Suppl A):101-10.
• Hug V, Keating M, McCredie K, Hester J, Bodey GP, Freireich EJ. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte countCancer. 1983 Sep 1;52(5):773-9.
• Fainstein V, Bodey GP, McCredie KB, Keating MJ, Estey EH, Bolivar R, Elting L. Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients. J Infect Dis. 1983 Oct;148(4):745-50.
• Talpaz M, Mavligit G, Keating M, Walters RS, Gutterman JU.Human leukocyte interferon to control thrombocytosis in chronic myelogenous leukemia. Ann Intern Med. 1983 Dec;99(6):789-92.

1984

• Plunkett W, Nowak B, Feun LG, Benjamin RS, Keating M, Freirich EJ.Modulation of arabinosyladenine metabolism by 2′-deoxycoformycin in the therapy of human acute leukemiaAdv Exp Med Biol. 1984;165 Pt B:345-50.
• Stewart DJ, Zhengang G, Lu K, Savaraj N, Feun LG, Luna M, Benjamin RS, Keating MJ, Loo TL.Human tissue distribution of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (NSC 141549, AMSA). Cancer Chemother Pharmacol. 1984;12(2):116-9.
• Lawson RD, Gentry LO, Bodey GP, Keating MJ, Smith TL.A randomized study of tobramycin plus ticarcillin, tobramycin plus cephalothin and ticarcillin, or tobramycin plus mezlocillin in the treatment of infection in neutropenic patients with malignancies.Am J Med Sci. 1984 Jan-Feb;287(1):16-23.
• Estey EH, Keating MJ, Smith TL, McCredie KB, Legha SS, Walters RS, Bodey GP, Freireich EJ.Prediction of complete remission in patients with refractory acute leukemia treated with AMSA. J Clin Oncol. 1984 Feb;2(2):102-6.
• Davis FM, Hittelman WN, McCredie KB, Keating MJ, Vellekoop L, Rao PN. Human malignancy-associated nucleolar antigen as a marker for tumor cells in patients with acute leukemia.Blood. 1984 Mar;63(3):676-83.
• Valdivieso M, Cabanillas F, Keating M, Barkley HT, Murphy WK, Burgess MA, Frazier H, Chen T, Bodey GP. Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic unitsAm J Med. 1984 Mar;76(3):405-12.
• Stewart DJ, Smith TL, Keating MJ, McCredie KB, Hersh EM, Quesada J, Freireich EJ.Prognostic factors in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer. 1984 Mar 1;53(5):1198-1201.
• Maddox AM, Johnston DA, Barlogie B, Haq M, Keating MJ, Freireich EJ.In vitro suppression of DNA synthesis by a remission induction agent and its correlation with response in adult acute leukemia.Eur J Cancer Clin Oncol. 1984 Apr;20(4):507-14.
• Dreizen S, McCredie KB, Keating MJ.Chemotherapy-associated oral hemorrhages in adults with acute leukemia. Oral Surg Oral Med Oral Pathol. 1984 May;57(5):494-8.
• Vellekoop L, Dicke KA, Zander AR, Spitzer G, Verma DS, Keating MJ, McCredie KB.Repeated high-dose cyclophosphamide, BCNU and VP-16-213 and autologous bone marrow transplantation in adult acute lymphocytic leukemia in first remission.Eur J Cancer Clin Oncol. 1984 May;20(5):593-9.
• Barlogie B, Johnston DA, Keating M, Spitzer G, Hittelman WN, Nishioki K, Freireich EJ. Evolution of oligoleukemia. Cancer. 1984 May 15;53(10):2115-24.
• Estey E, Maksymiuk A, Smith T, Fainstein V, Keating M, McCredie KB, Freireich EJ, Bodey GP. Infection prophylaxis in acute leukemia.Comparative effectiveness of sulfamethoxazole and trimethoprim, ketoconazole, and a combination of the two.Arch Intern Med. 1984 Aug;144(8):1562-8.
• Fainstein V, Bodey GP, Bolivar R, Elting L, McCredie KB, Keating MJ.Moxalactam plus ticarcillin or tobramycin for treatment of febrile episodes in neutropenic cancer patients. Arch Intern Med. 1984 Sep;144(9):1766-70.
• Jadeja L, Bolivar R, Fainstein V, Keating M, McCredie K, Hay M, Bodey GP.Piperacillin plus vancomycin in the therapy of febrile episodes in cancer patients. Antimicrob Agents Chemother. 1984 Sep;26(3):295-9.
• Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP. Phase I clinical investigation of homoharringtonine. Cancer Treat Rep. 1984 Sep;68(9):1085-91.
• Hittelman WN, Menegaz SD, McCredie KB, Keating MJ. Premature chromosome condensation studies in human leukemia: 5. Prediction of early relapse. Blood. 1984 Nov;64(5):1067-73.
• Blick M, Westin E, Gutterman J, Wong-Staal F, Gallo R, McCredie K, Keating M, Murphy E.Oncogene expression in human leukemia. Blood. 1984 Dec;64(6):1234-9.
• Freireich EJ, Keating M, Cabanillas F, Barlogie B.The hematologic malignancies. Leukemia, lymphoma, and myeloma. Cancer. 1984 Dec 1;54(11 Suppl):2741-50.

1985

• Maddox AM, Keating MJ, McCredie KE, Estey E, Freireich EJ.Phase I evaluation of intravenous difluoromethylornithine–a polyamine inhibitor. Invest New Drugs. 1985;3(3):287-92.
• McCredie KB, Kantarjian H, Keating MJ, Hester JP, Freireich EJ.New approaches to the treatment of chronic myelogenous leukemia. Haematol Blood Transfus. 1985;29:51-2.
• Kantarjian HM, Vellekoop L, McCredie KB, Keating MJ, Hester J, Smith T, Barlogie B, Trujillo J, Freireich EJ.Intensive combination chemotherapy (ROAP 10) and splenectomy in the management of chronic myelogenous leukemia.J Clin Oncol. 1985 Feb;3(2):192-200.
• Bodey GP, Keating MJ, McCredie KB, Elting L, Rosenbaum B, Freireich EJ.Prospective randomized trial 18 of antibiotic prophylaxis in acute leukemia. Am J Med. 1985 Mar;78(3):407-16.
• Lopez-Berestein G, Fainstein V, Hopfer R, Mehta K, Sullivan MP, Keating M, Rosenblum MG, Mehta R, Luna M, Hersh EM.Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary studyJ Infect Dis. 1985 Apr;151(4):704-10.
• Dreizen S, Bodey GP, McCredie KB, Keating MJ. Orofacial aspergillosis in acute leukemia. Oral Surg Oral Med Oral Pathol. 1985 May;59(5):499-504.
• Holmes R, Keating MJ, Cork A, Broach Y, Trujillo J, Dalton WT, McCredie KB, Freireich EJ.A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22).Blood. 1985 May;65(5):1071-8.
• Kantarjian HM, Keating MJ, McCredie KB, Beran M, Walters R, Dalton WT, Hittleman W, Freireich EJ.A characteristic pattern of leukemic cell differentiation without cytoreduction during remission induction in acute promyelocytic leukemia.J Clin Oncol. 1985 Jun;3(6):793-8.
• Maddox AM, Johnston DA, Barlogie B, Youness E, Keating M, Freireich EJ.DNA-RNA measurements in patients with acute leukemia undergoing remission induction therapy. J Clin Oncol. 1985 Jun;3(6):799-808.
• Plunkett W, Iacoboni S, Estey E, Danhauser L, Liliemark JO, Keating MJ. Pharmacologically directed ara-C therapy for refractory leukemia. Semin Oncol. 1985 Jun;12(2 Suppl 3):20-30.
• Keating MJ, Estey E, Plunkett W, Iacoboni S, Walters R, Kantarjian H, Andersson B, Beran M, McCredie KB, Freireich EJ. Evolution of clinical studies with high-dose cytosine arabinoside at the M.D. Anderson Hospital. Semin Oncol. 1985 Jun;12(2 Suppl 3):98-104.
• Holmes RI, Keating MJ, Cork A, Trujillo JM, McCredie KB, Freireich EJ.Loss of the Y chromosome in acute 19 myelogenous leukemia: a report of 13 patients. Cancer Genet Cytogenet. 1985 Jul;17(3):269-78.
• Kantarjian HM, Barlogie B, Pershouse M, Swartzendruber D, Keating MJ, McCredie KB, Freireich EJ.Preferential expression of double-stranded ribonucleic acid in tumor versus normal cells: biological and clinical implications.Blood. 1985 Jul;66(1):39-46.
• Kantarjian HM, Barlogie B, Keating MJ, Hall RR, Smith TL, McCredie KB, Freireich EJ.Pretreatment of cytokinetics in acute myelogenous leukemia. Age-related prognostic implications. J Clin Invest. 1985 Jul;76(1):319-24.
• Stewart DJ, Smith TL, Keating MJ, Maor M, Leavens M, Hurtubise M, McCredie KB, Bodey GP, Freireich EJ. Remission from central nervous system involvement in adults with acute leukemia. Effect of intensive therapy and prognostic factors.Cancer. 1985 Aug 1;56(3):632-41.
• Talpaz M, Trujillo JM, Hittelman WN, Keating MJ, Gutterman JU. Suppression of clonal evolution in two chronic myelogenous leukaemia patients treated with leucocyte interferon.Br J Haematol. 1985 Aug;60(4):619-24.
• Zander AR, Dicke KA, Keating M, Vellekoop L, Culbert S, Spitzer G, Kanojia M, Jagannath S, Schell S, Hester J. Allogeneic bone marrow transplantation for acute leukemia refractory to induction chemotherapy. Cancer. 1985 Sep 15;56(6):1374-9.
• Andersson BS, Cogan BM, Keating MJ, Estey EH, McCredie KB, Freireich EJ.Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemia. Cancer. 1985 Nov 1;56(9):2181-4.
• Kantarjian HM, Smith TL, McCredie KB, Keating MJ, Walters RS, Talpaz M, Hester JP, Bligham G, Gehan E, Freireich EJ.Chronic myelogenous leukemia: a multivariate analysis of the associations of patient characteristics and therapy with survivalBlood. 1985 Dec;66(6):1326-35.

1986

• Danhauser L, Plunkett W, Keating M, Cabanillas F. 9-beta-D-arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.Cancer Chemother Pharmacol. 1986;18(2):145-52.
• Maddox AM, Keating MJ, Smith TL, Speer J, Cork MA, Trujillo JM, McCredie KB, Freireich EJ. Prognostic factors for survival of 194 patients with low infiltrate leukemia. Leuk Res. 1986;10(8):995-1006.
• Plunkett W, Iacoboni S, Keating MJ.Cellular pharmacology and optimal therapeutic concentrations of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate in leukemic blasts during treatment of refractory leukemia with high-dose 1-beta-D-arabinofuranosylcytosine.Scand J Haematol Suppl. 1986;44:51-9.
• Plunkett W, Keating M.Effect of m-AMSA on the cellular pharmacology of ara-CTP in human leukemic cells during therapy with high-dose ara-CAdv Exp Med Biol. 1986;195 Pt B:171-5.
• Dreizen S, McCredie KB, Bodey GP, Keating MJ.Unusual mucocutaneous infections in immunosuppressed patients with leukemia–expansion of an earlier study.Postgrad Med. 1986 Mar;79(4):287-94.
• Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MJ, Gutterman JU. Hematologic remission and cytogenetic improvement induced by recombinant human interferon alpha A in chronic myelogenous leukemiaN Engl J Med. 1986 Apr 24;314(17):1065-9.
• Kantarjian HM, Keating MJ, Walters RS, Estey EH, McCredie KB, Smith TL, Dalton WT, Cork A, Trujillo JM, Freireich EJ. Acute promyelocytic leukemia. M.D. Anderson Hospital experience. Am J Med. 1986 May;80(5):789-97.
• Ho DH, Brown NS, Yen A, Holmes R, Keating M, Abuchowski A, Newman RA, Krakoff IH.Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos. 1986 May-Jun;14(3):349-52.
• Dreizen S, McCredie KB, Bodey GP, Keating MJ.Microbial mucocutaneous infections in acute adult leukemia. Results of an 18-year inpatient study. Postgrad Med. 1986 Jun;79(8):107-18.
• Iacoboni SJ, Plunkett W, Kantarjian HM, Estey E, Keating MJ, McCredie KB, Freireich EJ. High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis.J Clin Oncol. 1986 Jul;4(7):1079-88.
• Vellekoop L, Jagannath S, Spitzer G, Zander AR, Horwitz LJ, Keating M, McCredie KB, Dicke KA. High-dose cyclophosphamide, BCNU, and etoposide followed by autologous bone marrow rescue as treatment for adult acute leukemia in relapse.Am J Clin Oncol. 1986 Aug;9(4):307-10.
• Quesada JR, Hersh EM, Manning J, Reuben J, Keating M, Schnipper E, Itri L, Gutterman JU. Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood. 1986 Aug;68(2):493-7.
• Kantarjian HM, Keating MJ, Walters RS, Beran M, McLaughlin P, McCredie KB, Freireich EJ.The association of specific “favorable” cytogenetic abnormalities with secondary leukemia. Cancer. 1986 Aug 15;58(4):924-7.
• Kantarjian HM, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ. Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med. 1986 Sep;81(3):387-94.
• Talpaz M, McCredie K, Kantarjian H, Trujillo J, Keating M, Gutterman J. Chronic myelogenous leukaemia: haematological remissions with alpha interferon. Br J Haematol. 1986 Sep;64(1):87-95.
• Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Bodey GP, Freireich EJ.Early intensification and short-term maintenance chemotherapy does not prolong survival in acute myelogenous leukemia.Cancer. 1986 Oct 15;58(8):1603-8.
• Ventura GJ, Keating MJ, Castellanos AM, Glass JP.Reversible bilateral lateral rectus muscle palsy associated with high-dose cytosine arabinoside and mitoxantrone therapyCancer. 1986 Oct 15;58(8):1633-5.
• Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Smith TL, Talpaz M, Beran M, Cork A, Trujillo JM, Freireich EJ. Clinical and prognostic features of Philadelphia chromosome-negative chronic myelogenous leukemia.Cancer. 1986 Nov 1;58(9):2023-30.
• Dreizen S, McCredie KB, Bodey GP, Keating MJ.Quantitative analysis of the oral complications of antileukemia chemotherapy. Oral Surg Oral Med Oral Pathol. 1986 Dec;62(6):650-3.
• Kantarjian HM, Keating MJ, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ.Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features. J Clin Oncol. 1986 Dec;4(12):1748-57.

1987

• Lee MS, Chang KS, Trujillo JM, McCredie KB, Keating MJ, Freireich EJ, Stass SA. T-cell receptor gamma chain gene rearrangement in acute myelogenous leukemia–evidence for lymphoid lineage prematurity. Hematol Pathol. 1987;1(2):93-8.
• Dalton WT, Ahearn MJ, Cork A, Trujillo JM, Keating MJ, McCredie KB, Freireich EJ, Stass SA. Acute myelomonocytic leukemia associated with abnormalities of chromosome 16: a light and electron microscopic study. Hematol Pathol. 1987;1(2):105-12.
• Ventura GJ, Drewinko B, Keating MJ. Correlative patterns of neutrophil and platelet counts during very early remission of acute myeloblastic leukemia. Hematol Pathol. 1987;1(2):113-6.
• Kantarjian HM, Keating MJ. The eosinophilic variant of acute myelomonocytic leukemia developing as a secondary leukemia in a patient with mycosis fungoides. Hematol Pathol. 1987;1(3):191-2.
• Estey EH, Keating MJ, Dixon DO, Trujillo JM, McCredie KB, Freireich EJ. Karyotype is prognostically more important than the FAB system’s distinction between myelodysplastic syndrome and acute myelogenous leukemia. Hematol Pathol. 1987;1(4):203-8.
• Kantarjian HM, Talpaz M, Kurzrock R, Keating MJ, McCredie KB, Gutterman J, Freireich EJ.Intensive combination chemotherapy and interferons in the management of chronic myelogenous leukemia. Acta Haematol. 1987;78(Suppl 1):70-4.
• Keating MJ, Estey E, Kantarjian HM, Walters R, Smith T, McCredie KB, Freireich EJ.Comparison of results of salvage therapy in adult acute myelogenous leukemia. Acta Haematol. 1987;78(Suppl 1):120-6.
• Keating MJ, Cork A, Broach Y, Smith T, Walters RS, McCredie KB, Trujillo J, Freireich EJ.Toward a clinically relevant cytogenetic classification of acute myelogenous leukemia. Leuk Res. 1987;11(2):119-33.
• Lotzová E, Savary CA, Herberman RB, McCredie KB, Keating MJ, Freireich EJ. Augmentation of antileukemia lytic activity by OKT3 monoclonal antibody: synergism of OKT3 and interleukin-2. Nat Immun Cell Growth Regul. 1987;6(5):219-23.
• Dreizen S, McCredie KB, Keating MJ. Mucocutaneous granulocytic sarcomas of the head and neck. J Oral Pathol. 1987 Feb;16(2):57-60.
• Dreizen S, McCredie KB, Bodey GP, Keating MJ.Necrotizing dermatitis in patients receiving cancer chemotherapy. Postgrad Med. 1987 Mar;81(4):263-71.
• Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M.Prognosis of chronic lymphocytic leukemia: a multivariate regression analysis of 325 untreated patients. Blood. 1987 Mar;69(3):929-36.
• Maxwell SA, Kurzrock R, Parsons SJ, Talpaz M, Gallick GE, Kloetzer WS, Arlinghaus RB, Kouttab NM, Keating MJ, Gutterman JU.Analysis of P210bcr-abl tyrosine protein kinase activity in various subtypes of Philadelphia chromosome-positive cells from chronic myelogenous leukemia patients. Cancer Res. 1987 Mar 15;47(6):1731-9.
• Glass JP, Van Tassel P, Keating MJ, Cork A, Trujillo J, Holmes R.Central nervous system complications of a newly recognized subtype of leukemia: AMML with a pericentric inversion of chromosome 16.Neurology. 1987 Apr;37(4):639-44.
• Kantarjian HM, Keating MJ, Walters RS, Smith TL, McCredie KB, Freireich EJ.Role of maintenance chemotherapy in acute promyelocytic leukemia. Cancer. 1987 Apr 1;59(7):1258-63.
• Keating MJ, Gehan EA, Smith TL, Estey EH, Walters RS, Kantarjian HM, McCredie KB, Freireich EJ. A strategy for evaluation of new treatments in untreated patients: application to a clinical trial of AMSA for acute leukemia.J Clin Oncol. 1987 May;5(5):710-21.
• Plunkett W, Nowak B, Keating MJ. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy. Cancer Treat Rep. 1987 May;71(5):479-83.
• Talpaz M, Kantarjian HM, McCredie KB, Keating MJ, Trujillo J, Gutterman J.Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood. 1987 May;69(5):1280-8.
• Dekmezian R, Kantarjian HM, Keating MJ, Talpaz M, McCredie KB, Freireich EJ.The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987 May 15;59(10):1739-43.
• Estey E, Keating MJ, Plunkett W, McCredie KB, Freireich EJ. Continuous infusion high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia. Semin Oncol. 1987 Jun;14(2 Suppl 1):58-63.
• Plunkett W, Liliemark JO, Estey E, Keating MJ. Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol. 1987 Jun;14(2 Suppl 1):159-66.
• Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H, Keating MJ.Saturation of 1-beta-D-arabinofuranosylcytosine 5′-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res. 1987 Jun 1;47(11):3005-11.
• Walters RS, Kantarjian HM, Keating MJ, Estey EH, McCredie KB, Freireich EJ.Intensive treatment of acute leukemia in adults 70 years of age and older. Cancer. 1987 Jul 15;60(2):149-55.
• Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med. 1987 Sep;83(3):445-54.
• Dreizen S, McCredie KB, Bodey GP, Keating MJ. External expressions of internal malignancy. Postgrad Med. 1987 Oct;82(5):91-7, 100.
• Kantarjian HM, Keating MJ, McCredie KB, Walters R, Talpaz M, Smith TL, Freireich EJ. Old age: a sign of poor prognosis in patients with chronic myelogenous leukemia. South Med J. 1987 Oct;80(10):1228-32.
• Walters RS, Kantarjian HM, Keating MJ, Talpaz M, Childs CC, McCredie KB, Freireich EJ. Therapy of lymphoid and undifferentiated chronic myelogenous leukemia in blast crisis with continuous vincristine and adriamycin infusions plus high-dose decadron.Cancer. 1987 Oct 15;60(8):1708-12.
• Estey EH, Keating MJ, McCredie KB, Freireich EJ. Continuous-infusion amsacrine in patients with refractory acute myelogenous leukemia. Cancer Treat Rep. 1987 Nov;71(11):1113-4.
• Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol. 1987 Dec;14(4):435-43.

1988

• Keating MJ, Kantarjian H, Talpaz M, Redman J, McCredie KB. Fludarabine therapy in chronic lymphocytic leukemia (CLL). Nouv Rev Fr Hematol. 1988;30(5-6):461-6.
• Maddox AM, Keating MJ, Freireich EJ, Haddox MK. Polyamines increase in human peripheral blood and bone marrow mononuclear cells following administration of methylglyoxal bis(guanylhydrazone). Chemotherapy. 1988;34(5):419-29. 
• Ventura GJ, Hester JP, Smith TL, Keating MJ. Acute myeloblastic leukemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol. 1988 Jan;27(1):34-7. 
• Kantarjian HM, Keating MJ, Walters RS, McCredie KB, Freireich EJ. The characteristics and outcome of patients with late relapse acute myelogenous leukemia. J Clin Oncol. 1988 Feb;6(2):232-8. 
• Keating MJ, Scouros M, Murphy S, Kantarjian H, Hester J, McCredie KB, Hersh EM, Freireich EJ. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia. 1988 Mar;2(3):157-64.
• Maddox AM, Freireich EJ, Keating MJ, Haddox MK. Alterations in bone marrow and blood mononuclear cell polyamine and methylglyoxal bis(guanylhydrazone) levels: phase I evaluation of alpha-difluoromethylornithine and methylglyoxal bis(guanylhydrazone) treatment of human hematological malignancies. Cancer Res. 1988 Mar 1;48(5):1367-73. 
• Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988 Apr 1;61(7):1441-6. 
• Maddox AM, Freireich EJ, Keating MJ, Frasier-Scott KF, Haddox MK. Alterations in human circulating and bone marrow mononuclear cell polyamine levels in hematologic malignancies as a consequence of difluoromethylornithine administration. Invest New Drugs. 1988 Jun;6(2):125-34. 
• Keating MJ, Smith TL, Kantarjian H, Cork A, Walters R, Trujillo JM, McCredie KB, Gehan EA, Freireich EJ. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome. Leukemia. 1988 Jul;2(7):403-12.
• Beran M, McCredie KB, Keating MJ, Gutterman JU. Antileukemic effect of recombinant tumor necrosis factor alpha in vitro and its modulation by alpha and gamma interferons. Blood. 1988 Aug;72(2):728-38. 
• Dreizen S, McCredie KB, Bodey GP, Keating MJ. Mucocutaneous herpetic infections during cancer chemotherapy. Postgrad Med. 1988 Aug;84(2):181-4, 187-90. 
• Kantarjian HM, Walters RS, Keating MJ, Talpaz M, Andersson B, Beran M, McCredie KB, Freireich EJ. Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer. 1988 Aug 15;62(4):672-6. 
• Walters RS, Kantarjian HM, Keating MJ, Plunkett WK, Estey EH, Andersson B, Beran M, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia. Cancer. 1988 Aug 15;62(4):677-82. 
• Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988 Nov;29(3):152-63. 
• Kantarjian HM, Walters RS, Smith TL, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Identification of risk groups for development of central nervous system leukemia in adults with acute lymphocytic leukemia. Blood. 1988 Nov;72(5):1784-9. 

1989

• Maddox AM, Johnson DA, Keating MJ. 5-bromodeoxyuridine (BUdR) quenching of acridine orange fluorescence distinguishes cycling and non-cycling normal and malignant bone marrow cells in vitro. Leuk Res. 1989;13(9):781-90. 
• Vadhan-Raj S, Hittelman WN, Broxmeyer HE, Keating M, Urdal D, Gutterman JU. In vivo biologic activities of recombinant human granulocyte-macrophage colony-stimulating factor. Ann N Y Acad Sci. 1989;554:231-40. 
• Ventura GJ, Hester JP, Dixon DO, Khorana S, Keating MJ. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematol Pathol. 1989;3(1):23-8.
• Horwitz LJ, Kantarjian HM, Jagannath S, Keating MJ, McCredie KB, Spitzer G, Vellekoop L, Zander AR, Dicke KA. Piperazinedione plus total body irradiation: an alternative preparative regimen for allogeneic bone marrow transplantation in advanced phases of chronic myelogenous leukemia. Bone Marrow Transplant. 1989 Jan;4(1):101-5.
• Dreizen S, McCredie KB, Keating MJ, Andersson BS, Schachner JR. Leukemia-associated skin infiltrates. Postgrad Med. 1989 Feb 1;85(2):45-50, 53. 
• Kantarjian HM, Keating MJ, Walters RS, Koller CA, McCredie KB, Freireich EJ. Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia. Cancer. 1989 Mar 1;63(5):813-7. 
• Estey E, Smith TL, Keating MJ, McCredie KB, Gehan EA, Freireich EJ. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia. 1989 Apr;3(4):257-63.
• Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Oken MM, Schiffer CA, Keating MJ, Boldt DH, Kempin SJ, Foon KA. Chronic lymphocytic leukemia: recommendations. Ann Intern Med. 1989 Apr 15;110(8):664-5. 
• Heinemann V, Estey E, Keating MJ, Plunkett W. Patient-specific dose rate for continuous infusion high-dose cytarabine in relapsed acute myelogenous leukemia. J Clin Oncol. 1989 May;7(5):622-8. https://doi.org/10.1200/JCO.1989.7.5.622
• Dreizen S, McCredie KB, Keating MJ, Bodey GP. Intertriginous infections in adults receiving antileukemia chemotherapy. Postgrad Med. 1989 Jun;85(8):223-30. 
• Kantarjian HM, Walters RS, Keating MJ, Barlogie B, McCredie KB, Freireich EJ. Experience with vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy in adults with refractory acute lymphocytic leukemia. Cancer. 1989 Jul 1;64(1):16-22. 
• Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood. 1989 Jul;74(1):19-25. 
• Maddox AM, Keating MJ, Freireich EJ, Haddox MK. Mononuclear cell polyamine content associated with myeloid maturation in patients with leukemia during administration of polyamine inhibitors. Invest New Drugs. 1989 Jul;7(2-3):119-29. 
• Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B, Beran M, McCredie KB, Freireich EJ. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989 Aug;7(8):1071-80. 
• Crane MM, Keating MJ, Trujillo JM, Labarthe DR, Frankowski RF. Environmental exposures in cytogenetically defined subsets of acute nonlymphocytic leukemia. JAMA. 1989 Aug 4;262(5):634-9. 
• Gandhi V, Nowak B, Keating MJ, Plunkett W. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood. 1989 Nov 1;74(6):2070-5. 
• Gagnon GA, Childs CC, LeMaistre A, Keating M, Cork A, Trujillo JM, Nellis K, Freireich E, Stass SA. Molecular heterogeneity in acute leukemia lineage switch. Blood. 1989 Nov 1;74(6):2088-95. 

1990

• Keating MJ, Hester JP, McCredie KB, Burgess MA, Murphy WK, Freireich EJ. Long-Term Results of CAP Therapy in Chronic Lymphocytic Leukemia. Leuk Lymphoma. 1990;2(6):391-7. 
• Keating MJ, Kantarjian H, Estey E, Plunkett W, Trujillo J, McCredie KB. Karyotype of leukemia cells consistently predicts for response to therapy and survival following salvage therapy in acute myeloblastic leukemia. Haematol Blood Transfus. 1990;33:593-603. 
• Plunkett W, Heinemann V, Estey E, Keating M. Pharmacologically directed design of leukemia therapy. Haematol Blood Transfus. 1990;33:610-3. 
• Estey EH, Kantarjian HM, Beran M, McCredie KB, Keating MJ, Deisseroth A, Gutterman JU. Treatment of poor-prognosis, newly diagnosed acute myelogenous leukemia with high-dose cytosine arabinoside (Ara-C) and rHUGM-CSF. Haematol Blood Transfus. 1990;33:732-6. 
• Dreizen S, McCredie KB, Keating MJ, Andersson BS. Nutritional deficiencies in patients receiving cancer chemotherapy. Postgrad Med. 1990 Jan;87(1):163-7, 170. 
• Kantarjian HM, Keating MJ, Smith TL, Talpaz M, McCredie KB. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am J Med. 1990 Jan;88(1):1-8. 
• Kantarjian HM, Walters RL, Keating MJ, Estey EH, O’Brien S, Schachner J, McCredie KB, Freireich EJ. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia. Cancer. 1990 Jan 1;65(1):5-8. 
• Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W. Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia. 1990 Feb;4(2):95-9.
• Vadhan-Raj S, Velasquez WS, Butler JJ, LeMaistre A, Lepe-Zuniga J, Keating MJ, Koller CA, Gutterman JU. Stimulation of myelopoiesis in chronic lymphocytic leukemia and in other lymphoproliferative disorders by recombinant human granulocyte-macrophage colony-stimulating factor. Am J Hematol. 1990 Mar;33(3):189-97. 
• Andersson BS, Luna MA, Yee C, Hui KK, Keating MJ, McCredie KB. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer. 1990 Mar 1;65(5):1079-84. 
• Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990 May;8(5):813-9. 
• Estey EH, Dixon D, Kantarjian HM, Keating MJ, McCredie K, Bodey GP, Kurzrock R, Talpaz M, Freireich EJ, Deisseroth AB. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor. Blood. 1990 May 1;75(9):1766-9. 
• Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ. Fludarabine therapy in macroglobulinemic lymphoma. Blood. 1990 May 15;75(10):1928-31. 
• Kantarjian HM, Walters RS, Keating MJ, Smith TL, O’Brien S, Estey EH, Huh YO, Spinolo J, Dicke K, Barlogie B. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990 Jun;8(6):994-1004. 
• Keating MJ, Dana WJ. Formulary decision making in a specialty hospital: effective management of potent and costly drug therapies. Hosp Formul. 1990 Jun;25(6):639-44.
• Spitz MR, Fueger JJ, Newell GR, Keating MJ. Leukemia and cigarette smoking. Cancer Causes Control. 1990 Sep;1(2):195-6. 
• Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia. Semin Oncol. 1990 Oct;17(5 Suppl 8):49-62.
• Kantarjian HM, Redman JR, Keating MJ. Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol. 1990 Oct;17(5 Suppl 8):66-70.
• Walters R, Kantarjian HM, Keating MJ, Estey EH, Trujillo J, Cork A, McCredie KB, Freireich EJ. The importance of cytogenetic studies in adult acute lymphocytic leukemia. Am J Med. 1990 Nov;89(5):579-87. 
• Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (Gemcitabine) administration in leukemia. Cancer Res. 1990 Nov 1;50(21):6823-6. 

1991

• Keating MJ, Kantarjian H, O’Brien S, Robertson L, Huh Y. New Agents and Strategies in CLL Treatment. Leuk Lymphoma. 1991;5(Suppl 1):139-42. 
• Dreizen S, Menkin DJ, Keating MJ, McCredie KB, O’Neill PA. Effect of antileukemia chemotherapy on marrow, blood, and oral granulocyte counts. Oral Surg Oral Med Oral Pathol. 1991 Jan;71(1):45-9. 
• Keating MJ, Kantarjian H, O’Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol. 1991 Jan;9(1):44-9. 
• Kantarjian HM, Childs C, O’Brien S, Huh Y, Beran M, Schachner J, Koller C, Keating MJ. Efficacy of fludarabine, a new adenine nucleoside analogue, in patients with prolymphocytic leukemia and the prolymphocytoid variant of chronic lymphocytic leukemia. Am J Med. 1991 Feb;90(2):223-8. 
• O’Brien S, Benvenuto JA, Estey E, Beran M, Felder TB, Keating M. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia. Cancer Res. 1991 Feb 1;51(3):935-8. 
• Estey EH, Kurzrock R, Talpaz M, McCredie KB, O’Brien S, Kantarjian HM, Keating MJ, Deisseroth AB, Gutterman JU. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes. Br J Haematol. 1991 Mar;77(3):291-5. 
• Kantarjian HM, Schachner J, Keating MJ. Fludarabine therapy in hairy cell leukemia. Cancer. 1991 Mar 1;67(5):1291-3.
• Crane MM, Keating MJ. Exposure histories in acute nonlymphocytic leukemia patients with a prior preleukemic condition. Cancer. 1991 Apr 15;67(8):2211-4. 
• Bodey G, Reuben A, Elting L, Kantarjian H, Keating M, Hagemeister F, Koller C, Velasquez W, Papadopoulos N. Comparison of two schedules of cefoperazone plus aztreonam in the treatment of neutropenic patients with fever. Eur J Clin Microbiol Infect Dis. 1991 Jul;10(7):551-8. 
• O’Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia. Cancer. 1991 Aug 15;68(4):691-4. 
• Kantarjian HM, Talpaz M, Keating MJ, Estey EH, O’Brien S, Beran M, McCredie KB, Gutterman J, Freireich EJ. Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 1991 Sep 15;68(6):1201-7. 
• Robertson LE, Keating MJ. Therapeutic approaches to chronic lymphocytic leukemia. Tex Med. 1991 Nov;87(11):68-74.
• Kantarjian HM, Talpaz M, Dhingra K, Estey E, Keating MJ, Ku S, Trujillo J, Huh Y, Stass S, Kurzrock R. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosomepositive acute leukemia. Blood. 1991 Nov 1;78(9):2411-8. 

1992

• Estey E, Trujillo JM, Cork A, O’Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes. Hematol Pathol. 1992;6(1):43-8.
• Keating MJ, Estey E, Kantarjian H, Plunkett W, O’Brien S, Koller C, Beran M, Freireich EJ. Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991. Leukemia. 1992;6(Suppl 2):78-80.
• Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med. 1992 Feb;152(2):283-91. 
• Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992 Feb 15;52(4):897-903. 
• Kantarjian HM, Estey EH, O’Brien S, Anaissie E, Beran M, Rios MB, Keating MJ, Gutterman J. Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. Blood. 1992 Feb 15;79(4):876-81. 
• Estey EH, Kurzrock R, Kantarjian HM, O’Brien SM, McCredie KB, Beran M, Koller C, Keating MJ, Hirsch-Ginsberg C, Huh YO. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood. 1992 Feb 15;79(4):882-7. 
• Kantarjian HM, Talpaz M, Kontoyiannis D, Gutterman J, Keating MJ, Estey EH, O’Brien S, Rios MB, Beran M, Deisseroth A. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol. 1992 Mar;10(3):398-405. 
• Crane MM, Godwin JE, Annegers JF, Keating MJ. Is histological subtype a marker for environmental exposures in acute myelogenous leukemia? Cancer Epidemiol Biomarkers Prev. 1992 Mar-Apr;1(3):183-8. 
• Dreizen S, Keating MJ, Beran M. Orofacial fungal infections. Nine pathogens that may invade during chemotherapy. Postgrad Med. 1992 Apr;91(5):349-50, 353-4, 357-60 passim. 
• Kantarjian HM, Keating MJ, Estey EH, O’Brien S, Pierce S, Beran M, Koller C, Feldman E, Talpaz M. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine. J Clin Oncol. 1992 May;10(5):772-8. 
• Redman JR, Cabanillas F, Velasquez WS, McLaughlin P, Hagemeister FB, Swan F, Rodriguez MA, Plunkett WK, Keating MJ. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma. J Clin Oncol. 1992 May;10(5):790-4. 
• Estey E, Thall PF, Kantarjian H, O’Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF. Blood. 1992 May 1;79(9):2246-55. 
• del Giglio A, O’Brien S, Ford R, Saya H, Manning J, Keating M, Johnston D, Khetan R, el-Naggar A, Deisseroth A. Prognostic value of proliferating cell nuclear antigen expression in chronic lymphoid leukemia. Blood. 1992 May 15;79(10):2717-20. 
• Freireich EJ, Cork A, Stass SA, McCredie KB, Keating MJ, Estey EH, Kantarjian HM, Trujillo JM. Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia. 1992 Jun;6(6):500-6.
• Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S, Kantarjian H, Keating MJ. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood. 1992 Jul 1;80(1):29-36. 
• Anaissie E, Kontoyiannis DP, Kantarjian H, Elting L, Robertson LE, Keating M. Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone. Ann Intern Med. 1992 Sep 15;117(6):466-9. 
• Keating MJ, O’Brien S, Robertson L, Plunkett W, Kantarjian H, Koller C. New drugs in the treatment of chronic lymphocytic leukemia. Leukemia. 1992 Nov;6(Suppl 4):140-1.
• Kantarjian HM, Smith T, Estey E, Polyzos A, O’Brien S, Pierce S, Beran M, Feldman E, Keating MJ. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med. 1992 Dec;93(6):599-604. 

1993

• Keating MJ. Chemotherapy in chronic lymphocytic leukemia. In Cheson B, Ed. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments. New York, NY: Marcel Dekker; 1993:297-336.
• Feldman EJ, Keating MJ. Fludarabine in the treatment of lymphoproliferative malignancies. Cancer Invest. 1993;11(3):314-8. 
• Robertson LE, Keating MJ. Fludarabine phosphate in the treatment of chronic lymphocytic leukemia: biology, clinical impact, and future directions. Cancer Treat Res. 1993;64:105-19. 
• Derderian PM, Kantarjian HM, Talpaz M, O’Brien S, Cork A, Estey E, Pierce S, Keating M. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis. Am J Med. 1993 Jan;94(1):69-74. 
• Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993 Jan;11(1):116-24. 
• Keating MJ. Chronic lymphoproliferative disorders: chronic lymphocytic leukemia and hairy-cell leukemia. Curr Opin Oncol. 1993 Jan;5(1):35-41.
• Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 1993 Feb;7(1):81-107. 
• Dimopoulos MA, Kantarjian H, Estey E, O’Brien S, Delasalle K, Keating MJ, Freireich EJ, Alexanian R. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med. 1993 Feb 1;118(3):195-8. 
• Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993 Mar;9(4-5):343-50. 
• Kantarjian HM, Beran M, Ellis A, Zwelling L, O’Brien S, Cazenave L, Koller C, Rios MB, Plunkett W, Keating MJ. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood. 1993 Mar 1;81(5):1146-51. 
• Keating MJ. Immunosuppression with purine analogues–the flip side of the gold coin. Ann Oncol. 1993 May;4(5):347-8. 
• Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W. High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma. 1993 May;10(1-2):43-8.
• Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma. 1993 May;10(1-2):49-56. 
• Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993;10 Suppl:109-14. 
• Estey EH, Plunkett W, Kantarjian H, Rios MB, Keating MJ. Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C. Leuk Lymphoma. 1993;10 Suppl:115-21. 
• Keating MJ, O’Brien S, Kantarjian H, Robertson LB, Koller C, Beran M, Estey E. Nucleoside analogs in treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 1993;10 Suppl:139-45. 
• Keating MJ, Holmes R, Lerner S, Ho DH. L-asparaginase and PEG asparaginase–past, present, and future. Leuk Lymphoma. 1993;10 Suppl:153-7. 
• Escudier SM, Pereira-Leahy JM, Drach JW, Weier HU, Goodacre AM, Cork MA, Trujillo JM, Keating MJ, Andreeff M. Fluorescent in situ hybridization and cytogenetic studies of trisomy 12 in chronic lymphocytic leukemia. Blood. 1993 May 15;81(10):2702-7. 
• Keating MJ, O’Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ. Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993 Jun 1;81(11):2878-84. 
• Kemena A, O’Brien S, Kantarjian H, Robertson L, Koller C, Beran M, Estey E, Plunkett W, Lerner S, Keating MJ. Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma. 1993 Jun;10(3):187-93. 
• Keating M. Response. Science. 1993 Jun 25;260(5116):1962. 
• Dimopoulos MA, O’Brien S, Kantarjian H, Pierce S, Delasalle K, Barlogie B, Alexanian R, Keating MJ. Fludarabine therapy in Waldenström’s macroglobulinemia. Am J Med. 1993 Jul;95(1):49-52. 
• Del Giglio A, O’Brien S, Ford RJ, Manning J, Saya H, Keating M, Johnston D, Chamone DF, Deisseroth AB. Proliferating cell nuclear antigen (PCNA) expression in chronic lymphocytic leukemia (CLL). Leuk Lymphoma. 1993 Jul;10(4-5):265-71.
• Di Raimondo F, Giustolisi R, Cacciola E, O’Brien S, Kantarjian H, Robertson LB, Keating MJ. Autoimmune hemolytic anemia in chronic lymphocytic leukemia patients treated with fludarabine. Leuk Lymphoma. 1993 Sep;11(1-2):63-8. 
• Dimopoulos MA, O’Brien S, Kantarjian H, Estey EE, Keating MJ, Alexanian R. Treatment of Waldenstrom’s macroglobulinemia with nucleoside analogues. Leuk Lymphoma. 1993;11(Suppl 2):105-8. 
• Keating MJ, O’Brien S, Robertson L, Huh Y, Kantarjian H, Plunkett W. Chronic lymphocytic leukemia–correlation of response and survival. Leuk Lymphoma. 1993;11(Suppl 2):167-75. 
• O’Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response to treatment. Blood. 1993 Sep 15;82(6):1695-700. 
• Suki S, Kantarjian H, Gandhi V, Estey E, O’Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 1993 Oct 1;72(7):2155-60. 
• Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E, Keating MJ. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 1993 Oct;20(5 Suppl 7):2-12.
• Keating MJ, O’Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol. 1993 Oct;20(5 Suppl 7):13-20.
• Robertson LE, Pugh W, O’Brien S, Kantarjian H, Hirsch- Ginsberg C, Cork A, McLaughlin P, Cabanillas F, Keating MJ. Richter’s syndrome: a report on 39 patients. J Clin Oncol. 1993 Oct;11(10):1985-9. 
• Kantarjian HM, Estey E, O’Brien S, Anaissie E, Beran M, Pierce S, Robertson L, Keating MJ. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer. 1993 Nov 15;72(10):2950-5. 
• Estey EH, Kantarjian H, Keating M. Idarubicin plus continuous-infusion high-dose cytarabine as treatment for patients with acute myelogenous leukemia or myelodysplastic syndrome. Semin Oncol. 1993 Dec;20(6 Suppl 8):1-5.

1994

• Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994;34(1):30-6. 
• Keating MJ, Estey E, O’Brien S, Kantarjian H, Robertson LE, Plunkett W. Clinical experience with fludarabine in leukaemia. Drugs. 1994;47(Suppl 6):39-49. 
• Keating MJ, McLaughlin P, Plunkett W, Robertson LE, O’Brien S, Gandhi V, Gregoire V, Yang L, Cabanillas F. Fludarabine–present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol. 1994;5(Suppl 2):79-83. 
• Keating MJ, O’Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 1994;14(Suppl 2):11-6. https://doi.org/10.3109/10428199409052690
• Keating MJ, O’Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994 Jan;31(1):28-39.
• O’Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl J Med. 1994 Feb 3;330(5):319-22. 
• Dimopoulos MA, Weber DM, Kantarjian H, Keating M, Alexanian R. 2Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine. Ann Oncol. 1994 Mar;5(3):288-9. 
• Huh YO, Pugh WC, Kantarjian HM, Stass SA, Cork A, Trujillo JM, Keating MJ. Detection of subgroups of chronic B-cell leukemias by FMC7 monoclonal antibody. Am J Clin Pathol. 1994 Mar;101(3):283-9. 
• Mourad WA, Pugh WC, Huh YO, Keating MJ. Cell kinetic analysis of interleukin-2 receptor-tested chronic lymphocytic leukemia using the AgNOR silver stain. Am J Clin Pathol. 1994 Mar;101(3):300-4. 
• McLaughlin P, Hagemeister FB, Swan F, Cabanillas F, Pate O, Romaguera JE, Rodriguez MA, Redman JR, Keating M. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma. J Clin Oncol. 1994 Mar;12(3):575-9. 
• Keating MJ. Leukemia, whither goest thou? Mayo Clin Proc. 1994 Apr;69(4):397-8. 
• Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994 Apr;12(4):748-58. 
• Montserrat E, Binet JL, Dighiero G, Gale RP, Juliusson G, Keating M, Rai KR. Chronic lymphoproliferative disorders. Rev Invest Clin. 1994 Apr;Suppl:52-8.
• Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia. 1994 May;8(5):823-6.
• Cortes JE, Kantarjian H, O’Brien S, Robertson LE, Koller C, Hirsh-Ginsberg C, Stass S, Keating M, Estey E. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer. 1994 Jun 15;73(12):2946-52. 
• Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH. Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia. 1994 Aug;8(8):1269-74.
• O’Brien S, Kurzrock R, Duvic M, Kantarjian H, Stass S, Robertson LE, Estey E, Pierce S, Keating MJ. 2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. Blood. 1994 Aug 1;84(3):733-8. 
• Seymour JF, Khouri IF, Champlin RE, Keating MJ. Refractory chronic lymphocytic leukemia complicated by hypercalcemia treated with allogeneic bone marrow transplantation. Case report and review. Am J Clin Oncol. 1994 Aug;17(4):360-8. 
• Gale RP, Caligaris-Cappio F, Dighiero G, Keating M, Montserrat E, Rai K. Recent progress in chronic lymphocytic leukemia. International Workshop on chronic Lymphocytic Leukemia. Leukemia. 1994 Sep;8(9):1610-4.
• Kantarjian HM, O’Brien S, Smith T, Estey EH, Beran M, Preti A, Pierce S, Keating MJ. Acute lymphocytic leukaemia in the elderly: characteristics and outcome with the vincristine-adriamycin-dexamethasone (VAD) regimen. Br J Haematol. 1994 Sep;88(1):94-100. 
• Wright SJ, Robertson LE, O’Brien S, Plunkett W, Keating MJ. The role of fludarabine in hematological malignancies. Blood Rev. 1994 Sep;8(3):125-34. 
• Dimopoulos MA, Kantarjian H, Weber D, O’Brien S, Estey E, Delasalle K, Rose E, Cabanillas F, Keating M, Alexanian R. Primary therapy of Waldenström’s macroglobulinemia with 2-chlorodeoxyadenosine. J Clin Oncol. 1994 Dec;12(12):2694-8. 
• Robertson LE, Estey E, Kantarjian H, Koller C, O’Brien S, Brown B, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome in chronic lymphocytic leukemia. Leukemia. 1994 Dec;8(12):2047-51.
• Cortes J, O’Brien S, Kantarjian H, Cork A, Stass S, Freireich EJ, Keating M, Pierce S, Estey E. Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes. Leukemia. 1994 Dec;8(12):2174-8.

1995

• Cortes JE, Kantarjian H, O’Brien S, Keating M, Pierce S, Freireich EJ, Estey E. Clinical and prognostic significance of trisomy 21 in adult patients with acute myelogenous leukemia and myelodysplastic syndromes. Leukemia. 1995 Jan;9(1):115-7.
• Dimopoulos MA, Weber D, Delasalle KB, Keating M, Alexanian R. Treatment of Waldenstrom’s macroglobulinemia resistant to standard therapy with 2- chlorodeoxyadenosine: identification of prognostic factors. Ann Oncol. 1995 Jan;6(1):49-52.
• O’Brien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood. 1995 Jan 15;85(2):307-18. 
• Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colonystimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995 Feb;1(2):169-78. 
• Estey EH, Keating MJ. Post-remission chemotherapy for acute myeloid leukemia. N Engl J Med. 1995 Feb 2;332(5):334; author reply 334-5. 
• Bueso-Ramos CE, Manshouri T, Haidar MA, Huh YO, Keating MJ, Albitar M. Multiple patterns of MDM-2 deregulation in human leukemias: implications in leukemogenesis and prognosis. Leuk Lymphoma. 1995 Mar;17(1-2):13-8. 
• Estey EH, Kantarjian HM, O’Brien S, Kornblau S, Andreeff M, Beran M, Pierce S, Keating M. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF). Cytokines Mol Ther. 1995 Mar;1(1):21-8.
• Seymour JF, Keating MJ. Parathyroid hormone related protein in hypercalcaemia in CLL. Br J Haematol. 1995 Mar;89(3):685-6. 
• O’Brien S, Kantarjian H, Ellis A, Zwelling L, Estey E, Keating M. Topotecan in chronic lymphocytic leukemia. Cancer. 1995 Mar 1;75(5):1104-8. 
• Seymour JF, Estey EH, Keating MJ, Kurzrock R. Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2- chlorodeoxyadenosine. Leukemia. 1995 May;9(5):929-32.
• Yang LY, Li L, Keating MJ, Plunkett W. Arabinosyl-2-fluoroadenine augments cisplatin cytotoxicity and inhibits cisplatin-DNA cross-link repair. Mol Pharmacol. 1995 May;47(5):1072-9. 
• Robertson LE, O’Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Keating MJ. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Jun;9(6):943-5.
• Marlton P, Keating M, Kantarjian H, Pierce S, O’Brien S, Freireich EJ, Estey E. Cytogenetic and clinical correlates in AML patients with abnormalities of chromosome 16. Leukemia. 1995 Jun;9(6):965-71.
• Estey E, Keating MJ, Pierce S, Stass S. Change in karyotype between diagnosis and first relapse in acute myelogenous leukemia. Leukemia. 1995 Jun;9(6):972-6.
• Haidar MA, Cao XB, Manshouri T, Chan LL, Glassman A, Kantarjian HM, Keating MJ, Beran MS, Albitar M. p16INK4A and p15INK4B gene deletions in primary leukemias. Blood. 1995 Jul 1;86(1):311-5. 
• Seymour JF, Robertson LE, O’Brien S, Lerner S, Keating MJ. Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies. Leuk Lymphoma. 1995 Aug;18(5-6):493-6. 
• O’Brien S, Kantarjian H, Beran M, Robertson LE, Koller C, Lerner S, Keating MJ. Interferon maintenance therapy for patients with chronic lymphocytic leukemia in remission after fludarabine therapy. Blood. 1995 Aug 15;86(4):1298-300. 
• Robertson LE, O’Brien S, Kantarjian H, Koller C, Beran M, Andreeff M, Lerner S, Plunkett W, Keating MJ. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia. Leukemia. 1995 Sep;9(9):1444-9.
• Cortes J, O’Brien SM, Pierce S, Keating MJ, Freireich EJ, Kantarjian HM. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood. 1995 Sep 15;86(6):2091-7. 
• Verschraegen CF, Kantarjian HM, Hirsch-Ginsberg C, Lee MS, O’Brien S, Rios MB, Stass SA, Keating M, Talpaz M. The breakpoint cluster region site in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Clinical, laboratory, and prognostic correlations. Cancer. 1995 Sep 15;76(6):992-7. 
• O’Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood. 1995 Nov 1;86(9):3322-6. 
• Preti HA, Huh YO, O’Brien SM, Andreeff M, Pierce ST, Keating M, Kantarjian HM. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer. 1995 Nov 1;76(9):1564-70. 
• Wright SJ, Keating MJ. Cyclosporine A in chronic lymphocytic leukemia: dual anti-leukemic and immunosuppressive role? Leuk Lymphoma. 1995 Dec;20(1-2):131-6. 

1996

• O’Brien S, Kantarjian H, Keating MJ. Purine analogs in chronic lymphocytic leukemia and Waldenström’s macroglobulinemia. Ann Oncol. 1996;7(Suppl 6):S27-33. 
• McLaughlin P, Robertson LE, Keating MJ. Fludarabine phosphate in lymphoma: an important new therapeutic agent. Cancer Treat Res. 1996;85:3-14. 
• Robertson LE, Denny AW, Huh YO, Plunkett W, Keating MJ, Nelson JA. Natural killer cell activity in chronic lymphocytic leukemia patients treated with fludarabine. Cancer Chemother Pharmacol. 1996;37(5):445-50. 
• Pollicardo N, O’Brien S, Estey EH, al-Bitar M, Pierce S, Keating M, Kantarjian HM. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution. Leukemia. 1996 Jan;10(1):27-31.
• Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996 Jan 1;87(1):256-64. 
• O’Brien S, Jeha S, Kantarjian H, Pisa P, Jin G, Keating M, Beran M. Engraftment of chronic prolymphocytic and T cell leukemia in SCID mice. Leukemia. 1996 Feb;10(2):338-44.
• Kantarjian HM, Beran M, O’Brien S, Robertson L, Siddik Z, Yoshida M, Yang LY, Rios MB, Keating MJ, Meyer M. Evaluation of CI-973, a platinum analogue, in refractory or relapsed acute leukemia. Leukemia. 1996 Mar;10(3):396-401.
• Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996 Mar;10(3):456-9.
• Sarris A, Cortes J, Kantarjian H, Pierce S, Smith T, Keating M, Koller C, Kornblau S, O’Brien S, Andreeff M. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dl. Leuk Lymphoma. 1996 Mar;21(1-2):85-92. 
• Anderlini P, Luna M, Kantarjian HM, O’Brien S, Pierce S, Keating MJ, Estey EH. Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 1996 Apr;10(4):600-8.
• Gandhi V, Estey EH, Keating MJ, Plunkett W. Intracellular pharmacodynamics in leukemia therapy. Rinsho Ketsueki. 1996 May;37(5):369-79.
• Anderlini P, Ghaddar HM, Smith TL, Pierce S, Kantarjian HM, O’Brien S, Keating MJ, Freireich EJ, Estey EH. Factors predicting complete remission and subsequent disease-free survival after a second course of induction therapy in patients with acute myelogenous leukemia resistant to the first. Leukemia. 1996 Jun;10(6):964-9.
• Ghaddar HM, Pierce S, Kantarjian HM, Freireich EJ, Keating MJ, Estey EH. Amsacrine and continuous infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Leuk Lymphoma. 1996 Jun;22(1-2):71-6. 
• Marin MC, Fernandez A, Bick RJ, Brisbay S, Buja LM, Snuggs M, McConkey DJ, von Eschenbach AC, Keating MJ, McDonnell TJ. Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+. Oncogene. 1996 Jun 6;12(11):2259-66.
• Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O’Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15;87(12):4990-7. 
• Estey E, Kornblau S, Pierce S, Kantarjian H, Beran M, Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia. Blood. 1996 Jul 15;88(2):756. 
• Crane MM, Strom SS, Halabi S, Berman EL, Fueger JJ, Spitz MR, Keating MJ. Correlation between selected environmental exposures and karyotype in acute myelocytic leukemia. Cancer Epidemiol Biomarkers Prev. 1996 Aug;5(8):639-44. 
• Haidar MA, Loya F, Yang Y, Lin H, Glassman A, Keating MJ, Goldwasser E, Albitar M. Differential expression of lacZ in the liver and kidney of transgenic mice carrying chimeric lacZ-erythropoietin gene constructs with or without its 1.2 kb 3′-flanking sequence. Nucleic Acids Res. 1996 Sep 15;24(18):3621-8. 
• Keating M, Cheson B, Gribben JG, Robertson B, Nadler L. Innovative strategies for the treatment of CLL. Leuk Lymphoma. 1996 Oct;22(Suppl 2):53-64.
• Fayad L, Robertson LE, O’Brien S, Manning JT, Wright S, Hagemeister F, Cabanillas F, Keating MJ. Hodgkin’s disease variant of Richter’s syndrome: experience at a single institution. Leuk Lymphoma. 1996 Oct;23(3-4):333-7. 
• Beran M, Kantarjian H, O’Brien S, Koller C, al-Bitar M, Arbuck S, Pierce S, Moore M, Abbruzzese JL, Andreeff M, Keating M, Estey E. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 1996 Oct 1;88(7):2473-9. 
• Keating MJ, O’Brien S, McLaughlin P, Dimopoulos M, Gandhi V, Plunkett W, Lerner S, Kantarjian H, Estey E. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996 Dec;38(Suppl 2):S83-91.
• Wilhelm M, Kantarjian HM, O’Brien S, Pierce S, Keating MJ, Freireich EJ, Estey EH. Pneumonia during remission induction chemotherapy in patients with AML or MDS. Leukemia. 1996 Dec;10(12):1870-3.

1997

• Seymour JF, Cusack JD, Lerner SA, Pollock RE, Keating MJ. Case/control study of the role of splenectomy in chronic lymphocytic leukemia. J Clin Oncol. 1997 Jan;15(1):52-60. 
• Estey E, Thall PF, Pierce S, Kantarjian H, Keating M. Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol. 1997 Feb;15(2):483-90. 
• Haidar MA, El-Hajj H, Bueso-Ramos CE, Manshouri T, Glassman A, Keating MJ, Maher A. Expression profile of MDM-2 proteins in chronic lymphocytic leukemia and their clinical relevance. Am J Hematol. 1997 Mar;54(3):189-95. 
• Kantarjian HM, O’Brien SM, Estey E, Giralt S, Beran M, Rios MB, Keating M, de Vos D, Talpaz M. Decitabine studies in chronic and acute myelogenous leukemia. Leukemia. 1997 Mar;11 Suppl 1:S35-6.
• Manshouri T, Yang Y, Lin H, Stass SA, Glassman AB, Keating MJ, Albitar M. Downregulation of RARα in Mice by Antisense Transgene Leads to a Compensatory Increase in RARβ and RARγ and Development of Lymphoma. Blood. 1997 Apr 1;89(7):2507-15. 
• Li L, Liu X, Glassman AB, Keating MJ, Stros M, Plunkett W, Yang LY. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro. Cancer Res. 1997 Apr 15;57(8):1487-94. https://cancerres.aacrjournals.org/content/57/8/1487.long
• Fayad L, Kantarjian H, O’Brien S, Seong D, Albitar M, Keating M, Talpaz M. Emergence of new clonal abnormalities following interferon-alpha induced complete cytogenetic response in patients with chronic myeloid leukemia: report of three cases. Leukemia. 1997 May;11(5):767-71.
• Khouri IF, Przepiorka D, van Besien K, O’Brien S, Palmer JL, Lerner S, Mehra RC, Vriesendorp HM, Andersson BS, Giralt S, Körbling M, Keating MJ, Champlin RE. Allogeneic blood or marrow transplantation for chronic lymphocytic leukaemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease. Br J Haematol. 1997 May;97(2):466-73. 
• Kornblau SM, Estey E, Madden T, Tran HT, Zhao S, Consoli U, Snell V, Sanchez-Williams G, Kantarjian H, Keating M, Newman RA, Andreeff M. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol. 1997 May;15(5):1796-802. 
• Kurzrock R, Strom SS, Estey E, O’Brien S, Keating MJ, Jiang H, Adams T, Talpaz M. Second cancer risk in hairy cell leukemia: analysis of 350 patients. J Clin Oncol. 1997 May;15(5):1803-10. 
• Giralt S, Estey E, Albitar M, van Besien K, Rondón G, Anderlini P, O’Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Kørbling M, Keating M, Kantarjian H, Champlin R. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997 Jun 15;89(12):4531-6. 
• Cortes J, Kantarjian H, Talpaz M, O’Brien S, Beran M, Koller C, Keating M. Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine. Leukemia. 1997 Jun;11(6):788-91.
• Cortes J, Kantarjian H, O’Brien S, Beran M, Estey E, Keating M, Talpaz M. A pilot study of all-trans retinoic acid in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Leukemia. 1997 Jul;11(7):929-32.
• Iwasaki H, Huang P, Keating MJ, Plunkett W. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood. 1997 Jul 1;90(1):270-8. 
• Bseiso AW, Kantarjian HM, Guo JQ, Cortes J, Talpaz M, Koller C, AlBitar M, Keating M, Arlinghaus R. Analysis of the BCR-ABL protein in Philadelphia chromosome-positive adult acute lymphocytic leukemia. Leukemia. 1997 Sep;11(9):1583-7.
• Cusack JC, Seymour JF, Lerner S, Keating MJ, Pollock RE. Role of splenectomy in chronic lymphocytic leukemia. J Am Coll Surg. 1997 Sep;185(3):237-43. 
• Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997 Sep;3(9):1539-45. 
• Sacchi S, Kantarjian HM, O’Brien S, Beran M, Koller C, Pierce S, Kornblau S, Estey E, Keating MJ, Talpaz M. Long-term follow-up results of alpha-interferon-based regimens in patients with late chronic phase chronic myelogenous leukemia. Leukemia. 1997 Oct;11(10):1610-6. 
• Kantarjian HM, O’Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D, Talpaz M. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997 Oct;11(10):1617-20. 
• O’Brien S, Kantarjian H, Beran M, Koller C, Talpaz M, Lerner S, Keating MJ. Fludarabine and granulocyte colony-stimulating factor (G-CSF) in patients with chronic lymphocytic leukemia. Leukemia. 1997 Oct;11(10):1631-5. 
• Estey E, Thall P, Kantarjian H, Pierce S, Kornblau S, Keating M. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997 Oct;11(10):1661-4. 
• Estey E, Keating M, Pierce S, Beran M. Application of the International Scoring System for myelodysplasia to M.D. Anderson patients. Blood. 1997 Oct 1;90(7):2843-6. 
• Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood. 1997 Oct 15;90(8):2969-77. 
• Li L, Keating MJ, Plunkett W, Yang LY. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol Pharmacol. 1997 Nov;52(5):798-806. 
• Rodriguez CO, Legha JK, Estey E, Keating MJ, Gandhi V. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphate in primary human leukemia cells. Clin Cancer Res. 1997 Nov;3(11):2107-13. 
• Chandra J, Gilbreath J, Freireich EJ, Kliche KO, Andreeff M, Keating M, McConkey DJ. Protease activation is required for glucocorticoid-induced apoptosis in chronic lymphocytic leukemia lymphocytes. Blood. 1997 Nov 1;90(9):3673-81. 
• Beran M, Jeha S, O’Brien S, Estey E, Vitek L, Zurlo MG, Rios MB, Keating M, Kantarjian H. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study. Clin Cancer Res. 1997 Dec;3(12 Pt 1):2377-84. 
• Kantarjian HM, Talpaz M, O’Brien S, Kurzrock R, Gutterman J, Keating MJ, McCredie KB, Freireich EJ. Chronic myelogenous leukemia–progress at the M. D. Anderson Cancer Center over the past two decades and future directions: first Emil J Freireich Award Lecture. Clin Cancer Res. 1997 Dec;3(12 Pt 2):2723-33. 
• Keating MJ, McLaughlin P, Cabanillas F. Low-grade non-Hodgkin’s lymphoma–development of a new effective combination regimen (fludarabine, mitoxantrone and dexamethasone; FND). Eur J Cancer Care (Engl). 1997 Dec;6(4 Suppl):21-6. 
• Estey E, deLima M, Strom S, Pierce S, Freireich EJ, Keating MJ. Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M.D. Anderson Cancer Center. Cancer. 1997 Dec 1;80(11 Suppl):2176-80. 
• Freireich EJ, Keating MJ. Conclusions regarding leukemia long-term survival. Cancer. 1997 Dec 1;80(11 Suppl):2215-7. 
• de Lima M, Strom SS, Keating M, Kantarjian H, Pierce S, O’Brien S, Freireich E, Estey E. Implications of potential cure in acute myelogenous leukemia: development of subsequent cancer and return to work. Blood. 1997 Dec 15;90(12):4719-24. 

1998

• Munker R, Kantarjian H, O’Brien S, Keating M, Andreeff M, Estey EH. Phase I study of taxol in refractory acute myelogenous leukemias using a weekly schedule. Acta Haematol. 1998;99(2):106-8. 
• Kornblau SM, Kantarjian H, O’Brien S, Andreeff M, Koller CA, Beran M, Keating M, Estey E. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside–a new salvage regimen for relapsed or refractory acute myelogenous leukemia. Leuk Lymphoma. 1998 Jan;28(3-4):371-5. 
• Wilhelm M, Bueso-Ramos C, O’Brien S, Pierce S, Keating M, Talpaz M, Kantarjian HM. Effect of interferon-alpha therapy on bone marrow fibrosis in chronic myelogenous leukemia. Leukemia. 1998 Jan;12(1):65-70. 
• de Lima M, O’Brien S, Lerner S, Keating MJ. Chronic lymphocytic leukemia in the young patient. Semin Oncol. 1998 Feb;25(1):107-16.
• Giles FJ, O’Brien SM, Keating MJ. Chronic lymphocytic leukemia in (Richter’s) transformation. Semin Oncol. 1998 Feb;25(1):117-25.
• Khouri IF, Keating MJ. High-dose chemotherapy for chronic lymphocytic leukemia: eligibility, timing, and benefit? Ann Oncol. 1998 Feb;9(2):131-2. 
• DeLima M, Albitar M, O’Brien S, Pierce S, Kantarjian H, Andreeff M, Fayad L, Keating M, Estey E. Comparison of referring and tertiary cancer center physician’s diagnoses in patients with leukemia. Am J Med. 1998 Mar;104(3):246-51. 
• Sacchi S, Kantarjian HM, Smith TL, O’Brien S, Pierce S, Kornblau S, Beran M, Keating MJ, Talpaz M. Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia. J Clin Oncol. 1998 Mar;16(3):882-9. 
• Cortes J, Kantarjian H, O’Brien S, Kurzrock R, Keating M, Talpaz M. GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia. 1998 Jun;12(6):860-4. 
• Keating MJ. Chronic lymphocytic leukemia in the next decade: where do we go from here? Semin Hematol. 1998 Jul;35(3 Suppl 3):27-33.
• Khouri IF, Keating M, Körbling M, Przepiorka D, Anderlini P, O’Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998 Aug;16(8):2817-24. 
• Keating MJ, O’Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998 Aug 15;92(4):1165-71. 
• Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997 Sep;3(9):1539-45. 
• Anaissie EJ, Kontoyiannis DP, O’Brien S, Kantarjian H, Robertson L, Lerner S, Keating MJ. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med. 1998 Oct 1;129(7):559-66. 
• Starostik P, Manshouri T, O’Brien S, Freireich E, Kantarjian H, Haidar M, Lerner S, Keating M, Albitar M. Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res. 1998 Oct 15;58(20):4552-7. 
• Beran M, Estey E, O’Brien SM, Giles FJ, Koller CA, Kornblau S, Keating M, Kantarjian HM. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma. 1998 Nov;31(5-6):521-31. 
• Gandhi V, Plunkett W, Rodriguez CO, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998 Nov;16(11):3607-15. 
• Khouri IF, Keating MJ, Champlin R. Hematopoietic stem cell transplantation for chronic lymphocytic leukemia. Curr Opin Hematol. 1998 Nov;5(6):454-9. 
• Keating MJ. Leukemia: A model for drug development. Clin Cancer Res. 1997 Dec;3(12 Pt 2):2598-604. 
• Koller CA, Kantarjian HM, Thomas D, O’Brien S, Rios MB, Kornblau S, Murphy S, Keating M. The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia. 1997 Dec;11(12):2039-44. 
• Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood. 1998 Dec 1;92(11):4220-9. 

1999

• Cortes J, O’Brien S, Estey E, Giles F, Keating M, Kantarjian H. Phase I study of liposomal daunorubicin in patients with acute leukemia. Invest New Drugs. 1999;17(1):81-7. 
• Albitar M, Manshouri T, Kantarjian H, Keating M, Estrov Z, Faber J, Freireich EJ, Pierce S, Estey E. Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia. Leuk Res. 1999 Jan;23(1):63-9. 
• Kantarjian HM, O’Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon-alpha and low dose cytosine arabinoside. J Clin Oncol. 1999 Jan;17(1):284-92. 
• Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 1999 Jan 1;85(1):58-64. 
• Cortes JE, Kantarjian HM, O’Brien S, Giles F, Keating MJ, Freireich EJ, Estey EH. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer. 1999 Apr 1;85(7):1506-13. 
• Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood. 1999 Apr 15;93(8):2478-84. 
• Vey N, Keating M, Giles F, Cortes J, Beran M, Estey E. Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy. Blood. 1999 May 1;93(9):3149-50. 
• Estey EH, Thall PF, Reed P, Kantarjian H, Beran M, Pierce S, Keating MJ. Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy. Leukemia. 1999 Jun;13(6):850-4. 
• Dabaja BS, Faderl S, Thomas D, Cortes J, O’Brien S, Nasr F, Pierce S, Hayes K, Glassman A, Keating M, Kantarjian HM. Deletions and losses in chromosomes 5 or 7 in adult acute lymphocytic leukemia: incidence, associations and implications. Leukemia. 1999 Jun;13(6):869-72. 
• O’Brien S, Kantarjian H, Koller C, Feldman E, Beran M, Andreeff M, Giralt S, Cheson B, Keating M, Freireich E, Rios MB, Talpaz M. Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia. Blood. 1999 Jun 15;93(12):4149-53. 
• Kornblau SM, Thall PF, Estrov Z, Walterscheid M, Patel S, Theriault A, Keating MJ, Kantarjian H, Estey E, Andreeff M. The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics. Clin Cancer Res. 1999 Jul;5(7):1758-66. 
• Thomas DA, Cortes J, O’Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H. Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999 Aug;17(8):2461-70. 
• Wilhelm M, O’Brien S, Rios MB, Estey E, Keating MJ, Plunkett W, Sorenson M, Kantarjian HM. Phase I study of arabinosyl-5-azacytidine (fazarabine) in adult acute leukemia and chronic myelogenous leukemia in blastic phase. Leuk Lymphoma. 1999 Aug;34(5-6):511-8. 
• Hallas C, Albitar M, Letofsky J, Keating MJ, Huebner K, Croce CM. Loss of FHIT expression in acute lymphoblastic leukemia. Clin Cancer Res. 1999 Sep;5(9):2409-14. 
• Cortes J, Fayad L, O’Brien S, Keating M, Kantarjian H. Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity. Clin Cancer Res. 1999 Sep;5(9):2491-7. 
• Beran M, Estey E, O’Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999 Sep;17(9):2819-30. 
• Starostik P, O’Brien S, Chung CY, Haidar M, Manshouri T, Kantarjian H, Freireich E, Keating M, Albitar M. The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia. Leuk Res. 1999 Sep;23(9):795-801. 
• Keating MJ. Chronic lymphocytic leukemia. Semin Oncol. 1999 Oct;26(5 Suppl 14):107-14.
• Aguayo A, Cortes J, Thomas D, Pierce S, Keating M, Kantarjian H. Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer. 1999 Oct 1;86(7):1203-9. 
• Thomas DA, Kantarjian H, Smith TL, Koller C, Cortes J, O’Brien S, Giles FJ, Gajewski J, Pierce S, Keating MJ. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999 Oct 1;86(7):1216-30. 
• Estey EH, Giles FJ, Kantarjian H, O’Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood. 1999 Oct 1;94(7):2230-5. 
• Giles FJ, O’Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999 Dec;36(1-2):57-65. 
• Partyka S, O’Brien S, Podoloff D, Kantarjian H, Keating MJ. The usefulness of high dose (7-10mci) gallium (67Ga) scanning to diagnose Richter’s transformation. Leuk Lymphoma. 1999 Dec;36(1-2):151-5. 
• Lin CW, O’Brien S, Faber J, Manshouri T, Romaguera J, Huh YO, Kantarjian H, Keating M, Albitar M. De novo CD5+ Burkitt lymphoma/leukemia. Am J Clin Pathol. 1999 Dec;112(6):828-35. 
• Aguayo A, Estey E, Kantarjian H, Mansouri T, Gidel C, Keating M, Giles F, Estrov Z, Barlogie B, Albitar M. Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood. 1999 Dec 1;94(11):3717-21. 
• Koller CA, Kantarjian HM, Feldman EJ, O’Brien S, Rios MB, Estey E, Keating M. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer. 1999 Dec 1;86(11):2246-51. 
• Sacchi S, Kantarjian HM, O’Brien S, Cortes J, Rios MB, Giles FJ, Beran M, Koller CA, Keating MJ, Talpaz M. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer. 1999 Dec 15;86(12):2632-41. 

2000

• D’Arena G, Keating MJ, Carotenuto M. Chronic lymphoproliferative disorders: an integrated point of view for the differential diagnosis. Leuk Lymphoma. 2000 Jan;36(3-4):225-37. 
• Faber J, Kantarjian H, Roberts MW, Keating M, Freireich E, Albitar M. Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia. Arch Pathol Lab Med. 2000 Jan;124(1):92-7. 
• Cortes J, Estey E, Beran M, O’Brien S, Giles F, Koller C, Keating M, Kantarjian H. Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia. Leuk Lymphoma. 2000 Feb;36(5-6):479-84. 
• Kantarjian HM, O’Brien S, Smith TL, Cortes J, Giles FJ, Beran M, Pierce S, Huh Y, Andreeff M, Koller C, Ha CS, Keating MJ, Murphy S, Freireich EJ. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000 Feb;18(3):547-61. 
• Estey EH, Pierce S, Keating MJ. Identification of a group of AML/MDS patients with a relatively favorable prognosis who have chromosome 5 and/or 7 abnormalities. Haematologica. 2000 Mar;85(3):246-9. 
• Haidar MA, Manshouri T, Keating MJ, Kantarjian HM, Freireich EJ, Mehta K, Albitar M. Downregulation of the p53 tumor suppressor gene and upregulation of the bcl-2 gene in retinoic acid receptor alpha-deficient transgenic mice. Int J Oncol. 2000 Mar;16(3):561-5. 
• Keating MJ, Smith TL, Lerner S, O’Brien S, Robertson LE, Kantarjian H, Freireich EJ. Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2000 Mar;37(1-2):71-85. 
• Giles FJ, Wong GC, Clark SJ, Pierce S, Kantarjian HM, Keating MJ. Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia. Leuk Lymphoma. 2000 Mar;37(1-2):87-95. 
• Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000 Mar;18(5):995-1003. 
• Haidar MA, Kantarjian H, Manshouri T, Chang CY, O’Brien S, Freireich E, Keating M, Albitar M. ATM gene deletion in patients with adult acute lymphoblastic leukemia. Cancer. 2000 Mar 1;88(5):1057-62. 
• Chung CY, Kantarjian H, Haidar M, Starostik P, Manshouri T, Gidel C, Freireich E, Keating M, Albitar M. Deletions in the 13q14 locus in adult lymphoblastic leukemia: rate of incidence and relevance. Cancer. 2000 Mar 15;88(6):1359-64. 
• Keating MJ. Chronic lymphocytic leukemia. Clinical oral poster session. Hematol Cell Ther. 2000 Jun;42(1):35-9.
• Ravandi-Kashani F, O’Brien S, Manshouri T, Lerner S, Sim S, Dodd K, Kantarjian H, Freireich E, Keating M, Albitar M. Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia. Leuk Res. 2000 Jun;24(6):469-74. 
• Saad ED, Thomas DA, O’Brien S, Fuller GN, Medeiros LJ, Forman A, Albitar M, Schomer D, Kantarjian HM, Keating MJ. Progressive multifocal leukoencephalopathy with concurrent Richter’s syndrome. Leuk Lymphoma. 2000 Jun;38(1-2):183-90. 
• Albitar M, Beran M, O’Brien S, Kantarjian H, Frieriech E, Keating M, Estey E. Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Blood. 2000 Jul 1;96(1):372-3. 
• Aguayo A, O’Brien S, Keating M, Manshouri T, Gidel C, Barlogie B, Beran M, Koller C, Kantarjian H, Albitar M. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood. 2000 Jul 15;96(2):768-70. 
• Huang P, Sandoval A, Van Den Neste E, Keating MJ, Plunkett W. Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia. 2000 Aug;14(8):1405-13. 
• Rodriguez CO, Plunkett W, Paff MT, Du M, Nowak B, Ramakrishna P, Keating MJ, Gandhi V. High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl. 2000 Aug 18;745(2):421-30. 
• Rodriguez J, Keating MJ, O’Brien S, Champlin RE, Khouri IF. Allogeneic haematopoietic transplantation for Richter’s syndrome. Br J Haematol. 2000 Sep;110(4):897-9. 
• Aguayo A, Kantarjian H, Manshouri T, Gidel C, Estey E, Thomas D, Koller C, Estrov Z, O’Brien S, Keating M, Freireich E, Albitar M. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood. 2000 Sep 15;96(6):2240-5. 
• Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000 Sep 21;407(6802):390-5. 
• Byrd JC, Waselenko JK, Keating M, Rai K, Grever MR. Novel therapies for chronic lymphocytic leukemia in the 21st century. Semin Oncol. 2000 Oct;27(5):587-97.
• Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc. 2000 Oct;75(10):1039-54. 
• Faderl S, Kantarjian HM, Estey E, Manshouri T, Chan CY, Rahman Elsaied A, Kornblau SM, Cortes J, Thomas DA, Pierce S, Keating MJ, Estrov Z, Albitar M. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia. Cancer. 2000 Nov 1;89(9):1976-82. 
• Ibrahim S, Estey EH, Pierce S, Glassman A, Keating M, O’Brien S, Kantarjian HM, Albitar M. 11q23 abnormalities in patients with acute myelogenous leukemia and myelodysplastic syndrome as detected by molecular and cytogenetic analyses. Am J Clin Pathol. 2000 Nov;114(5):793-7. 
• Keating M, O’Brien S. High-dose rituximab therapy in chronic lymphocytic leukemia. Semin Oncol. 2000 Dec;27(6 Suppl 12):86-90.

2001

• Thomas DA, O’Brien SM, Keating MJ. Management of the patient with relapsed or refractory chronic lymphocytic leukemia. In Cheson B, Ed. Chronic Lymphocytic Leukemia. Second edition. Marcel Dekker, Inc. 2001; 275-333.
• Ravandi F, Keating MJ, O’Brien SM. Supportive care in chronic lymphocytic leukemia. In Cheson B, Ed. Chronic Lymphocytic Leukemia. Second edition. Marcel Dekker, Inc. 2001; 485-504.
• Lee S, Van NT, Vachhani NB, Uthman M, Keating MJ, Juneja HS. Adhesion of B-Cell Chronic Lymphocytic Leukemia Cells to Marrow Stromal Cells is Mediated by α4β1 but not β2αL Integrin: MSC also Prevent Apoptosis of B-CLL Cells. Hematology. 2001;5(6):463-73. 
• Rai KR, Döhner H, Keating MJ, Montserrat E. Chronic lymphocytic leukemia: case-based session. Hematology Am Soc Hematol Educ Program. 2001:140-56. 
• Faderl S, Gidel C, Kantarjian HM, Manshouri T, Keating M, Albitar M. Loss of heterozygosity on chromosome 5 in adults with acute lymphoblastic leukemia. Leuk Res. 2001 Jan;25(1):39-43. 
• Fayad L, Keating MJ, Reuben JM, O’Brien S, Lee BN, Lerner S, Kurzrock R. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001 Jan 1;97(1):256-63. 
• O’Brien SM, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, Lerner S, Keating M. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001 Mar 1;19(5):1414-20. 
• Aguayo A, Manshouri T, O’Brien S, Keating M, Beran M, Koller C, Kantarjian H, Rogers A, Albitar M. Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL). Leuk Res. 2001 Apr;25(4):279-85. 
• Ferrajoli A, Manshouri T, Estrov Z, Keating MJ, O’Brien S, Lerner S, Beran M, Kantarjian HM, Freireich EJ, Albitar M. High levels of vascular endothelial growth factor receptor-2 correlate with shortened survival in chronic lymphocytic leukemia. Clin Cancer Res. 2001 Apr;7(4):795-9. 
• Giles FJ, Kantarjian H, O’Brien S, Rios MB, Cortes J, Beran M, Koller C, Keating M, Talpaz M. Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase. Leuk Lymphoma. 2001 Apr;41(3-4):309-19. 
• Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO, Ramakrishna P, Rosner GL, Hodge JP, O’Brien S, Keating MJ. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001 Apr 15;19(8):2142-52. 
• O’Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001 Apr 15;19(8):2165-70. 
• Di Raimondo F, Giustolisi R, Lerner S, Cacciola E, O’Brien S, Kantarjian H, Keating MJ. Retrospective study of the prognostic role of serum thymidine kinase level in CLL patients with active disease treated with fludarabine. Ann Oncol. 2001 May;12(5):621-5. 
• Verstovsek S, Manshouri T, Kantarjian H, Giles FJ, Keating M, Estey E, Albitar M. Highly reproducible detection and semi-quantification of telomerase activity. Biotechniques. 2001 May;30(5):930-4. 
• Giles FJ, Shen Y, Kantarjian HM, Korbling MJ, O’Brien S, Anderlini P, Donato M, Pierce S, Keating MJ, Freireich EJ, Estey E. Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long-term survival. Leuk Lymphoma. 2001 Jun;42(1-2):67-73. 
• Dabaja BS, O’Brien SM, Kantarjian HM, Cortes JE, Thomas DA, Albitar M, Schlette ES, Faderl S, Sarris A, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter’s syndrome. Leuk Lymphoma. 2001 Jul;42(3):329-37. 
• Verstovsek S, Estey E, Manshouri T, Keating M, Kantarjian H, Giles FJ, Albitar M. High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2001 Jul;42(3):511-6. 
• Cortes J, Estey E, O’Brien S, Giles F, Shen Y, Koller C, Beran M, Thomas D, Keating M, Kantarjian H. High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia. Cancer. 2001 Jul 1;92(1):7-14. 
• Ibrahim S, Keating M, Do KA, O’Brien S, Huh YO, Jilani I, Lerner S, Kantarjian HM, Albitar M. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood. 2001 Jul 1;98(1):181-6. 
• Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T, Koller C, Estrov Z, Freireich E, Keating M, Albitar M. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia. 2001 Aug;15(8):1165-70. 
• Verstovsek S, Kantarjian H, Aguayo A, Manshouri T, Freireich E, Keating M, Estey E, Albitar M. Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome. Br J Haematol. 2001 Aug;114(2):290-5. 
• Huh YO, Keating MJ, Saffer HL, Jilani I, Lerner S, Albitar M. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. Am J Clin Pathol. 2001 Sep;116(3):437-43. 
• Bullrich F, Fujii H, Calin G, Mabuchi H, Negrini M, Pekarsky Y, Rassenti L, Alder H, Reed JC, Keating MJ, Kipps TJ, Croce CM. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res. 2001 Sep 15;61(18):6640-8. 
• Aboul-Nasr R, O’Brien S, Freireich EJ, Ginsberg CF, Kantarjian HM, Koller CA, Keating MJ, Albitar M. “T-cell-rich B-cell lymphoproliferative disorder” of the bone marrow. Leuk Lymphoma. 2001 Sep-Oct;42(5):1023-31. 
• Cortes J, O’Brien S, Loscertales J, Kantarjian H, Giles F, Thomas D, Koller C, Keating M. Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia. Cancer. 2001 Oct 15;92(8):2016-22. 
• Ferrajoli A, O’Brien S, Keating MJ. Alemtuzumab: a novel monoclonal antibody. Expert Opin Biol Ther. 2001 Nov;1(6):1059-65. 
• Keating MJ. Progress in CLL, chemotherapy, antibodies and transplantation. Biomed Pharmacother. 2001 Nov;55(9-10):524-8. 
• Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res. 2001 Nov;7(11):3580-9. 
• Onciu M, Schlette E, Medeiros LJ, Abruzzo LV, Keating M, Lai R. Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. Am J Clin Pathol. 2001 Dec;116(6):886-92. 
• Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells. Clin Cancer Res. 2001 Dec;7(12):3884-93. 

2002

• Coombes KR, Zhang L, Bueso-Ramos C, Brisbay S, Logothetis C, Roth J, Keating MJ, McDonnell TJ. TAD: a web interface and database for tissue microarrays. Appl Bioinformatics. 2002;1(3):155-8.
• Khouri IF, Keating MJ, Saliba RM, Champlin RE. Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation. Cytotherapy. 2002;4(3):217-21. 
• Keating MJ, Cazin B, Coutré S, Birhiray R, Kovacsovics T, Langer W, Leber B, Maughan T, Rai K, Tjønnfjord G, Bekradda M, Itzhaki M, Hérait P. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. J Clin Oncol. 2002 Jan 1;20(1):205-13. 
• Keating MJ, O’Brien S, Albitar M. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol. 2002 Feb;29(1 Suppl 2):70-4. 
• Yamauchi T, Keating MJ, Plunkett W. UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes. Mol Cancer Ther. 2002 Feb;1(4):287-94. 
• Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH, Glassman AB, Albitar M, Kwari MI, Beran M. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002 Feb 1;99(3):840-9. 
• DiRaimondo F, Albitar M, Huh Y, O’Brien S, Montillo M, Tedeschi A, Kantarjian H, Lerner S, Giustolisi R, Keating M. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer. 2002 Mar 15;94(6):1721-30. 
• Oudat R, Keating MJ, Lerner S, O’Brien S, Albitar M. Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission. Leukemia. 2002 Apr;16(4):632-5. 
• Tsimberidou AM, O’Brien SM, Cortes JE, Faderl S, Andreeff M, Kantarjian HM, Keating MJ, Giles FJ. Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter’s syndrome or refractory lymphoproliferative disorders. Leuk Lymphoma. 2002 Apr;43(4):767-72. 
• O’Brien S, Talpaz M, Cortes J, Shan J, Giles FJ, Faderl S, Thomas D, Garcia-Manero G, Mallard S, Beth M, Koller C, Kornblau S, Andreeff M, Murgo A, Keating M, Kantarjian HM. Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia. Cancer. 2002 Apr 1;94(7):2024-32. 
• Abruzzo LV, Rosales CM, Medeiros LJ, Vega F, Luthra R, Manning JT, Keating MJ, Jones D. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol. 2002 May;26(5):630-6. 
• Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, Albitar M, Brettman L, Santabarbara P, Wacker B, Rai KR. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002 May 15;99(10):3554-61. 
• Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells. Cancer. 2002 May 15;94(10):2653-62. 
• Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O’Brien S, Garcia-Manero G, Manshouri T, Albitar M. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2002 Jun;16(6):1045-52. 
• Kantarjian HM, O’Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res. 2002 Jul;8(7):2167-76. 
• Kantarjian HM, Talpaz M, O’Brien S, Smith TL, Giles FJ, Faderl S, Thomas DA, Garcia-Manero G, Issa JP, Andreeff M, Kornblau SM, Koller C, Beran M, Keating M, Rios MB, Shan J, Resta D, Capdeville R, Hayes K, Albitar M, Freireich EJ, Cortes JE. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res. 2002 Jul;8(7):2177-87. 
• Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, Koller CA, Kurzrock R, Thomas DA, Faderl S, Lerner S, O’Brien S, Albitar M. The clinical significance of tumor necrosis factor-α plasma level in patients having chronic lymphocytic leukemia. Blood. 2002 Aug 15;100(4):1215-9. 
• Keating MJ, O’Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, Lerner S, Kantarjian H. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma. 2002 Sep;43(9):1755-62. 
• Lai R, McDonnell TJ, O’Connor SL, Medeiros LJ, Oudat R, Keating M, Morgan MB, Curiel TJ, Ford RJ. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res. 2002 Sep;26(9):849-55. 
• Tsimberidou AM, Thomas D, O’Brien S, Andreeff M, Kurzrock R, Keating M, Albitar M, Kantarjian H, Giles F. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies. Cancer Chemother Pharmacol. 2002 Sep;50(3):237-42. Epub 2002 Jul 26. 
• Lai R, O’Brien S, Maushouri T, Rogers A, Kantarjian H, Keating M, Albitar M. Prognostic value of plasma interleukin-6 levels in patients with chronic lymphocytic leukemia. Cancer. 2002 Sep 1;95(5):1071-5. 
• Giles FJ, Kantarjian HM, Bekele BN, Cortes JE, Faderl S, Thomas DA, Manshouri T, Rogers A, Keating MJ, Talpaz M, O’Brien S, Albitar M. Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival. Br J Haematol. 2002 Oct;119(1):38-45. 
• Onida F, Ball G, Kantarjian HM, Smith TL, Glassman A, Albitar M, Scappini B, Rios MB, Keating MJ, Beran M. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia. Cancer. 2002 Oct 15;95(8):1673-84. 
• Bosly A, Keating MJ, Stasi R, Bradstock K. Rituximab in B-cell disorders other than non-Hodgkin’s lymphoma. Anticancer Drugs. 2002 Nov;13(Suppl 2):S25-33. 
• Aguayo A, Kantarjian HM, Estey EH, Giles FJ, Verstovsek S, Manshouri T, Gidel C, O’Brien S, Keating MJ, Albitar M. Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer. 2002 Nov 1;95(9):1923-30. 
• Keating MJ. Management of chronic lymphocytic leukemia: a changing field. Rev Clin Exp Hematol. 2002 Dec;6(4):350-65; discussion 449-50. 

2003

• Keating MJ, Chiorazzi N, Messmer B, Damle RN, Allen SL, Rai KR, Ferrarini M, Kipps TJ. Biology and treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003:153-75. 
• Jilani I, Estey E, Manshouri T, Caligiuri M, Keating M, Giles F, Thomas D, Kantarjian H, Albitar M. Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA. Leukemia. 2003 Jan;17(1):114-9. 
• Lai R, Rassidakis GZ, Medeiros LJ, Leventaki V, Keating M, McDonnell TJ. Expression of STAT3 and its phosphorylated forms in mantle cell lymphoma cell lines and tumours. J Pathol. 2003 Jan;199(1):84-9. 
• Montillo M, Tedeschi A, O’Brien S, Di Raimondo F, Lerner S, Ferrajoli A, Morra E, Keating MJ. Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer. 2003 Jan 1;97(1):114-20. 
• Lu D, Nounou R, Beran M, Estey E, Manshouri T, Kantarjian H, Keating MJ, Albitar M. The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2003 Jan 15;97(2):441-9. 
• D’Arena G, Di Renzo N, Brugiatelli M, Vigliotti ML, Keating MJ. Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2003 Feb;44(2):223-8. 
• Wierda WG, Johnson MM, Do KA, Manshouri T, Dey A, O’Brien S, Giles FJ, Kantarjian H, Thomas D, Faderl S, Lerner S, Keating M, Albitar M. Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. Br J Haematol. 2003 Feb;120(3):452-6. 
• Kantarjian HM, O’Brien S, Cortes JE, Shan J, Giles FJ, Rios MB, Faderl SH, Wierda WG, Ferrajoli A, Verstovsek S, Keating MJ, Freireich EJ, Talpaz M. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer. 2003 Feb 15;97(4):1033-41. 
• Cortes J, Kantarjian H, Albitar M, Thomas D, Faderl S, Koller C, Garcia-Manero G, Giles F, Andreeff M, O’Brien S, Keating M, Estey E. A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2003 Mar 1;97(5):1234-41. 
• Verstovsek S, Kantarjian H, Manshouri T, Cortes J, Faderl S, Giles FJ, Keating M, Albitar M. Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia. Cancer. 2003 Mar 1;97(5):1248-52. 
• Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O’Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15;21(6):1167-73. 
• Tsimberidou A, Estey E, Cortes J, Thomas D, Faderl S, Verstovsek S, Garcia-Manero G, Keating M, Albitar M, O’Brien S, Kantarjian H, Giles F. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003 Mar 15;97(6):1481-7. 
• Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, O’Connor SL, Keating MJ, Lai R. Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med. 2003 Apr;127(4):424-31. 
• Manshouri T, Do KA, Wang X, Giles FJ, O’Brien SM, Saffer H, Thomas D, Jilani I, Kantarjian HM, Keating MJ, Albitar M. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003 Apr 1;101(7):2507-13. Epub 2002 Nov 21. 
• Tsimberidou AM, Kantarjian HM, Cortes J, Thomas DA, Faderl S, Garcia-Manero G, Verstovsek S, Ferrajoli A, Wierda W, Alvarado Y, O’Brien SM, Albitar M, Keating MJ, Giles FJ. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2003 Apr 1;97(7):1711-20. 
• Ibrahim S, Jilani I, O’Brien S, Rogers A, Manshouri T, Giles F, Faderl S, Thomas D, Kantarjian H, Keating M, Albitar M. Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia. Cancer. 2003 Apr 15;97(8):1914-9. 
• Giles FJ, Bekele BN, O’Brien S, Cortes JE, Verstovsek S, Balerdi M, Yared M, Zhou X, Kantarjian HM, Keating MJ, Thall P, Albitar M. A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression. Br J Haematol. 2003 May;121(4):578-85. 
• Schlette E, Medeiros LJ, Keating M, Lai R. CD79b expression in chronic lymphocytic leukemia. Association with trisomy 12 and atypical immunophenotype. Arch Pathol Lab Med. 2003 May;127(5):561-6. 
• Faderl S, Thomas DA, O’Brien S, Garcia-Manero G, Kantarjian HM, Giles FJ, Koller C, Ferrajoli A, Verstovsek S, Pro B, Andreeff M, Beran M, Cortes J, Wierda W, Tran N, Keating MJ. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood. 2003 May 1;101(9):3413-5. Epub 2003 Jan 9. 
• Verstovsek S, Manshouri T, Smith FO, Giles FJ, Cortes J, Estey E, Kantarjian H, Keating M, Jeha S, Albitar M. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia. Cancer. 2003 May 1;97(9):2212-7. 
• Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood. 2003 May 15;101(10):4098-104. Epub 2003 Jan 16. 
• Tsimberidou AM, Kantarjian HM, Estey E, Cortes JE, Verstovsek S, Faderl S, Thomas DA, Garcia-Manero G, Ferrajoli A, Manning JT, Keating MJ, Albitar M, O’Brien S, Giles FJ. Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy. Leukemia. 2003 Jun;17(6):1100-3. 
• McCarthy H, Wierda WG, Barron LL, Cromwell CC, Wang J, Coombes KR, Rangel R, Elenitoba-Johnson KS, Keating MJ, Abruzzo LV. High expression of activation induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. Blood. 2003 Jun 15;101(12):4903-8. Epub 2003 Feb 13. 
• Kantarjian H, O’Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth Rios M, Keating M, Freireich E, Talpaz M. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer. 2003 Jul 1;98(1):81-5. 
• Carew JS, Zhou Y, Albitar M, Carew JD, Keating MJ, Huang P. Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications. Leukemia. 2003 Aug;17(8):1437-47. 
• Gatto S, Scappini B, Pham L, Onida F, Milella M, Ball G, Ricci C, Divoky V, Verstovsek S, Kantarjian HM, Keating MJ, Cortes-Franco JE, Beran M. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate. Haematologica. 2003 Aug;88(8):853-63. 
• Kantarjian HM, O’Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, Garcia-Manero G, Rios MB, Shan J, Andreeff M, Keating M, Talpaz M. Results of decitabine (5-aza-2’deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003 Aug 1;98(3):522-8. 
• Ferrajoli A, O’Brien SM, Cortes JE, Giles FJ, Thomas DA, Faderl S, Kurzrock R, Lerner S, Kontoyiannis DP, Keating MJ. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer. 2003 Aug 15;98(4):773-8. 
• Giles FJ, Shi GG, Cortes JE, Thomas D, Keating AR, Kantarjian HM, Keating MJ, O’Brien SM. Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia. Cancer Chemother Pharmacol. 2003 Sep;52(3):223-8. Epub 2003 Jun 3. 
• Amin HM, Jilani I, Estey EH, Keating MJ, Dey AL, Manshouri T, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Giles FJ, Albitar M. Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome. Blood. 2003 Sep 1;102(5):1866-8. Epub 2003 May 1. 
• Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ, Huang P. Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 2003 Sep 26;278(39):37832-9. Epub 2003 Jul 9. 
• Lee JN, Giles F, Huh YO, Manshouri T, O’Brien S, Kantarjian HM, Keating MJ, Albitar M. Molecular differences between small and large cells in patients with chronic lymphocytic leukemia. Eur J Haematol. 2003 Oct;71(4):235-42. 
• Tsimberidou AM, Giles FJ, Kantarjian HM, Keating MJ, O’Brien SM. Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia–long-term follow-up of a monoclonal antibody-based approach to residual disease. Leuk Lymphoma. 2003 Oct;44(10):1719-25. 
• Thomas DA, Estey E, Giles FJ, Faderl S, Cortes J, Keating M, O’Brien S, Albitar M, Kantarjian H. Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia. Br J Haematol. 2003 Nov;123(3):436-41. 
• Giles FJ, Vose JM, Do KA, Johnson MM, Manshouri T, Bociek G, Bierman PJ, O’Brien SM, Keating MJ, Kantarjian HM, Armitage JO, Albitar M. Circulating CD20 and CD52 in patients with non-Hodgkin’s lymphoma or Hodgkin’s disease. Br J Haematol. 2003 Dec;123(5):850-7. 
• Tsimberidou AM, Estey E, Cortes JE, Garcia-Manero G, Faderl S, Verstovsek S, Thomas DA, Ferrajoli A, Keating MJ, O’Brien S, Kantarjian HM, Giles FJ. Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia. Cancer Chemother Pharmacol. 2003 Dec;52(6):449-52. Epub 2003 Sep 9. 
• Thomas DA, O’Brien S, Bueso-Ramos C, Faderl S, Keating MJ, Giles FJ, Cortes J, Kantarjian HM. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003 Dec 1;102(12):3906-11. Epub 2003 Jun 19. 
• Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003 Dec 15;9(17):6335-42. 
• O’Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG, Koller CA, Ferrajoli A, Browning M, Lerner S, Albitar M, Keating MJ. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer. 2003 Dec 15;98(12):2657-63. 

2004

• Ferrajoli A, Keating MJ, O’Brien SM. Chemotherapy of chronic lymphocytic leukemia. In Faguet GB, Ed. Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Totowa, NJ: Humana Press Inc. 2004; 241-254.
• Bodey GP, Kontoyiannis D, Keating MJ. Infections in patients with chronic lymphocytic leukemia. In Faguet GB, Ed. Chronic Lymphocytic Leukemia: Molecular Genetics, Biology, Diagnosis, and Management. Totowa, NJ: Humana Press Inc. 2004; 343-359.
• Khouri IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Couriel D, Hosing C, Giralt S, Korbling M, McMannis J, Keating MJ, Champlin RE. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol. 2004 Jan;32(1):28-35. 
• Kantarjian H, O’Brien S, Cortes J, Giles F, Shan J, Rios MB, Faderl S, Verstovsek S, Garcia-Manero G, Wierda W, Kornblau S, Ferrajoli A, Keating M, Talpaz M. Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous leukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):68-75. 
• Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 1;103(3):784-9. Epub 2003 Oct 9. 
• Hileman EO, Liu J, Albitar M, Keating MJ, Huang P. Intrinsic oxidative stress in cancer cells: a biochemical basis for therapeutic selectivity. Cancer Chemother Pharmacol. 2004 Mar;53(3):209-19. Epub 2003 Nov 11. 
• Keating M, Coutre S, Rai K, Osterborg A, Faderl S, Kennedy B, Kipps T, Bodey G, Byrd JC, Rosen S, Dearden C, Dyer MJ, Hillmen P. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma. 2004 Mar;4(4):220-7. 
• Khouri IF, Albitar M, Saliba RM, Ippoliti C, Ma YC, Keating MJ, Champlin RE. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics. Bone Marrow Transplant. 2004 Apr;33(8):833-7. 
• Ma Y, Mansour A, Bekele BN, Zhou X, Keating MJ, O’Brien S, Giles FJ, Albitar M. The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia. Cancer. 2004 May 15;100(10):2167-75. 
• Tsimberidou AM, Murray JL, O’Brien S, Wierda WG, Keating MJ. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome. Cancer. 2004 May 15;100(10):2195-200. 
• Thomas DA, Faderl S, Cortes J, O’Brien S, Giles FJ, Kornblau SM, Garcia-Manero G, Keating MJ, Andreeff M, Jeha S, Beran M, Verstovsek S, Pierce S, Letvak L, Salvado A, Champlin R, Talpaz M, Kantarjian H. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004 Jun 15;103(12):4396-407. Epub 2003 Oct 9. 
• Tsimberidou AM, Keating MJ, Giles FJ, Wierda WG, Ferrajoli A, Lerner S, Beran M, Andreeff M, Kantarjian HM, O’Brien S. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia. Cancer. 2004 Jun 15;100(12):2583-91. 
• Verstovsek S, Giles FJ, O’Brien S, Faderl S, Kantarjian HM, Keating MJ, Albitar M. Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia. Leuk Res. 2004 Jul;28(7):707-11. 
• Herling M, Khoury JD, Washington LT, Duvic M, Keating MJ, Jones D. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood. 2004 Jul 15;104(2):328-35. Epub 2004 Mar 25. 
• Bueso-Ramos CE, Ferrajoli A, Medeiros LJ, Keating MJ, Estrov Z. Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. Hematology. 2004 Aug;9(4):279-86. 
• Ferrajoli A, Keating MJ. Current guidelines in defining therapeutic strategies. Hematol Oncol Clin North Am. 2004 Aug;18(4):881-93, ix. 
• Jabbour E, Keating MJ, Champlin RE, Khouri IF. Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant? Bone Marrow Transplant. 2004 Aug;34(4):289-97. 
• Lenihan DJ, Alencar AJ, Yang D, Kurzrock R, Keating MJ, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood. 2004 Aug 1;104(3):655-8. Epub 2004 Apr 8. 
• Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004 Aug 26;351(9):893-901. 
• Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O’Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer. 2004 Sep 1;101(5):999-1008. 
• Thomas DA, O’Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H. Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood. 2004 Sep 15;104(6):1624-30. Epub 2004 Jun 3. 
• Sun X, Amin HM, Freireich EJ, Keating MJ, Kantarjian HM, Koller CA, O’Brien SM, Giles F, Albitar M. Hairy cell leukemia with large cells: long disease course with adequate response to therapy. Leukemia. 2004 Nov;18(11):1912-4. 
• Wang J, Coombes KR, Highsmith WE, Keating MJ, Abruzzo LV. Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. Bioinformatics. 2004 Nov 22;20(17):3166-78. Epub 2004 Jul 1. 
• Carew JS, Nawrocki ST, Xu RH, Dunner K, McConkey DJ, Wierda WG, Keating MJ, Huang P. Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine. Leukemia. 2004 Dec;18(12):1934-40. 
• Jilani I, Keating M, Giles FJ, O’Brien S, Kantarjian HM, Albitar M. Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay. Leuk Res. 2004 Dec;28(12):1255-62. 
• Kantarjian H, Thomas D, O’Brien S, Cortes J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, Beran M, Keating M, Freireich EJ. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004 Dec 15;101(12):2788-801. 

2005

• Tsimberidou AM, Keating MJ. Hyperuricemic syndromes in cancer patients. Contrib Nephrol. 2005;147:47-60. 
• Faderl SJ, Keating MJ. Treatment of chronic lymphocytic leukemia. Curr Hematol Rep. 2005 Jan;4(1):31-8.
• Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005 Jan 15;103(2):216-28. 
• Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005 Jan 15;65(2):613-21. 
• Faderl S, Gandhi V, O’Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 1;105(3):940-7. Epub 2004 Oct 14. 
• Yin CC, Lin P, Carney DA, Handy BC, Rassidakis GZ, Admirand JH, Keating MJ, Medeiros LJ. Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. Am J Clin Pathol. 2005 Apr;123(4):594-602. 
• Abruzzo LV, Lee KY, Fuller A, Silverman A, Keating MJ, Medeiros LJ, Coombes KR. Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. Biotechniques. 2005 May;38(5):785-92. 
• Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies–development of a next-generation nucleoside analog. Cancer. 2005 May 15;103(10):1985-95. 
• Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, Mitchell BS. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005 May 20;23(15):3396-403. 
• Balakrishnan K, Stellrecht CM, Genini D, Ayres M, Wierda WG, Keating MJ, Leoni LM, Gandhi V. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 2005 Jun 1;105(11):4455-62. Epub 2005 Feb 17. 
• Wierda W, O’Brien S, Wen S, Faderl S, Garcia-Manero G, Thomas D, Do KA, Cortes J, Koller C, Beran M, Ferrajoli A, Giles F, Lerner S, Albitar M, Kantarjian H, Keating M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4070-8. Epub 2005 Mar 14. 
• Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 20;23(18):4079-88. Epub 2005 Mar 14. 
• Abruzzo LV, Wang J, Kapoor M, Medeiros LJ, Keating MJ, Edward Highsmith W, Barron LL, Cromwell CC, Coombes KR. Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays. J Mol Diagn. 2005 Aug;7(3):337-45. 
• Keating MJ, Rai KR, Wierda WG. Evolution of treatment strategies in chronic lymphocytic leukemia. Part 2 of a 3-Part series: Advances in the treatment of hematologic malignancies. Clin Adv Hematol Oncol. 2005 Aug;3(8):1-10; quiz 11-2.
• Giles F, O’Brien S, Cortes J, Verstovsek S, Bueso-Ramos C, Shan J, Pierce S, Garcia-Manero G, Keating M, Kantarjian H. Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer. 2005 Aug 1;104(3):547-54. 
• Wierda WG, Kipps TJ, Keating MJ. Novel immune-based treatment strategies for chronic lymphocytic leukemia. J Clin Oncol. 2005 Sep 10;23(26):6325-32. 
• Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res. 2005 Sep 15;11(18):6745-52. 
• Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, Wierda WG. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia. 2005 Oct;19(10):1788-93. 
• Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005 Oct 1;106(7):2513-9. Epub 2005 Jun 21. 
• Achanta G, Sasaki R, Feng L, Carew JS, Lu W, Pelicano H, Keating MJ, Huang P. Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma. EMBO J. 2005 Oct 5;24(19):3482-92. Epub 2005 Sep 15. 
• Ravandi F, O’Brien S, Jones D, Lerner S, Faderl S, Ferrajoli A, Wierda W, Garcia-Manero G, Thomas D, Koller C, Verstovsek S, Giles F, Cortes J, Herling M, Kantarjian H, Keating M. T-cell prolymphocytic leukemia: A single-institution experience. Clin Lymphoma Myeloma. 2005 Nov;6(3):234-9. 
• Ravandi F, Kantarjian H, Jones D, Dearden C, Keating M, O’Brien S. Mature T-cell leukemias. Cancer. 2005 Nov 1;104(9):1808-18. 
• Faderl S, Coutre S, Byrd JC, Dearden C, Denes A, Dyer MJ, Gregory SA, Gribben JG, Hillmen P, Keating M, Rosen S, Venugopal P, Rai K. The evolving role of alemtuzumab in management of patients with CLL. Leukemia. 2005 Dec;19(12):2147-52. 
• Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P. Synergistic effect of targeting in mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia. 2005 Dec;19(12):2153-8. 
• Zhou Y, Garcia-Prieto C, Carney DA, Xu RH, Pelicano H, Kang Y, Yu W, Lou C, Kondo S, Liu J, Harris DM, Estrov Z, Keating MJ, Jin Z, Huang P. OSW-1: A natural compound with potent anticancer activity and a novel mechanism of action. J Natl Cancer Inst. 2005 Dec 7;97(23):1781-5. 
• Faderl S, Do KA, Johnson MM, Keating M, O’Brien S, Jilani I, Ferrajoli A, Ravandi-Kashani F, Aguilar C, Dey A, Thomas DA, Giles FJ, Kantarjian HM, Albitar M. Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. Blood. 2005 Dec 15;106(13):4303-7. Epub 2005 Aug 25. 

2006

• Faderl S, O’Brien S, Keating MJ. Monoclonal antibody combinations in CLL: evolving strategies. Best Pract Res Clin Haematol. 2006;19(4):781-93. 
• Gandhi V, Keating MJ, Bate G, Kirkpatrick P. Nelarabine. Nat Rev Drug Discov. 2006 Jan;5(1):17-8. 
• Carew JS, Nawrocki ST, Krupnik YV, Dunner K, McConkey DJ, Keating MJ, Huang P. Targeting endoplasmic reticulum protein transport: A novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood. 2006 Jan 1;107(1):222-31. Epub 2005 Sep 6. 
• Wierda W, O’Brien S, Faderl S, Ferrajoli A, Wang X, Do KA, Garcia-Manero G, Thomas D, Cortes J, Ravandi-Kashani F, Giles F, Lerner S, Kantarjian H, Keating M. A retrospective comparison of three sequential groups of patients with recurrent/refractory chronic lymphocytic leukemia treated with fludarabine-based regimens. Cancer. 2006 Jan 15;106(2):337-45. 
• Tsimberidou AM, Giles FJ, Estey E, O’Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2006 Feb;132(4):398-409. 
• Binet JL, Caligaris-Cappio F, Catovsky D, Cheson B, Davis T, Dighiero G, Dohner H, Hallek M, Hillmen P, Keating M, Montserrat E, Kipps TJ, Rai K. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006 Feb 1;107(3):859-61. Epub 2005 Oct 13. 
• Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O’Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Adult acute megakaryocytic leukemia: An analysis of 37 patients treated at M. D. Anderson Cancer Center. Blood. 2006 Feb 1;107(3):880-4. Epub 2005 Aug 25. 
• Ault P, Kantarjian H, O’Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006 Mar 1;24(7):1204-8. Epub 2006 Jan 30. 
• Kantarjian H, Beran M, Cortes J, O’Brien S, Giles F, Pierce S, Shan J, Plunkett W, Keating M, Estey E. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome. Cancer. 2006 Mar 1;106(5):1099-109. 
• Pelicano H, Carew JS, McQueen TJ, Andreeff M, Plunkett W, Keating MJ, Huang P. Targeting Hsp90 by 17-AAG in leukemia cells: Mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. Leukemia. 2006 Apr;20(4):610-9. 
• Tsimberidou AM, Keating MJ. Richter’s transformation in chronic lymphocytic leukemia. Semin Oncol. 2006 Apr;33(2):250-6. 
• Albitar M, Potts SJ, Giles FJ, O’Brien S, Keating M, Thomas D, Clarke C, Jilani I, Aguilar C, Estey E, Kantarjian H. Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1587-94. 
• Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, Giles FJ, Verstovsek S, Wierda WG, Pierce SA, Shan J, Brandt M, Hagemeister FB, Keating MJ, Cabanillas F, Kantarjian H. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006 Apr 1;106(7):1569-80. 
• Tsimberidou AM, Keating MJ, Bueso-Ramos CE, Kurzrock R. Epstein-Barr virus in patients with chronic lymphocytic leukemia: a pilot study. Leuk Lymphoma. 2006 May;47(5):827-36. 
• Thomas DA, Giles FJ, Albitar M, Cortes JE, Verstovsek S, Faderl S, O’Brien SM, Garcia-Manero G, Keating MJ, Pierce S, Zeldis J, Kantarjian HM. Thalidomide therapy for myelofibrosis with myeloid metaplasia. Cancer. 2006 May 1;106(9):1974-84. 
• Tsimberidou AM, O’Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, Wen S, Do KA, Smith SC, Lerner S, Freireich EJ, Keating MJ. Clinical outcomes and prognostic factors in patients with Richter’s syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 May 20;24(15):2343-51. 
• Ma W, Jilani I, Gorre M, Keating M, Chan H, Tseng R, Kantarjian H, O’Brien S, Giles FJ, Albitar M. Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia. Br J Haematol. 2006 Jun;133(6):690-2. 
• Tsimberidou AM, Tirado-Gomez M, Andreeff M, O’Brien S, Kantarjian H, Keating M, Lopez-Berestein G, Estey E. Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series. Leuk Lymphoma. 2006 Jun;47(6):1062-8. 
• Ravandi F, Jorgensen JL, O’Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006 Jun 15;107(12):4658-62. Epub 2006 Feb 23. 
• Tibes R, Keating MJ, Ferrajoli A, Wierda W, Ravandi F, Garcia-Manero G, O’Brien S, Cortes J, Verstovsek S, Browning ML, Faderl S. Activity of alemtuzumab in patients with CD52-positive acute leukemia. Cancer. 2006 Jun 15;106(12):2645-51. 
• Ruiz S, Krupnik Y, Keating M, Chandra J, Palladino M, McConkey D. The proteasome inhibitor NPI-0052 is a more effective inducer of apoptosis than bortezomib in lymphocytes from patients with chronic lymphocytic leukemia. Mol Cancer Ther. 2006 Jul;5(7):1836-43. 
• Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res. 2006 Jul 1;12(13):4011-7. 
• Tsimberidou AM, Catovsky D, Schlette E, O’Brien S, Wierda WG, Kantarjian H, Garcia-Manero G, Wen S, Do KA, Lerner S, Keating MJ. Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone. Cancer. 2006 Jul 1;107(1):125-35. 
• Sheikholeslami MR, Jilani I, Keating M, Uyeji J, Chen K, Kantarjian H, O’Brien S, Giles F, Albitar M. Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. Cytometry B Clin Cytom. 2006 Jul 15;70(4):270-5. 
• Bruzzi JF, Macapinlac H, Tsimberidou AM, Truong MT, Keating MJ, Marom EM, Munden RF. Detection of Richter’s transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med. 2006 Aug;47(8):1267-73. 
• Ma W, Kantarjian H, Verstovsek S, Jilani I, Gorre M, Giles F, Cortes J, O’Brien S, Keating M, Albitar M. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behavior. Br J Haematol. 2006 Aug;134(3):341-3. Epub 2006 Jun 20. 
• Tsimberidou AM, Estey E, Kantarjian H, Keating MJ, Pierce S, Garcia-Manero G. Granulocyte colony stimulating factor administration associated with cerebral hemorrhage in acute promyelocytic leukemia. Leukemia. 2006 Aug;20(8):1452-3. Epub 2006 May 25. 
• Koller C, Bekele BN, Zhou X, Park C, Estrov Z, O’Brien S, Keating M, Jilani I, Giles FJ, Kantarjian HM, Albitar M. Plasma thrombopoietin compared to immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. Blood. 2006 Aug 1;108(3):1001-6. Epub 2006 Mar 21. 
• Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A, Keating MJ, Champlin RE, Aguilera EA, Tarrand JJ, Raad II. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine (Baltimore). 2006 Sep;85(5):278-87. 
• Ferrajoli A, Faderl S, Keating MJ. Monoclonal antibodies in chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2006 Sep;6(9):1231-8. 
• O’Brien SM, Keating MJ, Mocarski ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma. 2006 Sep;7(2):125-30. 
• Faderl S, Rai K, Gribben J, Byrd JC, Flinn IW, O’Brien S, Sheng S, Esseltine DL, Keating MJ. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia. Cancer. 2006 Sep 1;107(5):916-24. 
• Tsimberidou AM, O’Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, Lerner S, Bueso-Ramos CE, Keating MJ. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer. 2006 Sep 15;107(6):1294-302. 
• Belov L, Mulligan SP, Barber N, Woolfson A, Scott M, Stoner K, Chrisp JS, Sewell WA, Bradstock KF, Bendall L, Pascovici DS, Thomas M, Erber W, Huang P, Sartor M, Young GA, Wiley JS, Juneja S, Wierda WG, Green AR, Keating MJ, Christopherson RI. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol. 2006 Oct;135(2):184-97. Epub 2006 Aug 25. 
• Jilani I, Keating M, Day A, William W, Kantarjian H, O’Brien S, Giles FJ, Albitar M. Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies. Clin Lab Haematol. 2006 Oct;28(5):325-31. 
• Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006 Oct 1;108(7):2392-8. Epub 2006 Jun 15. 
• Tsimberidou AM, Kantarjian H, Keating MJ, Estey E. Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide? Leuk Lymphoma. 2006 Nov;47(11):2282-8. 
• Morabito F, Damle RN, Deaglio S, Keating M, Ferrarini M, Chiorazzi N. The CD38 ectoenzyme family: advances in basic science and clinical practice. Mol Med. 2006 Nov-Dec;12(11-12):342-4. 
• Ahmed B, Estey E, Manning J, David C, Keating MJ, Kantarjian H, Tsimberidou AM. Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia–case report and review of the literature. Haematologica. 2006 Dec;91(12 Suppl):ECR55. 
• Faderl S, Wierda W, Keating MJ. New aspects of the treatment of chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2006 Dec;1(4):251-7. 
• Moufarij MA, Sampath D, Keating MJ, Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood. 2006 Dec 15;108(13):4187-93. Epub 2006 Sep 5. 
• Pelicano H, Xu RH, Du M, Feng L, Sasaki R, Carew JS, Hu Y, Ramdas L, Hu L, Keating MJ, Zhang W, Plunkett W, Huang P. Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism. J Cell Biol. 2006 Dec 18;175(6):913-23. Epub 2006 Dec 11. 

2007

• Huh YO, Abruzzo LV, Rassidakis GZ, Parry-Jones N, Schlette E, Brito-Bapabulle V, Matutes E, Wotherspoon A, Keating MJ, Medeiros LJ, Catovsky D. The t(14;19)(q32;q13)-positive small B-cell leukaemia: a clinicopathologic and cytogenetic study of seven cases. Br J Haematol. 2007 Jan;136(2):220-8. Epub 2006 Nov 27. 
• Albitar M, Vose JM, Johnson MM, Do KA, Day A, Jilani I, Kantarjian H, Keating M, O’Brien SM, Verstovsek S, Armitage JO, Giles FJ. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin’s lymphoma and Hodgkin’s disease. Leuk Res. 2007 Feb;31(2):139-45. Epub 2006 Mar 20. 
• Ma W, Tseng R, Gorre M, Jilani I, Keating M, Kantarjian H, Cortes J, O’Brien S, Giles F, Albitar M. Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia. Haematologica. 2007 Feb;92(2):170-5. 
• Safdar A, Rodriguez G, Rolston KV, O’Brien S, Khouri IF, Shpall EJ, Keating MJ, Kantarjian HM, Champlin RE, Raad II, Kontoyiannis DP. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Feb;39(3):157-64. 
• Albitar M, Johnson M, Do KA, Day A, Jilani I, Pierce S, Estey E, Kantarjian H, Keating M, Verstovsek S, O’Brien S, Giles FJ. Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy. Leukemia. 2007 Mar;21(3):480-8. Epub 2007 Jan 11. 
• Borthakur G, O’Brien S, Wierda WG, Thomas DA, Cortes JE, Giles FJ, Kantarjian HM, Lerner S, Keating MJ. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab–incidence and predictors. Br J Haematol. 2007 Mar;136(6):800-5. 
• Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG, Gandhi V. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood. 2007 Mar 15;109(6):2557-64. Epub 2006 Nov 21. 
• Khouri IF, Saliba RM, Admirand J, O’Brien S, Lee MS, Korbling M, Samuels BI, Giralt S, Lima de M, Keating MJ, Champlin RE, Bueso-Ramos C. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol. 2007 May;137(4):355-63. 
• Ravandi F, Jilani I, Estey E, Kantarjian H, Dey A, Aguilar C, Jitkaroon C, Giles F, O’Brien S, Keating M, Albitar M. Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML). Leuk Res. 2007 Jun;31(6):791-7. Epub 2006 Dec 6. 
• Wierda WG, O’Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007 Jun 1;109(11):4679-85. Epub 2007 Feb 13. 
• Aribi A, Huh Y, Keating M, O’Brien S, Ferrajoli A, Faderl S, Wierda W, Kantarjian H, Ravandi F. T-cell large granular lymphocytic (T-LGL) leukemia: Experience in a single institution over 8 years. Leuk Res. 2007 Jul;31(7):939-45. Epub 2006 Oct 12. 
• Abruzzo LV, Barron LL, Anderson K, Newman RJ, Wierda WG, O’brien S, Ferrajoli A, Luthra M, Talwalkar S, Luthra R, Jones D, Keating MJ, Coombes KR. Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. J Mol Diagn. 2007 Sep;9(4):546-55. Epub 2007 Aug 9. 
• Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, Brettman LR, Reif S, Bonate PL. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol. 2007 Sep;64(3):278-91. Epub 2007 May 16. 
• Tam CS, Keating MJ. Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol. 2007 Sep;20(3):479-98. 
• Catrina Reading F, Schlette EJ, Stewart JM, Keating MJ, Katz RL, Caraway NP. Fine-needle aspiration biopsy findings in patients with small lymphocytic lymphoma transformed to hodgkin lymphoma. Am J Clin Pathol. 2007 Oct;128(4):571-8. 
• Tsimberidou AM, Keating MJ, Wierda WG. Richter’s transformation in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2007 Oct;2(4):265-71. 
• Tsimberidou AM, Wen S, O’Brien S, McLaughlin P, Wierda WG, Ferrajoli A, Faderl S, Manning J, Lerner S, Mai CV, Rodriguez AM, Hess M, Do KA, Freireich EJ, Kantarjian HM, Medeiros LJ, Keating MJ. Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center. J Clin Oncol. 2007 Oct 10;25(29):4648-56. 
• Bürkle A, Niedermeier M, Schmitt-Gräff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007 Nov 1;110(9):3316-25. Epub 2007 Jul 25. 
• Sellick GS, Goldin LR, Wild RW, Slager SL, Ressenti L, Strom SS, Dyer MJ, Mauro FR, Marti GE, Fuller S, Lyttelton M, Kipps TJ, Keating MJ, Call TG, Catovsky D, Caporaso N, Houlston RS. A high-density SNP genome-wide linkage search of 206 families identifies susceptibility loci for chronic lymphocytic leukemia. Blood. 2007 Nov 1;110(9):3326-33. Epub 2007 Aug 8. 
• Atallah E, Cortes J, O’Brien S, Pierce S, Rios MB, Estey E, Markman M, Keating M, Freireich EJ, Kantarjian H. Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia. Blood. 2007 Nov 15;110(10):3547-51. Epub 2007 Aug 2. 
• Ault P, Lynn A, Tam CS, Medeiros LJ, Keating MJ. Systemic mastocytosis in association with chronic lymphocytic leukemia: a rare diagnosis. Leuk Res. 2007 Dec;31(12):1755-8. Epub 2007 May 22. 
• Borthakur G, Lin E, Faderl S, Ferrajoli A, Wierda W, Giles F, Browning ML, Kantarjian H, Keating M, O’Brien S. Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies. Cancer. 2007 Dec 1;110(11):2478-83. 

2008

• Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O’Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter’s syndrome or fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2008 Jan 10;26(2):196-203. 
• Tsimberidou AM, Kantarjian HM, Wen S, O’Brien S, Cortes J, Wierda WG, Koller C, Pierce S, Brandt M, Freireich EJ, Keating MJ, Estey EH. The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients. Clin Cancer Res. 2008 Feb 1;14(3):721-30. 
• O’Brien S, Ravandi F, Riehl T, Wierda W, Huang X, Tarrand J, O’Neal B, Kantarjian H, Keating M. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy. Blood. 2008 Feb 15;111(4):1816-9. Epub 2007 Nov 26. 
• Gandhi V, Tam C, O’Brien S, Jewell RC, Rodriguez CO Jr, Lerner S, Plunkett W, Keating MJ. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008 Mar 1;26(7):1098-105. 
• Ma W, Kantarjian H, O’Brien S, Jilani I, Zhang X, Estrov Z, Ferrajoli A, Keating M, Giles F, Albitar M. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer. 2008 Mar 15;112(6):1306-12. 
• Widhopf GF, Goldberg CJ, Toy TL, Rassenti LZ, Wierda WG, Byrd JC, Keating MJ, Gribben JG, Rai KR, Kipps TJ. Nonstochastic pairing of immunoglobulin heavy and light chains expressed by chronic lymphocytic leukemia B cells is predicated on the heavy chain CDR3. Blood. 2008 Mar 15;111(6):3137-44. Epub 2007 Aug 3. 
• Ferrajoli A, Wierda WG, LaPushin R, O’Brien SM, Faderl S, Browning ML, Keating MJ. Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Eur J Haematol. 2008 Apr;80(4):296-8. Epub 2007 Dec 21. 
• Tam CS, Otero-Palacios J, Abruzzo LV, Jorgensen JL, Ferrajoli A, Wierda WG, Lerner S, O’Brien S, Keating MJ. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol. 2008 Apr;141(1):36-40. 
• Yu Z, Sun B, Kantarjian HM, Keating MJ, Amin HM, Sun X. Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. Leuk Lymphoma. 2008 Apr;49(4):751-6. 
• Awais A, Tam CS, Kontoyiannis D, Ferrajoli A, Duvic M, Cortes J, Keating MJ. Rapid resolution of Mycobacterium marinum chronic skin infection during lenalidomide therapy for chronic lymphocytic leukemia. Clin Infect Dis. 2008 Apr 1;46(7):e69-71. 
• Ghia EM, Jain S, Widhopf GF, Rassenti LZ, Keating MJ, Wierda WG, Gribben JG, Brown JR, Rai KR, Byrd JC, Kay NE, Greaves AW, Kipps TJ. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood. 2008 May 15;111(10):5101-8. Epub 2008 Mar 7. 
• Keating MJ, Bach C, Yasothan U, Kirkpatrick P. Bendamustine. Nat Rev Drug Discov. 2008 Jun;7(6):473-4. 
• Zhang H, Trachootham D, Lu W, Carew J, Giles FJ, Keating MJ, Arlinghaus RB, Huang P. Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism. Leukemia. 2008 Jun;22(6):1191-9. Epub 2008 Apr 3. 
• Ferrajoli A, Lee BN, Schlette EJ, O’Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN, Li C, Reuben JM, Keating MJ. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008 Jun 1;111(11):5291-7. Epub 2008 Mar 11. 
• Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ, International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 Jun 15;111(12):5446-56. Epub 2008 Jan 23. 
• Huh YO, Lin KI, Vega F, Schlette E, Yin CC, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol. 2008 Jul;142(1):36-44. Epub 2008 May 8. 
• Safdar A, Rodriguez GH, Rueda AM, Wierda WG, Ferrajoli A, Musher DM, O’Brien S, Koller CA, Bodey GP, Keating MJ. Multiple-dose granulocyte-macrophage-colony-stimulating factor plus 23-valent polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia: a prospective, randomized trial of safety and immunogenicity. Cancer. 2008 Jul 15;113(2):383-7. 
• Tam CS, O’Brien S, Wierda W, Kantarjian H, Wen S, Do KA, Thomas DA, Cortes J, Lerner S, Keating MJ. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008 Aug 15;112(4):975-80. Epub 2008 Apr 14. 
• Gunn SR, Mohammed MS, Gorre ME, Cotter PD, Kim J, Bahler DW, Preobrazhensky SN, Higgins RA, Bolla AR, Ismail SH, de Jong D, Eldering E, van Oers MH, Mellink CH, Keating MJ, Schlette EJ, Abruzzo LV, Robetorye RS. Whole-genome scanning by array comparative genomic hybridization as a clinical tool for risk assessment in chronic lymphocytic leukemia. J Mol Diagn. 2008 Sep;10(5):442-51. Epub 2008 Aug 7. 
• Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 2008 Sep 1;112(5):1912-22. Epub 2008 Jun 23. 
• Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood. 2008 Sep 1;112(5):1923-30. Epub 2008 Jun 24. 
• Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2008 Sep 1;112(5):1971-80. Epub 2008 Jun 19. 
• Tsimberidou AM, Kantarjian HM, Wen S, Keating MJ, O’Brien S, Brandt M, Pierce S, Freireich EJ, Medeiros LJ, Estey E. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer. 2008 Sep 15;113(6):1370-8. 
• Kantarjian H, O’Brien S, Cortes J, Wierda W, Faderl S, Garcia-Manero G, Issa JP, Estey E, Keating M, Freireich EJ. Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. Cancer. 2008 Oct 1;113(7 Suppl):1933-52. 
• Caraway NP, Thomas E, Khanna A, Payne L, Zhang HZ, Lin E, Keating MJ, Katz RL. Chromosomal abnormalities detected by multicolor fluorescence in situ hybridization in fine-needle aspirates from patients with small lymphocytic lymphoma are useful for predicting survival. Cancer. 2008 Oct 25;114(5):315-22. 
• Inamdar KV, O’Brien S, Sen S, Keating M, Nguyen MH, Wang X, Fernandez M, Thomazy V, Medeiros LJ, Bueso- Ramos CE. Aurora-A kinase nuclear expression in chronic lymphocytic leukemia. Mod Pathol. 2008 Dec;21(12):1428-35. Epub 2008 Oct 17. 

2009

• Burger JA, Quiroga MP, Balakrishnan K, Gandhi V, Kurtova A, Wierda WG, Keating MJ. The SYK inhibitor R406 blocks BCR signaling, cell adhesion and migration, and induces apoptosis in CLL cells: an explanation for the clinical activity of R406 in chronic lymphocytic leukemia. Haematologica. 2009;94(Suppl 2):135. 
• Freireich EJ, Kantarjian H, Keating MJ. Leukemia research, 2008. Clin Lymphoma Myeloma. 2009;9(Suppl 3):S178. 
• Ma W, Kantarjian H, Zhang X, Jilani I, Sheikholeslami MR, Donahue AC, Ravandi F, Estey E, O’Brien S, Keating M, Giles FJ, Albitar M. Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications. Cancer Biomark. 2009;5(1):51-8. 
• Ault P, Cortes J, Lynn A, Keating M, Verstovsek S. Pregnancy in a patient with hypereosinophilic syndrome. Leuk Res. 2009 Jan;33(1):186-7. Epub 2008 Jul 1. 
• Sargent R, Jones D, Abruzzo LV, Yao H, Bonderover J, Cisneros M, Wierda WG, Keating MJ, Luthra R. Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. J Mol Diagn. 2009 Jan;11(1):25-34. Epub 2008 Dec 12. 
• O’Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood. 2009 Jan 8;113(2):299-305. Epub 2008 Oct 17. 
• Tsimberidou AM, Tam C, Abruzzo LV, O’Brien S, Wierda WG, Lerner S, Kantarjian HM, Keating MJ. Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia. Cancer. 2009 Jan 15;115(2):373-80. 
• Jilani I, Wei C, Bekele BN, Zhang ZJ, Keating M, Wierda W, Ferrajoli A, Estrov Z, Kantarjian H, O’Brien SM, Giles FJ, Albitar M. Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia. Int J Lab Hematol. 2009 Feb;31(1):97-105. Epub 2008 Jan 7. 
• Yeh CH, Tseng R, Zhang Z, Cortes J, O’Brien S, Giles F, Hannah A, Estrov Z, Keating M, Kantarjian H, Albitar M. Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia. Leuk Res. 2009 Feb;33(2):212-7. Epub 2008 Aug 19. 
• Tsimberidou AM, Wen S, McLaughlin P, O’Brien S, Wierda WG, Lerner S, Strom S, Freireich EJ, Medeiros LJ, Kantarjian HM, Keating MJ. Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma. J Clin Oncol. 2009 Feb 20;27(6):904-10. Epub 2008 Dec 29. 
• Burger JA, Quiroga MP, Hartmann E, Bürkle A, Wierda WG, Keating MJ, Rosenwald A. High-level expression of the T cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell co-cultures and after BCR stimulation. Blood. 2009 Mar 26;113(13):3050-8. Epub 2008 Dec 12. 
• Wierda WG, O’Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller C, Burger J, Lerner S, Kantarjian H, Keating M. Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment. J Clin Oncol. 2009 Apr 1;27(10):1637-43. Epub 2009 Feb 17. 
• Lin KI, Tam CS, Keating MJ, Wierda WG, O’Brien S, Lerner S, Coombes KR, Schlette E, Ferrajoli A, Barron LL, Kipps TJ, Rassenti L, Faderl S, Kantarjian H, Abruzzo LV. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. Blood. 2009 Apr 2;113(14):3168-71. Epub 2008 Dec 2. 
• Sampath D, Calin GA, Puduvalli VK, Gopisetty G, Taccioli C, Liu CG, Ewald B, Liu C, Keating MJ, Plunkett W. Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood. 2009 Apr 16;113(16):3744-53. Epub 2008 Dec 18. 
• Tam CS, Abruzzo LV, Lin KI, Cortes J, Lynn A, Keating MJ, Thomas DA, Pierce S, Kantarjian H, Verstovsek S. The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: Applicability at the time of diagnosis and later during disease course. Blood. 2009 Apr 30;113(18):4171-8. Epub 2009 Jan 8. 
• Miller CP, Rudra S, Keating MJ, Wierda WG, Palladino M, Chandra J. Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood. 2009 Apr 30;113(18):4289-99. Epub 2009 Jan 30. 
• Yin CC, Lin KI, Ketterling RP, Knudson RA, Medeiros LJ, Barron LL, Huh YO, Luthra R, Keating MJ, Abruzzo LV. Chronic lymphocytic leukemia with t(2;14)(p16;q32) involves the BCL11A and IgH genes and is associated with atypical morphologic features and unmutated IgVH genes. Am J Clin Pathol. 2009 May;131(5):663-70. 
• Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45. Epub 2009 Feb 20. 
• Niedermeier M, Hennessy BT, Knight ZA, Henneberg M, Hu J, Kurtova AV, Wierda WG, Keating MJ, Shokat KM, Burger JA. Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood. 2009 May 28;113(22):5549-57. Epub 2009 Mar 24. 
• Tsai CY, Ray AS, Tumas DB, Keating MJ, Reiser H, Plunkett W. Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219. Clin Cancer Res. 2009 Jun 1;15(11):3760-9. Epub 2009 May 12. 
• Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, O’Brien S, Estey E, Estrov Z, Cortes J, Keating M, Giles F, Albitar M. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009 Jun 1;15(11):3820-6. Epub 2009 May 19. 
• Thomas DA, O’Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, Verstovsek S, Koller C, Pierce S, Huh Y, Wierda W, Keating MJ, Kantarjian HM. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009 Jun 18;113(25):6330-7. Epub 2008 Aug 14. 
• Tsimberidou AM, Keating MJ. Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer. 2009 Jul 1;115(13):2824-36. 
• Tam CS, Shanafelt TD, Wierda WG, Abruzzo LV, Van Dyke DL, O’Brien S, Ferrajoli A, Lerner SA, Lynn A, Kay NE, Keating MJ. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009 Jul 30;114(5):957-64. Epub 2009 May 4. 
• Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30;114(5):1029-37. Epub 2009 Jun 2. 
• Gunn SR, Bolla AR, Barron LL, Gorre ME, Mohammed MS, Bahler DW, Mellink CH, van Oers MH, Keating MJ, Ferrajoli A, Coombes KR, Abruzzo LV, Robetorye RS. Array CGH analysis of chronic lymphocytic leukemia reveals frequent cryptic monoallelic and biallelic deletions of chromosome 22q11 that include the PRAME gene. Leuk Res. 2009 Sep;33(9):1276-81. Epub 2008 Nov 21. 
• Schlette EJ, Admirand J, Wierda W, Abruzzo L, Lin KI, O’Brien S, Lerner S, Keating MJ, Tam C. p53 expression by immunohistochemistry is an important determinant of survival in patients with chronic lymphocytic leukemia receiving frontline chemo-immunotherapy. Leuk Lymphoma. 2009 Oct;50(10):1597-605. 
• Thomas DA, Ravandi F, Keating M, Kantarjian HM. Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy. Leuk Lymphoma. 2009 Oct;50(Suppl 1):27-31. 
• Jain N, Wierda W, Ferrajoli A, Wong F, Lerner S, Keating M, O’Brien S. A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia. Cancer. 2009 Oct 1;115(19):4533-9. 
• Ravandi F, Aribi A, O’Brien S, Faderl S, Jones D, Ferrajoli A, Huang X, York S, Pierce S, Wierda W, Kontoyiannis D, Verstovsek S, Pro B, Fayad L, Keating M, Kantarjian H. Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms. J Clin Oncol. 2009 Nov 10;27(32):5425-30. Epub 2009 Oct 5. 
• Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Jäger U, Gandhi V, Kay NE, Plunkett W, Burger JA. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12;114(20):4441-50. Epub 2009 Sep 17. 
• Herling M, Patel KA, Weit N, Lilienthal N, Hallek M, Keating MJ, Jones D. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia. Blood. 2009 Nov 19;114(21):4675-86. Epub 2009 Sep 21. 
• Tam CS, Kantarjian H, Cortes J, Lynn A, Pierce S, Zhou L, Keating MJ, Thomas DA, Verstovsek S. Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. J Clin Oncol. 2009 Nov 20;27(33):5587-93. Epub 2009 Sep 28. 
• Santos FP, Faderl S, Garcia-Manero G, Koller C, Beran M, O’Brien S, Pierce S, Freireich EJ, Huang X, Borthakur G, Bueso-Ramos C, de Lima M, Keating M, Cortes J, Kantarjian H, Ravandi F. Adult acute erythroleukemia: an analysis of 91 patients treated at a single institution. Leukemia. 2009 Dec;23(12):2275-80. Epub 2009 Sep 10. 

2010

• Al-Kali A, Wierda W, Keating M, O’Brien S. Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL). J Blood Med. 2010;1:115-22. Epub 2010 Jun 21. 
• Alatrash G, Albitar M, O’Brien S, Wang X, Manshouri T, Faderl S, Ferrajoli A, Burger J, Garcia-Manero G, Kantarjian HM, Lerner S, Keating MJ, Wierda WG. Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR). Br J Haematol. 2010 Feb;148(3):386-93. Epub 2009 Nov 6. 
• Keating MJ, Dritselis A, Yasothan U, Kirkpatrick P. Ofatumumab. Nat Rev Drug Discov. 2010 Feb;9(2):101-2. 
• Wojcik SE, Rossi S, Shimizu M, Nicoloso MS, Cimmino A, Alder H, Herlea V, Rassenti LZ, Rai KR, Kipps TJ, Keating MJ, Croce CM, Calin GA. Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. Carcinogenesis. 2010 Feb;31(2):208-15. Epub 2009 Nov 19. 
• Tarrand JJ, Keating MJ, Tsimberidou AM, O’Brien S, LaSala RP, Han XY, Bueso-Ramos CE. Epstein-Barr virus latent membrane protein 1 mRNA is expressed in a significant proportion of patients with chronic lymphocytic leukemia. Cancer. 2010 Feb 15;116(4):880-7. 
• Faderl S, Wierda W, O’Brien S, Ferrajoli A, Lerner S, Keating MJ. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 Years. Leuk Res. 2010 Mar;34(3):284-8. Epub 2009 Jul 30. 
• Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, Chen X, Shanker S, Ferrajoli A, Keating MJ, Estrov Z. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood. 2010 Apr 8;115(14):2852-63. Epub 2010 Feb 12. 
• Koehrer S, Keating MJ, Wierda WG. Eltrombopag, a second-generation thrombopoietin receptor agonist, for chronic lymphocytic leukemia-associated ITP. Leukemia. 2010 May;24(5):1096-8. Epub 2010 Mar 25. 
• Verma D, Kantarjian H, Faderl S, O’Brien S, Pierce S, Vu K, Freireich E, Keating M, Cortes J, Ravandi F. Late relapses in acute myeloid leukemia: analysis of characteristics and outcome. Leuk Lymphoma. 2010 May;51(5):778-82. 
• Faderl S, Ferrajoli A, Wierda W, O’Brien S, Lerner S, Keating MJ. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence. Cancer. 2010 May 15;116(10):2360-5. 
• Tsimberidou AM, Keating MJ. Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. Leuk Lymphoma. 2010 Jul;51(7):1188-99. 
• Li P, Harris D, Liu Z, Liu J, Keating M, Estrov Z. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One. 2010 Jul 29;5(7):e11859. 
• Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi F. Forodesine: review of preclinical and clinical data. Future Oncol. 2010 Aug;6(8):1211-7. 
• Rossi S, Shimizu M, Barbarotto E, Nicoloso MS, Dimitri F, Sampath D, Fabbri M, Lerner S, Barron LL, Rassenti LZ, Jiang L, Xiao L, Hu J, Secchiero P, Zauli G, Volinia S, Negrini M, Wierda W, Kipps TJ, Plunkett W, Coombes KR, Abruzzo LV, Keating MJ, Calin GA. microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. Blood. 2010 Aug 12;116(6):945-52. Epub 2010 Apr 14. 
• Balakrishnan K, Verma D, O’Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 2010 Aug 12;116(6):886-92. Epub 2010 Apr 28. 
• Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G. Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact. Epigenetics. 2010 Aug 16;5(6):499-508. Epub 2010 Aug 16. 
• Thomas DA, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20;28(24):3880-9. Epub 2010 Jul 26. 
• Konoplev SN, Fritsche HA, O’Brien S, Wierda WG, Keating MJ, Gornet TG, St Romain S, Wang X, Inamdar K, Johnson MR, Medeiros LJ, Bueso-Ramos CE. High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. Am J Clin Pathol. 2010 Sep;134(3):472-7. 
• Tam CS, Keating MJ. Chemoimmunotherapy of chronic lymphocytic leukemia. Nat Rev Clin Oncol. 2010 Sep;7(9):521-32. Epub 2010 Jul 6. 
• Bruey JM, Kantarjian H, Ma W, Estrov Z, Yeh C, Donahue A, Sanders H, O’Brien S, Keating M, Albitar M. Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia. Leuk Res. 2010 Oct;34(10):1320-4. Epub 2010 Apr 1. 
• Hu Y, Lu W, Chen G, Zhang H, Jia Y, Wei Y, Yang H, Zhang W, Fiskus W, Bhalla K, Keating M, Huang P, Garcia-Manero G. Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound β-phenylethyl isothiocyanate. Blood. 2010 Oct 14;116(15):2732-41. Epub 2010 Jun 21. 
• Admirand JH, Knoblock RJ, Coombes KR, Tam C, Schlette EJ, Wierda WG, Ferrajoli A, O’Brien S, Keating MJ, Luthra R, Medeiros LJ, Abruzzo LV. Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression. Mod Pathol. 2010 Nov;23(11):1518-23. Epub 2010 Jul 23. 
• Wierda WG, Castro JE, Aguillon R, Sampath D, Jalayer A, McMannis J, Prussak CE, Keating M, Kipps TJ. A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154. Leukemia. 2010 Nov;24(11):1893-900. Epub 2010 Sep 30. 
• Kantarjian H, Ravandi F, O’Brien S, Cortes J, Faderl S, Garcia-Manero G, Jabbour E, Wierda W, Kadia T, Pierce S, Shan J, Keating M, Freireich EJ. Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood. 2010 Nov 25;116(22):4422-9. Epub 2010 Jul 28. 

2011

• Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O’Brien SM. CLL Research Consortium. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. Cancer. 2011 Jan 1;117(1):116-24. Epub 2010 Aug 30. 
• Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, Barbarotto E, Cimmino A, Adair B, Wojcik SE, Valeri N, Calore F, Sampath D, Fanini F, Vannini I, Musuraca G, Dell’Aquila M, Alder H, Davuluri RV, Rassenti LZ, Negrini M, Nakamura T, Amadori D, Kay NE, Rai KR, Keating MJ, Kipps TJ, Calin GA, Croce CM. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA. 2011 Jan 5;305(1):59-67. 
• Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O’Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood. 2011 Feb 3;117(5):1662-9. Epub 2010 Nov 29. 
• Badoux XC, Keating MJ, Wierda WG. What is the best frontline therapy for patients with CLL and 17p deletion? Curr Hematol Malig Rep. 2011 Mar;6(1):36-46.
• Badoux XC, Keating MJ, Wang X, O’Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011 Mar 17;117(11):3016-24. Epub 2011 Jan 18. 
• Liu Z, Hazan-Halevy I, Harris DM, Li P, Ferrajoli A, Faderl S, Keating MJ, Estrov Z. STAT-3 Activates NF-κB in Chronic Lymphocytic Leukemia Cells. Mol Cancer Res. 2011 Apr;9(4):507-15. Epub 2011 Mar 1. 
• Duzkale H, Schweighofer CD, Coombes KR, Barron LL, Ferrajoli A, O’Brien S, Wierda WG, Pfeifer J, Majewski T, Czerniak BA, Jorgensen JL, Medeiros LJ, Freireich EJ, Keating MJ, Abruzzo LV. LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts over-all survival in untreated patients. Blood. 2011 Apr 14;117(15):4076-84. Epub 2011 Feb 10. 
• Huh YO, Schweighofer CD, Ketterling RP, Knudson RA, Vega F, Kim JE, Luthra R, Keating MJ, Medeiros LJ, Abruzzo LV. Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. Am J Clin Pathol. 2011 May;135(5):686-96. 
• Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May;121(5):1822-6. Epub 2011 Apr 11. 
• Ma D, Chen Z, Patel KP, Mishra BM, Yao H, Abruzzo LV, Medeiros LJ, Wierda W, Keating M, Sargent R, Luthra R. Array comparative genomic hybridization analysis identifies recurrent gain of chromosome 2p25.3 involving the ACP1 and MYCN genes in chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S17-24. Epub 2011 May 5. 
• Schweighofer CD, Huh YO, Luthra R, Sargent RL, Ketterling RP, Knudson RA, Barron LL, Medeiros LJ, Keating MJ, Abruzzo LV. The B cell antigen receptor in atypical chronic lymphocytic leukemia with t(14;19)(q32;q13) demonstrates remarkable stereotypy. Int J Cancer. 2011 Jun 1;128(11):2759-64. Epub 2010 Oct 26. 
• Ferrajoli A, Keating MJ, O’Brien S, Cortes J, Thomas DA. Experience with rituximab immunotherapy as an early intervention in patients with Rai stage 0 to II chronic lymphocytic leukemia. Cancer. 2011 Jul 15;117(14):3182-6. Epub 2011 Jan 18. 
• Parikh SA, Keating MJ, O’Brien S, Wang X, Ferrajoli A, Faderl S, Burger J, Koller C, Estrov Z, Badoux X, Lerner S, Wierda WG. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011 Aug 25;118(8):2062-8. Epub 2011 Jul 12. 
• Badoux XC, Keating MJ, Wang X, O’Brien SM, Ferrajoli A, Faderl S, Burger J, Koller C, Lerner S, Kantarjian H, Wierda WG. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia. Blood. 2011 Aug 25;118(8):2085-93. Epub 2011 Jun 13. 
• Lee BN, Gao H, Cohen EN, Badoux X, Wierda WG, Estrov Z, Faderl SH, Keating MJ, Ferrajoli A, Reuben JM. Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia. Cancer. 2011 Sep 1;117(17):3999-4008. Epub 2011 Feb 24. 
• Zhou Y, Zhou Y, Shingu T, Feng L, Chen Z, Ogasawara M, Keating MJ, Kondo S, Huang P. Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis. J Biol Chem. 2011 Sep 16;286(37):32843-53. Epub 2011 Jul 27. 
• Badoux XC, Keating MJ, Wen S, Lee BN, Sivina M, Reuben J, Wierda WG, O’Brien SM, Faderl S, Kornblau SM, Burger JA, Ferrajoli A. Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood. 2011 Sep 29;118(13):3489-98. Epub 2011 Jul 1. 
• Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, Giese N, O’Brien S, Yu A, Miller LL, Lannutti BJ, Burger JA. The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011 Sep 29;118(13):3603-12. Epub 2011 Jul 29. 
• Ravandi F, O’Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Koller C, Challagundla P, York S, Brandt M, Luthra R, Burger J, Thomas D, Keating M, Kantarjian H. Phase II study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood. 2011 Oct 6;118(14):3818-23. Epub 2011 Aug 5. 
• Khouri IF, Bassett R, Poindexter N, O’Brien S, Bueso- Ramos CE, Hsu Y, Ferrajoli A, Keating MJ, Champlin R, Fernandez-Vina M. Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia: long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome. Cancer. 2011 Oct 15;117(20):4679-88. Epub 2011 Mar 31. 
• Wierda WG, O’Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Garcia-Manero G, Cortes J, Thomas D, Koller CA, Burger JA, Lerner S, Schlette E, Abruzzo L, Kantarjian HM, Keating MJ. Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. J Clin Oncol. 2011 Nov 1;29(31):4088-95. Epub 2011 Oct 3. 
• Badoux X, Bueso-Ramos C, Harris D, Li P, Liu Z, Burger J, O’Brien S, Ferrajoli A, Keating MJ, Estrov Z. Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Hum Pathol. 2011 Dec;42(12):1989-2000. Epub 2011 Jul 5. 
• Tong WG, Estrov Z, Wang Y, O’Brien S, Faderl S, Harris DM, Van Pham Q, Hazan-Halevy I, Liu Z, Koch P, Kantarjian H, Keating MJ, Ferrajoli A. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells. Invest New Drugs. 2011 Dec;29(6):1206-12. Epub 2010 Jun 9. 
• Schweighofer CD, Coombes KR, Barron LL, Diao L, Newman RJ, Ferrajoli A, O’Brien S, Wierda WG, Luthra R, Medeiros LJ, Keating MJ, Abruzzo LV. A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia. PLoS One. 2011;6(12):e28277. Epub 2011 Dec 14. 

2012

• Hornberger J, Reyes C, Shewade A, Lerner S, Friedmann M, Han L, Gutierrez H, Satram-Hoang S, Keating MJ. Cost-effectiveness of adding rituximab to fludarabine and cyclophosphamide for the treatment of previously untreated chronic lymphocytic leukemiaLeuk Lymphoma. 2012 Feb;53(2):225-34. Epub 2011 Sep 19.
• Hu Y, Lu W, Chen G, Wang P, Chen Z, Zhou Y, Ogasawara M, Trachootham D, Feng L, Pelicano H, Chiao PJ, Keating MJ, Garcia-Manero G, Huang P.K-ras(G12V) transformation leads to mitochondrial dysfunction and a metabolic switch from oxidative phosphorylation to glycolysisCell Res. 2012 Feb;22(2):399-412. Epub 2011 Aug 30.
• Zhou Y, Tang G, Medeiros LJ, McDonnell TJ, Keating MJ, Wierda WG, Wang SA.Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphomaMod Pathol. 2012 Feb;25(2):237-45. Epub 2011 Nov 11.
• Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, Keating MJ.Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemiaBlood. 2012 Feb 2;119(5):1162-72. Epub 2011 Nov 16. https://doi.org/10.1182/blood-2011-05-351510
• Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O’Brien S, Chiorazzi N, Burger JA.The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivoBlood. 2012 Feb 2;119(5):1182-9. Epub 2011 Dec 16.
• Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, Lu W, Burger JA, Croce CM, Plunkett W, Keating MJ, Huang P.Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012 Feb 19;14(3):276-86.
• Bazargan A, Tam CS, Keating MJ. Predicting survival in chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2012 Mar;12(3):393-403.
• Zenz T, Gribben JG, Hallek M, Döhner H, Keating MJ, Stilgenbauer S.Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 2012 May 3;119(18):4101-7. Epub 2012 Mar 6.
• Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating MJ, Liu J, McKeehan W, Wang H, Luo Y, Huang P.Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapyPLoS Biol. 2012;10(5):e1001326. Epub 2012 May 8. 
• Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A, Ravandi F, Wierda WG, O’Brien S, Keating MJ, Burger JA.Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migrationLeukemia. 2012 Jul;26(7):1576-83. Epub 2012 Feb 7.
• Garg R, Wierda W, Ferrajoli A, Abruzzo L, Pierce S, Lerner S, Keating M, O’Brien S.The prognostic difference of monoallelic versus biallelic deletion of 13q in chronic lymphocytic leukemia. Cancer. 2012 Jul 15;118(14):3531-7. Epub 2011 Dec 2.
• Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, Wierda WG, Rosenwald A, Herling M, Burger JA.Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemiaLeukemia. 2012 Aug;26(8):1812-20. Epub 2012 Mar 5.
• Pillai RN, Chen LS, Ayres ML, Nowak BJ, Thomas MW, Shpall EJ, Keating MJ, Gandhi V.Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma. 2012 Oct;53(10):2024-32. Epub 2012 Apr 23.
• Decker WK, Shah N, Xing D, Lapushin R, Li S, Robinson SN, Yang H, Parmar S, Halpert MM, Keating MJ, Gribben JG, Molldrem JJ, Shpall EJ, Wierda WG.Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC. PLoS One. 2012;7(12):e51390. Epub 2012 Dec 19.

2013

• Yuan S, Wang F, Chen G, Zhang H, Feng L, Wang L, Colman H, Keating MJ, Li X, Xu RH, Wang J, Huang P. Effective elimination of cancer stem cells by a novel drug combination strategy. Stem Cells. 2013 Jan;31(1):23-34.
• Badoux XC, Keating MJ, Wen S, Wierda WG, O’Brien SM, Faderl S, Sargent R, Burger JA, Ferrajoli A. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemiaJ Clin Oncol. 2013 Feb 10;31(5):584-91. Epub 2012 Dec 26.
• Balatti V, Lerner S, Rizzotto L, Rassenti LZ, Bottoni A, Palamarchuk A, Cascione L, Alder H, Keating MJ, Kipps TJ, Pekarsky Y, Croce CM. Trisomy 12 CLLs progress through NOTCH1 mutations. Leukemia. 2013 Mar;27(3):740-3. Epub 2012 Aug 20.
• Schweighofer CD, Coombes KR, Majewski T, Barron LL, Lerner S, Sargent RL, O’Brien S, Ferrajoli A, Wierda WG, Czerniak BA, Medeiros LJ, Keating MJ, Abruzzo LV.Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypesJ Mol Diagn. 2013 Mar;15(2):196-209. Epub 2012 Dec 27.
• Tam CS, Keating MJ. Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?Leuk Lymphoma. 2013 May;54(5):934-9. Epub 2012 Sep 28.
• Malik A, Shoukier M, Garcia-Manero G, Wierda W, Cortes J, Bickel S, Keating MJ, Estrov Z. Azacitidine in fludarabine-refractory chronic lymphocytic leukemia: a phase II study. Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):292-5. Epub 2012 Dec 21.
• Benjamini O, Jain P, Schlette E, Sciffman JS, Estrov Z, Keating M.Chronic lymphocytic leukemia with central nervous system involvement: a high-risk disease? Clin Lymphoma Myeloma Leuk. 2013 Jun;13(3):338-41. Epub 2013 Jan 16.
• Rozovski U, Calin GA, Setoyama T, D’Abundo L, Harris DM, Li P, Liu Z, Grgurevic S, Ferrajoli A, Faderl S, Burger JA, O’Brien S, Wierda WG, Keating MJ, Estrov Z.Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cellsMol Cancer. 2013 Jun 1;12:50.
• Li P, Grgurevic S, Liu Z, Harris D, Rozovski U, Calin GA, Keating MJ, Estrov Z.Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemiaPLoS One. 2013 Jun 4;8(6):e64678.
• Rozovski U, Keating M, Estrov Z. The significance of spliceosome mutations in chronic lymphocytic leukemiaLeuk Lymphoma. 2013 Jul;54(7):1364-6. Epub 2013 Jan 10.
• Kontoyiannis DP, Georgiadou SP, Wierda WG, Wright S, Albert ND, Ferrajoli A, Keating M, Lewis RE.Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemiaLeuk Lymphoma. 2013 Aug;54(8):1730-3. Epub 2013 Feb 20.
• Strati P, Keating MJ, Wierda WG, Badoux XC, Calin S, Reuben JM, O’Brien S, Kornblau SM, Kantarjian HM, Gao H, Ferrajoli A. Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia. Blood. 2013 Aug 1;122(5):734-7. Epub 2013 Jun 25.
• Freireich EJ, Kantarjian H, Keating MJ. Retrospect of hematological malignancies 2012. Clin Lymphoma Myeloma Leuk. 2013 Sep;13(Suppl 2):S271.
• Falchi L, Keating MJ, Wang X, Coombs CC, Lanasa MC, Strom S, Wierda WG, Ferrajoli A.Clinical characteristics, response to therapy, and survival of African American patients diagnosed with chronic lymphocytic leukemia: joint experience of the MD Anderson Cancer Center and Duke University Medical CenterCancer. 2013 Sep 1;119(17):3177-85. Epub 2013 Jul 8.
• Nazha A, Bueso-Ramos C, Estey E, Faderl S, O’Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M, Pierce S, Keating M, Cortes J, Kantarjian H, Ravandi F.The addition of all-trans retinoic acid to chemotherapy may not improve the outcome of patient with NPM1 mutated acute myeloid leukemiaFront Oncol. 2013 Sep 6;3:218.
• Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O’Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA.Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B-chronic lymphocytic leukemiaBlood. 2013 Sep 12;122(11):1891-9. Epub 2013 Jul 2.
• Benjamini O, Jain P, Konoplev SN, Yin CC, Abruzzo L, Wotherspoon AC, Dearden C, Shpall EJ, Estrov Z, Keating MJ.CD4(-)/CD8(-) variant of T-cell large granular lymphocytic leukemia or hepatosplenic T-cell lymphoma: a clinicopathologic dilemmaClin Lymphoma Myeloma Leuk. 2013 Oct;13(5):610-3. Epub 2013 Jun 22.
• Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O’Brien S, Kipps TJ, Jones JA, Badoux X, Kantarjian H, Keating MJ, Chronic Lymphocytic Leukemia Research Consortium.Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndromeClin Lymphoma Myeloma Leuk. 2013 Oct;13(5):568-74. Epub 2013 Jun 27.
• Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O’Brien S.Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopeniaCancer. 2013 Nov 1;119(21):3805-11. Epub 2013 Aug 13.
• Rozovski U, Keating MJ, Estrov Z. Targeting inflammatory pathways in chronic lymphocytic leukemia. Crit Rev Oncol Hematol. 2013 Dec;88(3):655-66. Epub 2013 Aug 12.
• Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O’Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA.The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.PLoS One. 2013 Dec 23;8(12):e83830.

2014

• Liu J, Chen G, Feng L, Zhang W, Pelicano H, Wang F, Ogasawara MA, Lu W, Amin HM, Croce CM, Keating MJ, Huang P.Loss of p53 and altered miR15-a/16-1→MCL-1 pathway in CLL: insights from TCL1-Tg:p53−/− mouse model and primary human leukemia cellsLeukemia. 2014 Jan;28(1):118-28. Epub 2013 Apr 23.
• Hoellenriegel J, Zboralski D, Maasch C, Rosin NY, Wierda WG, Keating MJ, Kruschinski A, Burger JA.The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitizationBlood. 2014 Feb 13;123(7):1032-9. Epub 2013 Nov 25.
• Chae YK, Trinh L, Jain P, Wang X, Rozovski U, Wierda WG, Keating MJ, Estrov Z.Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemiaBlood. 2014 Feb 27;123(9):1424-6.
• Strati P, Ferrajoli A, Lerner S, O’Brien S, Wierda W, Keating MJ, Faderl S.Fludarabine, cyclophosphamide and rituximab plus granulocyte macrophage colony-stimulating factor as frontline treatment for patients with chronic lymphocytic leukemiaLeuk Lymphoma. 2014 Apr;55(4):828-33. Epub 2013 Jul 29.
• Sandoval MR, Balakrishnan K, Luthra R, Keating M, Gandhi V.DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cellsLeuk Lymphoma. 2014 Apr;55(4):876-83. Epub 2013 Jul 29.
• Jain P, Baez-Vallecillo L, Huh YO, Benjamini O, Abruzzo L, O’Brien S, Pemmaraju N, Keating M, Gagel RF, Estrov Z.Atypical chronic lymphocytic leukemia with polyglandular autoimmune endocrinopathy type II: a complex profileLeuk Lymphoma. 2014 Apr;55(4):944-6. Epub 2014 Jan 24.
• Nazha A, Kantarjian HM, Bhatt VR, Nogueras-Gonzalez G, Cortes JE, Kadia T, Garcia-Manero G, Abruzzo L, Daver N, Pemmaraju N, Quintas-Cardama A, Ravandi F, Keating M, Borthakur G.Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogeneticsClin Lymphoma Myeloma Leuk. 2014 Apr;14(2):163-71. Epub 2014 Jan 22.
• Falchi L, Keating MJ, Marom EM, Truong MT, Schlette EJ, Sargent RL, Trinh L, Wang X, Smith SC, Jain N, Estrov Z, O’Brien S, Wierda WG, Lerner S, Ferrajoli A.Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemiaBlood. 2014 May 1;123(18):2783-90. Epub 2014 Mar 10.
• Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, O’Brien S, Wierda W, Keating M, Shpall EJ. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplantClin Lymphoma Myeloma Leuk. 2014 Jun;14(3):e105-9. Epub 2013 Dec 27.
• Strati P, Keating MJ, O’Brien SM, Burger J, Ferrajoli A, Jain N, Tambaro FP, Estrov Z, Jorgensen J, Challagundla P, Faderl SH, Wierda WG.Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014 Jun 12;123(24):3727-32. Epub 2014 Apr 4.
• El-Mabhouh AA, Ayres ML, Shpall EJ, Baladandayuthapani V, Keating MJ, Wierda WG, Gandhi V.Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cellsBlood. 2014 Jun 12;123(24):3780-9. Epub 2014 Apr 18.
• Rozovski U, Wu JY, Harris DM, Liu Z, Li P, Hazan- Halevy I, Ferrajoli A, Burger JA, O’Brien S, Jain N, Verstovsek S, Wierda WG, Keating MJ, Estrov Z.Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cellsBlood. 2014 Jun 12;123(24):3797-802. Epub 2014 Apr 28.
• Wodarz D, Garg N, Komarova NL, Benjamini O, Keating MJ, Wierda WG, Kantarjian H, James D, O’Brien S, Burger JA. Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 2014 Jun 26;123(26):4132-5. Epub 2014 May 14.
• Strati P, Keating MJ, O’Brien SM, Ferrajoli A, Burger J, Faderl S, Tambaro FP, Jain N, Wierda WG.Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica. 2014 Aug;99(8):1350-5. Epub 2014 May 23.
• Chen LS, Keating MJ, Gandhi V.Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLLBlood. 2014 Aug 14;124(7):1192-5.
• Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-González GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O’Brien S.Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyLancet Oncol. 2014 Sep;15(10):1090-9. Epub 2014 Aug 20.
• Freireich EJ, Kantarjian H, Keating MJ.The proceedings of the initial meeting of the Society of Hematologic Oncology 2013. Clin Lymphoma Myeloma Leuk. 2014 Sep;14 Suppl:S1.
• Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O’Brien S, Faderl S, Keating M, Estrov Z.STAT3-activated GM-CSFRα translocates to the nucleus and protects CLL cells from apoptosis. Mol Cancer Res. 2014 Sep;12(9):1267-82. Epub 2014 May 16.
• Rozovski U, Hazan-Halevy I, Keating MJ, Estrov Z.Personalized medicine in CLL: current status and future perspectives. Cancer Lett. 2014 Sep 28;352(1):4-14. Epub 2013 Jul 20.
• Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi- Kashani F, O’Brien S, Estey E, Bekele N, Plunkett WK Jr, Kantarjian H, Borthakur G. A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemiaClin Lymphoma Myeloma Leuk. 2014 Oct;14(5):395-400.e1. Epub 2014 Feb 3.
• Ciccone M, Ferrajoli A, Keating MJ, Calin GA. SnapShot: chronic lymphocytic leukemia. Cancer Cell. 2014 Nov 10;26(5):770-770.e1. Epub 2014 Nov 10.
• Tam CS, O’Brien S, Plunkett W, Wierda W, Ferrajoli A, Wang X, Do KA, Cortes J, Khouri I, Kantarjian H, Lerner S, Keating MJ.Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)Blood. 2014 Nov 13;124(20):3059-64. Epub 2014 Oct 3.
• Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O’Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15;120(22):3494-501. Epub 2014 Jul 15.
• McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS.Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014 Dec 11;124(25):3829-30.

2015

• Thompson PA, Shpall EJ, Keating MJ. Shifting paradigms in the treatment of chronic lymphocytic leukemiaFuture Oncol. 2015;11(4):641-57.
• Lamothe B, Cervantes-Gomez F, Sivina M, Wierda WG, Keating MJ, Gandhi V.Proteasome inhibitor carfilzomib complements ibrutinib’s action in chronic lymphocytic leukemia. Blood. 2015 Jan 8;125(2):407-10.
• Patel V, Balakrishnan K, Keating MJ, Wierda WG, Gandhi V.Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. Blood2015 Feb 12;125(7):1126-36. Epub 2014 Dec 23.
• Londin E, Loher P, Telonis AG, Quann K, Clark P, Jing Y, Hatzimichael E, Kirino Y, Honda S, Lally M, Ramratnam B, Comstock CE, Knudsen KE, Gomella L, Spaeth GL, Hark L, Katz LJ, Witkiewicz A, Rostami A, Jimenez SA, Hollingsworth MA, Yeh JJ, Shaw CA, McKenzie SE, Bray P, Nelson PT, Zupo S, Van Roosbroeck K, Keating MJ, Calin GA, Yeo C, Jimbo M, Cozzitorto J, Brody JR, Delgrosso K, Mattick JS, Fortina P, Rigoutsos I. Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAsProc Natl Acad Sci U S A. 2015 Mar 10;112(10):E1106-15. Epub 2015 Feb 23.
• Jain P, Keating M, Wierda W, Estrov Z, Ferrajoli A, Jain N, George B, James D, Kantarjian H, Burger J, O’Brien S. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015 Mar 26;125(13):2062-7. Epub 2015 Jan 8.
• Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, Cole-Sinclair M, Reynolds J, Filshie R, Schischka S, Khot A, Sandhu S, Keating MJ, Nandurkar H, Tam CS.Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia. 2015 Apr;29(4):783-7. Epub 2014 Aug 20.
• Ferrajoli A, Ivan C, Ciccone M, Shimizu M, Kita Y, Ohtsuka M, D’Abundo L, Qiang J, Lerner S, Nouraee N, Rabe KG, Rassenti LZ, Van Roosbroeck K, Manning JT, Yuan Y, Zhang X, Shanafelt TD, Wierda WG, Sabbioni S, Tarrand JJ, Estrov Z, Radovich M, Liang H, Negrini M, Kipps TJ, Kay NE, Keating M, Calin GA.Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall SurvivalEBioMedicine. 2015 Apr 29;2(6):572-82.
• Rozovski U, Grgurevic S, Bueso-Ramos C, Harris DM, Li P, Liu Z, Wu JY, Jain P, Wierda W, Burger J, O’Brien S, Jain N, Ferrajoli A, Keating MJ, Estrov Z.Aberrant LPL Expression, Driven by STAT3, Mediates Free Fatty Acid Metabolism in CLL Cells. Mol Cancer Res. 2015 May;13(5):944-53. Epub 2015 Mar 2.
• Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O’Brien S, Burger JA, Ferrajoli A, Faderl S, Shpall E, Hosing C, Khouri IF, Champlin R, Keating MJ, Estrov Z. Outcomes of Patients With Chronic Lymphocytic Leukemia and Richter’s Transformation After Transplantation FailureJ Clin Oncol. 2015 May 10;33(14):1557-63. Epub 2015 Apr 6.
• Jain P, Keating M, Thompson PA, Trinh L, Wang X, Wierda W, Ferrajoli A, Burger J, Kantarjian H, Estrov Z, Abruzzo L, O’Brien S.High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcomeAm J Hematol. 2015 Jun;90(6):471-7. Epub 2015 Mar 30.
• Benjamini O, Jain P, Trinh L, Qiao W, Strom SS, Lerner S, Wang X, Burger J, Ferrajoli A, Kantarjian H, O’Brien S, Wierda W, Estrov Z, Keating M.Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomesLeuk Lymphoma. 2015 Jun;56(6):1643-50. Epub 2014 Nov 19.
• Strati P, Tong WG, Vitale C, Wierda WG, O’Brien S, Brown JR, Weng WK, Kipps T, Keating MJ, Ferrajoli A. A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemiaLeuk Lymphoma. 2015 Jun;56(6):1878-80. Epub 2014 Nov 20.
• Sanford DS, Wierda WG, Burger JA, Keating MJ, O’Brien SM.Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practiceClin Lymphoma Myeloma Leuk. 2015 Jul;15(7):385-91. Epub 2015 Feb 19.
• Strati P, Abruzzo LV, Wierda WG, O’Brien S, Ferrajoli A, Keating MJ.Second cancers and Richter transformation are the leading causes of death in patients with trisomy 12 chronic lymphocytic leukemiaClin Lymphoma Myeloma Leuk. 2015 Jul;15(7):420-7. Epub 2015 Feb 11.
• Thompson PA, Ferrajoli A, O’Brien S, Wierda WG, Keating MJ, Burger JA. Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemiaBr J Haematol. 2015 Jul;170(1):125-8. Epub 2014 Dec 18.
• Chakhachiro Z, Yin CC, Abruzzo LV, Aladily TN, Barron LL, Banks HE, Thomas DA, Keating M, Medeiros LJ, Huh YO. B-lymphoblastic leukemia in patients with chronic lymphocytic leukemia: a report of four cases. Am J Clin Pathol. 2015 Aug;144(2):333-40.
• Yin CC, Tang G, Lu G, Feng X, Keating MJ, Medeiros LJ, Abruzzo LV.Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cellsMod Pathol. 2015 Aug;28(8):1130-7. Epub 2015 May 8.
• Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic LeukemiaClin Cancer Res. 2015 Aug 15;21(16):3705-15. Epub 2015 Mar 31.
• Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O’Brien S, Kutok JL, Gandhi V.The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLLLeukemia. 2015 Sep;29(9):1811-22. Epub 2015 Apr 28.
• Coutré SE, Barrientos JC, Brown JR, de Vos S, Furman RR, Keating MJ, Li D, O’Brien SM, Pagel JM, Poleski MH, Sharman JP, Yao NS, Zelenetz AD.Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015 Oct;56(10):2779-86. Epub 2015 May 19.
• Thompson PA, Rozovski U, Keating MJ, Stingo F, Smith SC, Wierda WG, Falchi L, O’Brien SM, Estrov Z, Burger JA, Ferrajoli A. The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy – the MD Anderson Cancer Center experienceBr J Haematol. 2015 Oct;171(2):281-284. Epub 2015 Mar 30.
• Thompson PA, O’Brien SM, Wierda WG, Ferrajoli A, Stingo F, Smith SC, Burger JA, Estrov Z, Jain N, Kantarjian HM, Keating MJ.Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimensCancer. 2015 Oct 15;121(20):3612-21. Epub 2015 Jul 20.
• Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O’Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patientsAm J Hematol. 2015 Nov;90(11):967-9. Epub 2015 Oct 12.
• Short NJ, Keating MJ, Wierda WG, Faderl S, Ferrajoli A, Estrov Z, Smith SC, O’Brien SM. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemiaCancer. 2015 Nov 1;121(21):3869-76. Epub 2015 Jul 28.
• Alattar ML, Ciccone M, Gaballa MR, Vitale C, Badoux XC, Manoukian G, Keating MJ, Kroll MH, Ferrajoli A. Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemiaLeuk Lymphoma. 2015 Dec;56(12):3452-4. Epub 2015 May 26.
• Takahashi K, Sivina M, Hoellenriegel J, Oki Y, Hagemeister FB, Fayad L, Romaguera JE, Fowler N, Fanale MA, Kwak LW, Samaniego F, Neelapu S, Xiao L, Huang X, Kantarjian H, Keating MJ, Wierda W, Fu K, Chan WC, Vose JM, O’Brien S, Davis RE, Burger JA.CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma.Br J Haematol. 2015 Dec;171(5):726-35. Epub 2015 Sep 11.
• O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE.A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemiaBlood. 2015 Dec 17;126(25):2686-94. Epub 2015 Oct 15.

2016

• Kellner J, Wierda W, Shpall E, Keating M, McNiece I.Isolation of a novel chronic lymphocytic leukemic (CLL) cell line and development of an in vivo mouse model of CLLLeuk Res. 2016 Jan;40:54-9. Epub 2015 Oct 19.
• Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, Smith SC, Kantarjian HM, Freireich EJ, Keating MJ.Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemiaBlood. 2016 Jan 21;127(3):303-9. Epub 2015 Oct 22.
• Cervantes-Gomez F, Lavergne B, Keating MJ, Wierda WG, Gandhi V.Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2016 Feb;57(2):436-444. Epub 2015 Sep 28.
• Tambaro FP, Garcia-Manero G, O’Brien SM, Faderl SH, Ferrajoli A, Burger JA, Pierce S, Wang X, Do KA, Kantarjian HM, Keating MJ, Wierda WG.Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia. 2016 Feb;30(2):325-30. Epub 2015 Aug 20.
• Thompson PA, O’Brien SM, Xiao L, Wang X, Burger JA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG. β2-microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemiaCancer. 2016 Feb 15;122(4):565-73. Epub 2015 Nov 20.
• Rozovski U, Hazan-Halevy I, Barzilai M, Keating MJ, Estrov Z.Metabolism pathways in chronic lymphocytic leukemia. Leuk Lymphoma. 2016;57(4):758-65. Epub 2015 Dec 8.
• Sharman JP, Mato AR, Keating MJ. Ibrutinib for Chronic Lymphocytic Leukemia. N Engl J Med. 2016 Apr 21;374(16):1592-3.
• Todisco G, Manshouri T, Verstovsek S, Masarova L, Pierce SA, Keating MJ, Estrov Z.Chronic lymphocytic leukemia and myeloproliferative neoplasms concurrently diagnosed: clinical and biological characteristicsLeuk Lymphoma. 2016 May;57(5):1054-9. Epub 2015 Oct 19.
• Rozovski U, Harris DM, Li P, Liu Z, Wu JY, Grgurevic S, Faderl S, Ferrajoli A, Wierda WG, Martinez M, Verstovsek S, Keating MJ, Estrov Z.At High Levels, Constitutively Activated STAT3 Induces Apoptosis of Chronic Lymphocytic Leukemia Cells. J Immunol. 2016 May 15;196(10):4400-9. Epub 2016 Apr 13.
• Vitale C, Falchi L, Ten Hacken E, Gao H, Shaim H, Van Roosbroeck K, Calin G, O’Brien S, Faderl S, Wang X, Wierda WG, Rezvani K, Reuben JM, Burger JA, Keating MJ, Ferrajoli A.Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune CharacteristicsClin Cancer Res. 2016 May 15;22(10):2359-67. Epub 2016 Jan 5.
• Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchencko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O’Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ.Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nat Commun. 2016 May 20;7:11589.
• Patel V, Keating MJ, Wierda WG, Gandhi V.Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemiaLeuk Lymphoma. 2016;57(6):1494-7. Epub 2015 Nov 16.
• Falchi L, Vitale C, Keating MJ, Lerner S, Wang X, Elhor Gbito KY, Strom S, Wierda WG, Ferrajoli A. Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemiaAnn Oncol. 2016 Jun;27(6):1100-6. Epub 2016 Feb 23.
• Vitale C, Ahn IE, Sivina M, Ferrajoli A, Wierda WG, Estrov Z, Konoplev SN, Jain N, O’Brien S, Farooqui M, Keating MJ, Wiestner A, Burger JA.Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica. 2016 Jun;101(6):e254-8. Epub 2016 Mar 24.
• Rozovski U, Hazan-Halevy I, Calin G, Harris D, Li P, Liu Z, Keating MJ, Estrov Z.Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome. J Vis Exp. 2016 Jun 15;(112).
• Balakrishnan K, Fu M, Onida F, Wierda WG, Keating MJ, Gandhi V.Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimeticOncotarget. 2016 Jun 28;7(26):39458-39472.
• Cervantes-Gomez F, Kumar Patel V, Bose P, Keating MJ, Gandhi V.Decrease in total protein level of Bruton’s tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytesLeukemia. 2016 Aug;30(8):1803-4. Epub 2016 May 20.
• Jain N, Keating MJ. Richter transformation of CLL. Expert Rev Hematol. 2016 Aug;9(8):793-801. Epub 2016 Jun 28.
• Thompson PA, Stingo F, Keating MJ, Ferrajoli A, Burger JA, Wierda WG, Kadia TM, O’Brien SM. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicityCancer. 2016 Aug 15;122(16):2505-11. Epub 2016 May 16.
• Chihara D, Kantarjian H, O’Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, Poku R, Jain P, Thompson P, Brandt M, Luthra R, Burger J, Keating M, Ravandi F. Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trialBr J Haematol. 2016 Sep;174(5):760-6. Epub 2016 Jun 15.
• Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ.Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 Sep 1;126(9):3363-76. Epub 2016 Aug 2.
• Jiang Y, Chen HC, Su X, Thompson PA, Liu X, Do KA, Wierda W, Keating MJ, Plunkett W. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2)Blood Cancer J. 2016 Sep 2;6(9):e465.
• Lamothe B, Wierda WG, Keating MJ, Gandhi V.Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress ResponsesClin Cancer Res. 2016 Sep 15;22(18):4712-26. Epub 2016 Mar 29.
• Ten Hacken E, Sivina M, Kim E, O’Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA.Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. J Immunol. 2016 Sep 15;197(6):2522-31. Epub 2016 Aug 17.
• O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre studyLancet Oncol. 2016 Oct;17(10):1409-1418. Epub 2016 Sep 13.
• Liu PP, Liu J, Jiang WQ, Carew JS, Ogasawara MA, Pelicano H, Croce CM, Estrov Z, Xu RH, Keating MJ, Huang P. Elimination of chronic lymphocytic leukemia cells in stromal microenvironment by targeting CPT with an antiangina drug perhexilineOncogene. 2016 Oct 27;35(43):5663-5673. Epub 2016 Apr 11.
• Bose P, Gandhi VV, Keating MJ.Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower dosesExpert Opin Drug Metab Toxicol. 2016 Nov;12(11):1381-1392. Epub 2016 Oct 11.
• Jain P, Kanagal-Shamanna R, Wierda W, Keating M, Sarwari N, Rozovski U, Thompson P, Burger J, Kantarjian H, Patel KP, Medeiros LJ, Luthra R, Estrov Z.Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. Am J Hematol. 2016 Nov;91(11):E478-E479. Epub 2016 Aug 22.
• Ogasawara MA, Liu J, Pelicano H, Hammoudi N, Croce CM, Keating MJ, Huang P.Alterations of mitochondrial biogenesis in chronic lymphocytic leukemia cells with loss of p53. Mitochondrion. 2016 Nov;31:33-39. Epub 2016 Sep 17. https//doi.org/10.1016/j.mito.2016.09.001
• Thompson PA, Lévy V, Tam CS, Al Nawakil C, Goudot FX, Quinquenel A, Ysebaert L, Michallet AS, Dilhuydy MS, Van Den Neste E, Dupuis J, Keating MJ, Meune C, Cymbalista F. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study. Br J Haematol. 2016 Nov;175(3):462-466. Epub 2016 Sep 9.
• Liu J, Chen G, Pelicano H, Liao J, Huang J, Feng L, Keating MJ, Huang P.Targeting p53-deficient chronic lymphocytic leukemia cells in vitro and in vivo by ROS-mediated mechanismOncotarget. 2016 Nov 1;7(44):71378-71389.
• Ryan CE, Sahaf B, Logan AC, O’Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB.Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCTBlood. 2016 Dec 22;128(25):2899-2908. Epub 2016 Nov 1.

2017

• Cramer SL, Saha A, Liu J, Tadi S, Tiziani S, Yan W, Triplett K, Lamb C, Alters SE, Rowlinson S, Zhang YJ, Keating MJ, Huang P, DiGiovanni J, Georgiou G, Stone E.Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growthNat Med. 2017 Jan;23(1):120-127. Epub 2016 Nov 21.
• Chen Q, Jain N, Ayer T, Wierda WG, Flowers CR, O’Brien SM, Keating MJ, Kantarjian HM, Chhatwal J.Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J Clin Oncol. 2017 Jan 10;35(2):166-174. Epub 2016 Nov 21.
• Burger JA, Li KW, Keating MJ, Sivina M, Amer AM, Garg N, Ferrajoli A, Huang X, Kantarjian H, Wierda WG, O’Brien S, Hellerstein MK, Turner SM, Emson CL, Chen SS, Yan XJ, Wodarz D, Chiorazzi N.Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinibJCI Insight. 2017 Jan 26;2(2):e89904.
• Jain P, Keating M, Renner S, Cleeland C, Xuelin H, Gonzalez GN, Harris D, Li P, Liu Z, Veletic I, Rozovski U, Jain N, Thompson P, Bose P, DiNardo C, Ferrajoli A, O’Brien S, Burger J, Wierda W, Verstovsek S, Kantarjian H, Estrov Z. Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial.Lancet Haematol. 2017 Feb;4(2):e67-e74. Epub 2017 Jan 12.
• Yin Q, Sivina M, Robins H, Yusko E, Vignali M, O’Brien S, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Burger JA. Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. J Immunol. 2017 Feb 15;198(4):1740-1747. Epub 2017 Jan 11.
• Modi P, Balakrishnan K, Yang Q, Wierda WG, Keating MJ, Gandhi V.Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cellsOncotarget. 2017 Mar 7;8(10):16259-16274.
• Jain N, Balakrishnan K, Ferrajoli A, O’Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG.A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLLOncotarget. 2017 Mar 28;8(13):22104-22112.
• Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, O’Brien S, Bose P, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Constitutive Phosphorylation of STAT3 by the CK2-BLNK-CD5 Complex. Mol Cancer Res. 2017 May;15(5):610-618. Epub 2017 Jan 27.
• Thompson PA, Stingo F, Keating MJ, Wierda WG, O’Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Yago N, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 May;177(4):567-577. Epub 2017 Mar 14.
• Jain P, Keating MJ, Wierda WG, Sivina M, Thompson PA, Ferrajoli A, Estrov Z, Kantarjian H, O’Brien S, Burger JA. Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemiaClin Cancer Res. 2017 May 1;23(9):2154-2158. Epub 2016 Oct 19.
• Abou Zahr A, Bose P, Keating MJ. Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia. Expert Opin Pharmacother. 2017 Jun;18(9):857-873. Epub 2017 May 16.
• Fuentes-Mattei E, Giza DE, Shimizu M, Ivan C, Manning JT, Tudor S, Ciccone M, Kargin OA, Zhang X7, Mur P, do Amaral NS, Chen M, Tarrand JJ, Lupu F, Ferrajoli A, Keating MJ, Vasilescu C, Yeung SJ, Calin GA.Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections. EBioMedicine. 2017 Jun;20:182-192. Epub 2017 Apr 19.
• Van Roosbroeck K, Fanini F, Setoyama T, Ivan C, Rodriguez-Aguayo C, Fuentes-Mattei E, Xiao L, Vannini I, Redis RS, D’Abundo L, Zhang X, Nicoloso MS, Rossi S, Gonzalez-Villasana V, Rupaimoole R, Ferracin M, Morabito F, Neri A, Ruvolo PP, Ruvolo VR, Pecot CV, Amadori D, Abruzzo L, Calin S, Wang X, You MJ, Ferrajoli A, Orlowski R, Plunkett W, Lichtenberg TM, Davuluri RV, Berindan-Neagoe I, Negrini M, Wistuba II, Kantarjian HM, Sood AK, Lopez-Berestein G, Keating MJ, Fabbri M, Calin GA.Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clin Cancer Res. 2017 Jun 1;23(11):2891-2904. Epub 2016 Nov 30.
• Jain P, Thompson PA, Keating M, Estrov Z, Ferrajoli A, Jain N, Kantarjian H, Burger JA, O’Brien S, Wierda WG. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15;123(12):2268-2273. Epub 2017 Feb 7.
• Jain P, Aoki E, Keating M, Wierda WG, O’Brien S, Gonzalez GN, Ferrajoli A, Jain N, Thompson PA, Jabbour E, Kanagal-Shamanna R, Pierce S, Alousi A, Hosing C, Khouri I, Estrov Z, Cortes J, Kantarjian H, Ravandi F, Kadia TM.Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)Ann Oncol. 2017 Jul 1;28(7):1554-1559.
• Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, Gandhi V.Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia CellsClin Cancer Res. 2017 Jul 15;23(14):3734-3743. Epub 2016 Dec 29.
• Jain P, Kanagal-Shamanna R, Wierda W, Ferrajoli A, Keating M, Jain N.Membranoproliferative glomerulonephritis and acute renal failure in a patient with chronic lymphocytic leukemia: Response to obinutuzumabHematol Oncol Stem Cell Ther. 2017 Sep;10(3):151-154. Epub 2016 Jun 23.
• Stellrecht CM, Chen LS, Ayres ML, Dennison JB, Shentu S, Chen Y, Keating MJ, Wierda WG, Gandhi V.Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapyBr J Haematol. 2017 Oct;179(2):266-271. Epub 2017 Jul 24.
• ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarfò L, Kim E, Burks J, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA.Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica. 2017 Oct;102(10):e394-e396. Epub 2017 Jul 27.
• Vangapandu HV, Ayres ML, Bristow CA, Wierda WG, Keating MJ, Balakrishnan K, Stellrecht CM, Gandhi V. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia CellsNeoplasia. 2017 Oct;19(10):762-771. Epub 2017 Aug 30.
• Rozovski U, Harris DM, Li P, Liu Z, Jain P, Veletic I, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z.Activation of the B-cell receptor successively activates NF-κB and STAT3 in chronic lymphocytic leukemia cells. Int J Cancer. 2017 Nov 15;141(10):2076-2081. Epub 2017 Aug 4.
• Strati P, Keating MJ, Burger JA, O’Brien SM, Wierda WG, Estrov Z, Zacharian G, Ferrajoli A.Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemiaHaematologica. 2017 Dec;102(12):e494-e496. Epub 2017 Aug 10.
• Vangapandu HV, Havranek O, Ayres ML, Kaipparettu BA, Balakrishnan K, Wierda WG, Keating MJ, Davis RE, Stellrecht CM, Gandhi V. B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. Mol Cancer Res. 2017 Dec;15(12):1692-1703. Epub 2017 Aug 23.
• Lu W, Hu Y, Chen G, Chen Z, Zhang H, Wang F, Feng L, Pelicano H, Wang H, Keating MJ, Liu J, McKeehan W, Wang H, Luo Y, Huang P.Correction: novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapyPLoS Biol. 2017 Dec 11;15(12):e1002616.

2018

• Jain P, Nogueras González GM, Kanagal-Shamanna R, Rozovski U, Sarwari N, Tam C, Wierda WG, Thompson PA, Jain N, Luthra R, Quesada A, Sanchez-Petitto G, Ferrajoli A, Burger J, Kantarjian H, Cortes J, O’Brien S, Keating MJ, Estrov Z.The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximabBr J Haematol. 2018 Jan;180(1):33-40. Epub 2017 Nov 21.
• Schliffke S, Sivina M, Kim E, von Wenserski L, Thiele B, Akyüz N, Falker-Gieske C, Statovci D, Oberle A, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Jain N, Estrov Z, Ferrajoli A, Wierda W, Keating M, Burger JA, Binder M.Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapyOncoimmunology. 2018 Jan 15;7(4):e1417720.
• Shaim H, Estrov Z, Harris D, Hernandez Sanabria M, Liu Z, Ruvolo P, Thompson PA, Ferrajoli A, Daher M, Burger J, Muftuoglu M, Imahashi N, Li L, Liu E, Alsuliman AS, Basar R, Nassif Kerbauy L, Sobieski C, Gokdemir E, Kondo K, Wierda W, Keating M, Shpall EJ, Rezvani K.The CXCR4-STAT3-IL-10 pathway controls the immunoregulatory function of chronic lymphocytic leukemia and is modulated by lenalidomideFront Immunol. 2018 Jan 15;8:1773.
• Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, Gagea M, Banerjee P, Cai R, Bdaiwi MH, Basar R, Muftuoglu M, Li L, Marin D, Wierda W, Keating M, Champlin R, Shpall E, Rezvani K. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activityLeukemia. 2018 Feb;32(2):520-531. Epub 2017 Jul 20.
• Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O’Brien S, Neuberg D, Kipps T, Burger JA. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observationBr J Haematol. 2018 Feb;180(4):597-600. Epub 2016 Oct 21.
• Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V.Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapyLeukemia. 2018 Apr;32(4):920-930. Epub 2017 Nov 3.
• Kondo K, Shaim H, Thompson PA, Burger JA, Keating M, Estrov Z, Harris D, Kim E, Ferrajoli A, Daher M, Basar R, Muftuoglu M, Imahashi N, Alsuliman A, Sobieski C, Gokdemir E, Wierda W, Jain N, Liu E, Shpall EJ, Rezvani K. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathwayLeukemia. 2018 Apr;32(4):960-970. Epub 2017 Oct 3.
• Takahashi K, Hu B, Wang F, Yan Y, Kim E, Vitale C, Patel KP, Strati P, Gumbs C, Little L, Tippen S, Song X, Zhang J, Jain N, Thompson P, Garcia-Manero G, Kantarjian H, Estrov Z, Do KA, Keating M, Burger JA, Wierda WG, Futreal PA, Ferrajoli A.Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomideBlood. 2018 Apr 19;131(16):1820-1832. Epub 2018 Jan 22.
• Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3-activated CD36 facilitates fatty acid uptake in chronic lymphocytic leukemia cells. Oncotarget. 2018 Apr 20;9(30):21268-21280.
• Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, Marszalek JR, Gandhi V.Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cellsOncotarget. 2018 May 18;9(38):24980-24991.
• Vangapandu HV, Chen H, Wierda WG, Keating MJ, Korkut A, Gandhi V.Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cellsLeuk Lymphoma. 2018 Jun;59(6):1427-1438. Epub 2017 Oct 3.
• Kantarjian HM, DiNardo CD, Nogueras-Gonzalez GM, Kadia TM, Jabbour E, Bueso-Ramos CE, O’Brien SM, Konopleva M, Jain NB, Daver NG, Shpall EJ, Champlin RE, Simkins A, Garcia-Manero G, Keating MJ, Huang X, Cortes JE, Pierce SA, Ravandi F, Freireich EJ.Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000Cancer. 2018 Jun 15;124(12):2534-2540. Epub 2018 Apr 12.
• Rozovski U, Keating MJ, Estrov Z.Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?Acta Haematol. 2018;140(1):51-54. Epub 2018 Aug 16.
• Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. STAT3 is constitutively acetylated on lysine 685 residues in chronic lymphocytic leukemia cells. Oncotarget. 2018 Sep 14;9(72):33710-33718. https://doi.org/10.18632/oncotarget.26110
• Strati P, Ferrajoli A, Wierda WG, Jain N, Thompson PA, O’Brien SM, Rezvani K, Kantarjian HM, Burger JA, Hinojosa CO, Keating MJ, Estrov Z.Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemiaLeukemia. 2018 Oct;32(10):2278-2281. Epub 2018 Feb 20.
• Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger J, Thompson P, Jain N, Wierda W, Keating MJ, Estrov Z. Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia. Leuk Lymphoma. 2018 Nov;59(11):2686-2691. Epub 2018 Feb 21. 
• Thompson PA, Peterson CB, Strati P, Jorgensen J, Keating MJ, O’Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Kadia TM, Borthakur G, DiNardo CD, Daver N, Jabbour E, Wierda WG.Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategiesLeukemia. 2018 Nov;32(11):2388-2398. Epub 2018 Apr 17.
• Kantarjian HM, Keating MJ, Freireich EJ. Toward the potential cure of leukemias in the next decade. Cancer. 2018 Nov 15;124(22):4301-4313. Epub 2018 Oct 6.
• Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V.A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 Nov 22;132(21):2249-2259. Epub 2018 Sep 25.
• Abruzzo LV, Herling CD, Calin GA, Oakes C, Barron LL, Banks HE, Katju V, Keating MJ, Coombes KR. Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathwaysHaematologica. 2018 Dec;103(12):2069-2078. Epub 2018 Jul 5.

2019

• Kanagal-Shamanna R, Jain P, Patel KP, Routbort M, Bueso-Ramos C, Alhalouli T, Khoury JD, Luthra R, Ferrajoli A, Keating M, Jain N, Burger J, Estrov Z, Wierda W, Kantarjian HM, Medeiros LJ.Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformationCancer. 2019 Feb 15;125(4):559-574. Epub 2018 Dec 3.
• Burger JA, Sivina M, Jain N, Kim E, Kadia T, Estrov Z, Nogueras-Gonzalez GM, Huang X, Jorgensen J, Li J, Cheng M, Clow F, Ohanian M, Andreeff M, Mathew T, Thompson P, Kantarjian H, O’Brien S, Wierda WG, Ferrajoli A, Keating MJ. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019 Mar 7;133(10):1011-1019. Epub 2018 Dec 7.
• Vitale C, Falchi L, Ciccone M, Burger J, Pemmaraju N, Borthakur G, Wierda WG, Keating MJ, Ferrajoli A. Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignanciesJ Geriatr Oncol. 2019 Apr 18. pii: S1879-4068(19)30033-5. [Epub ahead of print]
• Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V.PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cellsOncotarget. 2019 Apr 19;10(29):2793-2809.
• Paul S, Jain N, Ferrajoli A, O’Brien S, Burger J, Keating M, Wierda W.A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. Br J Haematol. 2019 May;185(3):606-608. Epub 2018 Nov 8.
• Van Roosbroeck K, Bayraktar R, Calin S, Bloehdorn J, Dragomir MP, Okubo K, Bertilaccio MTS, Zupo S, You MJ, Gaidano G, Rossi D, Chen SS, Chiorazzi N, Thompson PA, Ferrajoli A, Bertoni F, Stilgenbauer S, Keating MJ, Calin GA. The involvement of microRNA in the pathogenesis of Richter syndrome. Haematologica. 2019 May;104(5):1004-1015. Epub 2018 Nov 8.
• Strati P, Takahashi K, Peterson CB, Keating MJ, Thompson PA, Daver NG, Jain N, Burger JA, Estrov Z, O’Brien SM, Kantarjian HM, Wierda WG, Futreal PA, Ferrajoli A.Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLLBlood Adv. 2019 May 14;3(9):1533-1539.
• Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and venetoclax for first-line treatment of CLLN Engl J Med. 2019 May 30;380(22):2095-2103.
• Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyetche R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, Neuberg D, Kipps TJ, Nowak MA, Getz G, Wu CJ.Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019 Jun;570(7762):474-479. Epub 2019 May 29.
• Hu B, Patel KP, Chen HC, Wang X, Wang F, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Wierda WG.Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatmentsBr J Haematol. 2019 Jun;185(5):852-864. Epub 2019 Mar 28.
• Zucker MR, Abruzzo LV, Herling CD, Barron LL, Keating MJ, Abrams ZB, Heerema N, Coombes KR.Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing. Bioinformatics. 2019 Sep 1;35(17):2924-2931.
• Zucker MR, Abruzzo LV, Herling CD, Barron LL, Keating MJ, Abrams ZB, Heerema N, Coombes KR.Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing. Bioinformatics. 2019 Sep 1;35(17):3216.
• Strati P, Wang F, Tambaro FP, Thompson PA, Burger JA, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating MJ, Futreal A, Takahashi K, Wierda WG.The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. Br J Haematol. 2019 Oct;187(1):e1-e4. Epub 2019 Jul 25.
• Herling CD, Coombes KR, Benner A, Bloehdorn J, Barron LL, Abrams ZB, Majewski T, Bondaruk JE, Bahlo J, Fischer K, Hallek M, Stilgenbauer S, Czerniak BA, Oakes CC, Ferrajoli A, Keating MJ, Abruzzo LV.Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort studyLancet Oncol. 2019 Nov;20(11):1576-1586. Epub 2019 Sep 30.
• Hu B, Patel KP, Chen HC, Wang X, Luthra R, Routbort MJ, Kanagal-Shamanna R, Medeiros LJ, Yin CC, Zuo Z, Ok CY, Loghavi S, Tang G, Tambaro FP, Thompson P, Burger J, Jain N, Ferrajoli A, Bose P, Estrov Z, Keating M, Wierda WG.Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patientsBr J Haematol. 2019 Nov;187(3):307-318. Epub 2019 Jun 26.
• Jain N, Keating MJ, Thompson PA, Ferrajoli A, Burger JA, Borthakur GM, Takahashi K, Estrov ZE, Fowler NH, Kadia TM, Konopleva MY, Alvarado Y, Yilmaz M, DiNardo CD, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen JL, Wang SA, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian HM, Gandhi V, Wierda WG.Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)Blood. 2019 Nov 13;134(Suppl 1):34.
• Thompson PA, Srivastava J, Peterson C, Strati P, Jorgensen JL, Hether T, Keating MJ, O’Brien SM, Ferrajoli A, Burger JA, Estrov Z, Jain N, Wierda WG.Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapyBlood. 2019 Nov 28;134(22):1951-1959.
• Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Scarfò L, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS.Trabectedin reveals a strategy of immunomodulation in chronic lymphocytic leukemia. Cancer Immunol Res. 2019 Dec;7(12):2036-2051. Epub 2019 Sep 17.
• Chen LS, Keating MJ, Wierda WG, Gandhi V.Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2019 Dec;60(12):3063-3066. Epub 2019 Jun 4.
• Rozovski U, Harris DM, Li P, Liu Z, Jain P, Ferrajoli A, Burger JA, Bose P, Thompson PA, Jain N, Wierda WG, Uziel O, Keating MJ, Estrov Z.STAT3-Induced Wnt5a Provides Chronic Lymphocytic Leukemia Cells with Survival Advantage. J Immunol. 2019 Dec 1;203(11):3078-3085. Epub 2019 Oct 23.

2020

• Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K.Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020 Feb 6;382(6):545-553.
• Strati P, Schlette EJ, Solis Soto L, Dueñas-Hancco DE, Sivina M, Kim E, Keating M, Wierda WG, Ferrajoli A, Kantarjian H, Estrov Z, Jain N, Thompson PA, Wistuba II, Burger JA.Achieving Complete Remission in CLL Patients Treated with Ibrutinib: Clinical Significance and Predictive FactorsBlood. 2020 Feb 13;135(7):510-513.
• Kim E, Ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, Ferrajoli A, Estrov Z, Keating MJ, Wierda WG, Bhalla KN, Burger JA.The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironmentLeukemia. 2020 Jun;34(6):1588-1598. Epub 2019 Dec 20.
• Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda W, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 antagonist, shows preclinical efficacy in chronic lymphocytic leukemia. Clin Cancer Res. 2020 Jul 15;26(14):3856-3867. Epub 2020 Jan 14.

2021

• Rozovski U, Harris DM, Li P, Liu Z, Jain P, Manshouri T, Veletic I, Ferrajoli A, Bose P, Thompson P, Jain N, Verstovsek S, Wierda W, Keating MJ, Estrov Z.STAT3 induces the expression of GLI1 in chronic lymphocytic leukemia cells. Oncotarget. 2021 Mar 2;12(5):401-411.
• Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, Burrows F, Sivina M, Burger JA, Keating MJ, Wierda WG, Plunkett W.The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of actionBlood Cancer J. 2021 Mar 13;11(3):57.
• Assi R, Kantarjian H, Keating M, Pemmaraju N, Verstovsek S, Garcia-Manero G, Ravandi F, Borthakur G, Dahl J, Jabbour E, Cortes JE.Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experienceLeuk Lymphoma. 2021 Apr;62(4):909-917. Epub 2020 Dec 7.
• Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O’Brien S, Keating M, Wierda WG.Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrationsLeukemia. 2021 May 18. [Epub ahead of print].
• Sivina M, Xiao L, Kim E, Vaca A, Chen SS, Keating MJ, Ferrajoli A, Estrov Z, Jain N, Wierda WG, Huang X, Chiorazzi N, Burger JA.CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemiaLeukemia. 2021 Jun;35(6):1610-1620. Epub 2020 Oct 21.
• Cherng HJ, Jammal N, Paul S, Wang X, Sasaki K, Thompson P, Burger J, Ferrajoli A, Estrov Z, O’Brien S, Keating M, Wierda WG, Jain N. Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemiaBr J Haematol. 2021 Jul;194(1):61-68. Epub 2021 May 10.